coverage of proton therapy · 2019-03-22 · scope of services associated with proton therapy...

101
Model Policy Coverage of Proton Therapy Last Revised - February 2019

Upload: others

Post on 14-Mar-2020

4 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

ModelPolicyCoverageofProtonTherapy

LastRevised-February2019

Page 2: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page2

INTRODUCTION

Proton therapy is a technologically advanced method to deliver curative radiation doses tocanceroustumors.Theuniquecharacteristicsofhowprotonsinteractwithinthehumanbodyallowthedeliveryofradiationdosestoatumorwhilereducingradiationdosestosurroundinghealthytissues and organs, resulting in fewer complications and side effects than standard radiationtherapy. Understanding how proton therapy works provides patients, providers, payers,policymakers, andother stakeholderswith insight into the clinical advantages of this treatmentmodality.

Fundamentally,alltissuecellsaremadeupofmoleculeswithatomsastheirbasicbuildingblocks.Inthecenterofeveryatomisthenucleus.Orbitingthenucleusoftheatomarenegativelychargedelectrons.Whenenergizedprotonspassnearorbitingelectrons,thepositivechargeoftheprotonsattractsthenegativelychargedelectrons,pullingthemoutoftheirorbits.Thisiscalledionization.Because of ionization, the radiation damages molecules within the cells, especially the DNA.DamagingtheDNAdestroysspecificcellfunctions,particularlytheabilitytodivideorproliferate.Whilebothnormalandcancerouscellsgothroughthisrepairprocess,acancercell'sabilitytorepairmolecularinjuryisfrequentlyinferior.Asaresult,cancercellssustainmorepermanentdamageandsubsequentcelldeaththanoccursinthenormalcellpopulation.

BothstandardradiationtherapyandprotontherapyworkonthesameprincipleofdamagingcellularDNA. Themajoradvantageofprotontherapyoverstandardradiationtherapy,however, is thatprotonsslowlydeposittheirenergyastheytraveltowardsthecanceroustumorandthen,duetoaunique physical characteristic called the Bragg Peak, deposit themajority of the radiation dosedirectly in the tumor and travel no further through the body. This signficiantlyminimizes theamount of unecesssary radiation delivered to healthy tissues and organs, thereby reducingunwantedcomplicationsandsideeffects.Standardradiationtherapyutilizesx-rayswhichdepositthemajorityoftheradiationdoseimmediatelyuponenteringthebodywhiletravelingtothetumor.Unlikeprotons,afterdepositingradiationdoseinthetumor,thex-rayscontinuetravelingthroughthebodyuntilexitingouttheotherside,resultinginthedeliveryofunnecessaryradiationtohealthytissuesandorgans.

Proton therapymay be delivered in twomethods: passive scattering (also known as single anddoublescattering)andactivescanning(alsoknownasuniformand“pencilbeamscanning”).Withpassivescatteringanduniformscanning,aperturesandcompensatorsareusedtoshapeandfinetune thedepthof theprotonbeam. Withpencilbeamscanning, there isgenerallynoneed foraperturesandcompensators,asthedoseis“painted”inlayers,producingmoreproximalconformityofthedosedistributionaswellasmodulationofthedosewithinafield,referredtoas“intensitymodulatedprotontherapy”orIMPT.

POLICYDESCRIPTION

This document is intended as a model coverage policy for proton therapy. This model policyidentifies underwhich clinical indications such therapy is clinically appropriate to administer topatients. The use of proton therapy in patientswith the indications delineated in the policy is

Page 3: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page3

supportedbyreferencestopeer-reviewed,scientific literature. Theapplicable ICD-10-CMcodesthatcorrelatetoeachoftheclinicalindicationsarelistedinAppendix1.

INDICATIONSFORCOVERAGE

Basedonthepeer-reviewedscientificliteraturereferenceslistedinAppendix2,protontherapyisconsideredmedicallynecessaryforthefollowingconditions:

• Ocular tumors*,+, including intraocular melanomas and ocular adnexal tumors such astumorsofthelacrimalgland;

• Malignantorbenignconditionsofthebaseoftheskulloraxialskeleton*,+includingbutnotlimitedtochordomas,chondrosarcomas,andosteosarcomas;

• Malignantorbenigncentralnervoussystemtumors*,+;

• Malignantorbenigntumorsofthespineoraroundthespinalcord*wheretheradiationtoleranceofthespinalcordmaybecomprisedorpreviousradiationhasoccurred;

• Hepatocellularcarcinoma*,+andcholangiocarcinoma;

• Malignantorbenignpediatricsolidtumors*inchildrenuptoage18;

• Malignantlesionsoftheheadandneck*,**,+,includingbutnotlimitedtonasopharyngeal,oropharyngeal,paranasalsinusandnasalcavitycancersaswellasbenignheadandnecktumorswithlonganticipatedsurvivorship,suchasglomustumors;

• Gastrointestinalcancers**includingpancreatic,rectalandanaltumors;

• Retroperitonealsarcomas*,+;

• ProstateCancer**,+(non-metastatic);

• BreastCancer**;

• Thoracictumors**,+includinglungcancers,esophagealcancers++,mediastinallymphomas,thymomas,sarcomas,andmesothelioma;

• Hodgkin’sLymphoma**,+;

• B-CellLymphomas+;and,

• Re-irradiation* ofpreviously treatedareaswhere the radiationdose toleranceof criticalorgansandstructureswouldbeexceeded.

Inaddition,ProtonTherapyisindicatedwhen:

• TheDoseVolumeHistogram(DVH)illustratesatleastone(1)ormorecriticalstructuresororgans that must be considered at risk in or adjacent to the treatment volume to beprotectedbytheuseofprotontherapy;

• Thereisdocumentedclinicalrationalethatdosesgenerallythoughttobeabovethelevelotherwiseattainablewithotherradiationmethodsmightimprovecontrolrates,and/or;

Page 4: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page4

• Otherradiationtherapytreatmentplans(e.g.,photonbasedtreatmentplans)wouldhaveagreaterprobabilityofcausingclinicallymeaningfulacuteandlatenormaltissuetoxicity;

• Theproposedtreatmentvolumeoran immediatelyadjacentvolumehasbeenpreviouslyirradiated, and the dose must therefore be tightly conformed to avoid exceeding thetolerancedoseofnearbynormalorgansandtissuesandprotontherapywouldresultinlessrisk;or

• There isdocumentedclinical rationale that thehigher levelsofprecisionassociatedwithprotontherapycomparedtootherradiationtreatmentsareclinicallynecessary.

Otherfactorsconsideredfavorableforcoverageforadditionalindicationsthanthoselistedaboveincludeenrollmentofthepatientinaclinicaltrialoranappropriateprospectiveclinicalregistryforplannedassessmentandpublication.Anydenialsforindicationsnotlistedinthispolicycanhavemedical documentation and adequate literature submitted in the appeals process for potentialcoverage.

LIMITATIONSFORCOVERAGE

• Protontherapyisgenerallynotindicatedforcancersthatarewidelydisseminated.

• For the treatment of primary lesions, the intent of treatment should be curative; in theretreatmentscenario,long-termdurablelocalcontrolisanacceptableintent.

• Forthetreatmentofrecurrentormetastaticlesions,thereshouldbetheexpectationatthetimeoftreatmentofalongtermbenefit(greaterthan12monthsoflifeexpectancy).

PROTONTHERAPYTREATMENTDELIVERYCPT®CODES

• 77520Protontreatmentdelivery;simple,withoutcompensation–Treatmenttoasingletreatment area utilizing a single non-tangential/oblique port, custom block, withoutcompensation.

• 77522 Proton treatment delivery; simple, with compensation – Treatment to a singletreatment area utilizing a single non-tangential/oblique port, custom block, withcompensation.

• 77523 Proton treatment delivery; intermediate – Treatment delivery to one or moretreatmentareasutilizingtwoormoreportsoroneormoretangential/obliqueports,withcustomblocksandcompensations.

• 77525Protontreatmentdelivery;complex–Treatmentdeliverytooneormoretreatmentareasutilizingtwoormoreportspertreatmentareawithmatchingorpatchingfieldsand/ormultipleisocenters,withcustomblocksandcompensators.

* AmericanSocietyofRadiationOncology(ASTRO)2017ModelPolicysupportstheuseofprotontherapy.** AmericanSocietyofRadiationOncology(ASTRO)2017ModelPolicysupportstheuseofprotontherapyundera

CoveragewithEvidenceDevelopmentmodel.+ NationalComprehensiveCancerNetwork(NCCN)Guidelinessupportstheuseofprotontherapywhenappropriate.++ NationalComprehensiveCancerNtwork(NCCN)Guidelinessupportstheuseofprotontherapywithinaclinicaltrial.

Page 5: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page5

• 77373Stereotacticbodyradiationtherapy–Treatmentdelivery,perfractionto1ormorelesions,includingimageguidance,entirecoursenottoexceed5fractions.

POLICYDISCLAIMERS

Whilethismodelcoveragepolicyforprotontherapyisanexcellentguideforcliniciansandpayersalike, it shouldnotbeusedasa comprehensive tool. As technologiesandbestpractices inourmedicalfieldchangeandevolve,sotoowillthismodelcoveragepolicy.Inaddition,clinicaldecision-makingregardingtheappropriateapplicationofprotontherapyforagivenpatientshouldremainsolelywiththepatientwithguidancefromthepatient’streatingphysician.Weacknowledgethattheinformationprovidedinthisdocumentisfocusedonthetypicalpatient’sclinicalindicationsandtherewillalwaysbepatientswhopresentwithindicationsorsymptomsnotcapturedwithinthismodelcoveragepolicy.Inthosecases,itisourexpectationthatproviderswilladheretoliteraturebasedguidelinesandprovidethepayerwithasmuchclinicalinformationaspossibletosupporttheuseofperformingaprotontherapyprocedureinanatypicalpatient.

Thispolicycoverstheprotontherapydeliveryserviceitselfandisnotintendedtocovertheentirescopeofservicesassociatedwithprotontherapy(i.e.,treatmentplanning,simulationandimaging,contouring, radiationdoseprescribing,dosimetricplanningandcalculations,andpatientspecificdoseverification).Theseservicesmayhaveseparatecodingandreportingrequirementsthatarenotaddressedinthispolicy.

AMACPT®

CPT®codes,descriptions,andotherdataonlyarecopyright2018AmericanMedicalAssociation(orsuchotherdateorpublicationofCPT®)/AllRightsReserved.

Page 6: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page6

APPENDIX1–CODINGANDDOCUMENTATIONINFORMATION

CPT®/HCPCSCodes

Italicized and/or quoted material is excerpted from the American Medical Association (AMA),CurrentProceduralTerminology(CPT®)codes.

Note:SBRTcanbedeliveredwithphotonsorprotons.OtherCPT/HCPCSradiationtherapyancillarycodesmaybeassociatedwiththetreatmentdeliverycodes

Code DescriptorPBTTreatmentDelivery77520 Protontreatmentdelivery;simple,withoutcompensation77522 Protontreatmentdelivery;simple,withcompensation77523 Protontreatmentdelivery;intermediate77525 Protontreatmentdelivery;complex

SBRTTreatmentDelivery77373 Stereotacticbodyradiationtherapy,treatmentdelivery

ICD-10-CMCodes

Itistheprovider’sresponsibilitytoselectcodescarriedouttothehighestlevelofspecificityandselectedfromtheICD-10-CMcodebookappropriatetotheyearinwhichtheserviceisrenderedfortheclaim(s)submitted.Iftheindicationsofthispolicyhavebeensatisfied,thenthefollowingICD-10-CMcodesmayberelevant

Code DescriptorOculartumorsC43.10 Malignantmelanomaofunspecifiedeyelid,includingcanthusC43.11 Malignantmelanomaofrighteyelid,includingcanthusC43.12 Malignantmelanomaoflefteyelid,includingcanthusC44.101 Unspecifiedmalignantneoplasmskin/Unspecifiedeyelid,includingcanthusC44.102 Unspecifiedmalignantneoplasmskin/righteyelid,includingcanthusC44.109 Unspecifiedmalignantneoplasmskin/lefteyelid,includingcanthusC44.111 Basalcellcarcinomaskin/unspecifiedeyelid,includingcanthusC44.112 Basalcellcarcinomaskin/righteyelid,includingcanthusC44.119 Basalcellcarcinomaskin/lefteyelid,includingcanthusC44.121 Squamouscellcarcinomaskin/unspecifiedeyelid,includingcanthusC44.122 Squamouscellcarcinomaskin/righteyelid,includingcanthusC44.129 Squamouscellcarcinomaskin/lefteyelid,includingcanthusC44.191 Othermalignantneoplasmskin/unspecifiedeyelid,includingcanthusC44.192 Othermalignantneoplasmskin/righteyelid,includingcanthusC44.199 Othermalignantneoplasmskin/lefteyelid,includingcanthusC4A.10 Merkelcellcarcinomaofunspecifiedeyelid,includingcanthusC4A.11 Merkelcellcarcinomaofrighteyelid,includingcanthus

Page 7: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page7

Code DescriptorC4A.12 Merkelcellcarcinomaoflefteyelid,includingcanthusC69.00 MalignantneoplasmofunspecifiedconjunctivaC69.01 MalignantneoplasmofrightconjunctivaC69.02 MalignantneoplasmofleftconjunctivaC69.10 MalignantneoplasmofunspecifiedcorneaC69.11 MalignantneoplasmofrightcorneaC69.12 MalignantneoplasmofleftcorneaC69.20 MalignantneoplasmofunspecifiedretinaC69.21 MalignantneoplasmofrightretinaC69.22 MalignantneoplasmofleftretinaC69.30 MalignantneoplasmofunspecifiedchoroidC69.31 MalignantneoplasmofrightchoroidC69.32 MalignantneoplasmofleftchoroidC69.40 MalignantneoplasmofunspecifiedciliarybodyC69.41 MalignantneoplasmofrightciliarybodyC69.42 MalignantneoplasmofleftciliarybodyC69.50 MalignantneoplasmofunspecifiedlacrimalglandandductC69.51 MalignantneoplasmofrightlacrimalglandandductC69.52 MalignantneoplasmofleftlacrimalglandandductC69.60 MalignantneoplasmofunspecifiedorbitC69.61 MalignantneoplasmofrightorbitC69.62 MalignantneoplasmofleftorbitC69.80 MalignantneoplasmofoverlappingsitesofunspecifiedeyeandadnexaC69.81 MalignantneoplasmofoverlappingsitesofrighteyeandadnexaC69.82 MalignantneoplasmofoverlappingsitesoflefteyeandadnexaC69.90 MalignantneoplasmofunspecifiedsiteofunspecifiedeyeC69.91 MalignantneoplasmofunspecifiedsiteofrighteyeC69.92 MalignantneoplasmofunspecifiedsiteoflefteyeD03.10 Melanomainsituofunspecifiedeyelid,includingcanthusD03.11 Melanomainsituofrighteyelid,includingcanthusD03.12 Melanomainsituoflefteyelid,includingcanthusD04.10 Carcinomainsituofskinofunspecifiedeyelid,includingcanthusD04.11 Carcinomainsituofskinofrighteyelid,includingcanthusD04.12 Carcinomainsituofskinoflefteyelid,includingcanthusD09.20 CarcinomainsituofunspecifiedeyeD09.21 CarcinomainsituofrighteyeD09.22 CarcinomainsituoflefteyeD22.10 Melanocyticneviofunspecifiedeyelid,includingcanthusD22.11 Melanocyticneviofrighteyelid,includingcanthusD22.12 Melanocyticnevioflefteyelid,includingcanthus

Page 8: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page8

Code DescriptorD23.10 Otherbenignneoplasmskin/unspecifiedeyelid,includingcanthusD23.11 Otherbenignneoplasmskin/righteyelid,includingcanthusD23.12 Otherbenignneoplasmskin/lefteyelid,includingcanthusD31.00 BenignneoplasmofunspecifiedconjunctivaD31.01 BenignneoplasmofrightconjunctivaD31.02 BenignneoplasmofleftconjunctivaD31.10 BenignneoplasmofunspecifiedcorneaD31.11 BenignneoplasmofrightcorneaD31.12 BenignneoplasmofleftcorneaD31.20 BenignneoplasmofunspecifiedretinaD31.21 BenignneoplasmofrightretinaD31.22 BenignneoplasmofleftretinaD31.30 BenignneoplasmofunspecifiedchoroidD31.31 BenignneoplasmofrightchoroidD31.32 BenignneoplasmofleftchoroidD31.40 BenignneoplasmofunspecifiedciliarybodyD31.41 BenignneoplasmofrightciliarybodyD31.42 BenignneoplasmofleftciliarybodyD31.50 BenignneoplasmofunspecifiedlacrimalglandandductD31.51 BenignneoplasmofrightlacrimalglandandductD31.52 BenignneoplasmofleftlacrimalglandandductD31.60 BenignneoplasmofunspecifiedsiteofunspecifiedorbitD31.61 BenignneoplasmofunspecifiedsiteofrightorbitD31.62 BenignneoplasmofunspecifiedsiteofleftorbitD31.90 BenignneoplasmofunspecifiedpartofunspecifiedeyeD31.91 BenignneoplasmofunspecifiedpartofrighteyeD31.92 BenignneoplasmofunspecifiedpartoflefteyeD49.81 NeoplasmofunspecifiedbehaviorofretinaandchoroidMalignantorBenignConditionsoftheBaseoftheSkullorAxialSkeletonC41.0 MalignantneoplasmofbonesofskullandfaceC41.1 MalignantneoplasmofmandibleC41.2 MalignantneoplasmofvertebralcolumnC41.3 Malignantneoplasmofribs,sternumandclavicleC41.4 Malignantneoplasmofpelvicbones,sacrumandcoccyxC41.9 Malignantneoplasmofboneandarticularcartilage,unspecifiedD16.4 BenignneoplasmofbonesofskullandfaceD16.5 BenignneoplasmoflowerjawboneD16.6 BenignneoplasmofvertebralcolumnD16.7 Benignneoplasmofribs,sternumandclavicleD16.8 Benignneoplasmofpelvicbones,sacrumandcoccyx

Page 9: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page9

Code DescriptorD16.9 Benignneoplasmofboneandarticularcartilage,unspecifiedCentralNervousSystemTumors(includingspineandspinalcord)C70.0 MalignantneoplasmofcerebralmeningesC70.1 MalignantneoplasmofspinalmeningesC70.9 Malignantneoplasmofmeninges,unspecifiedC71.0 Malignantneoplasmofcerebrum,exceptlobesandventriclesC71.1 MalignantneoplasmoffrontallobeC71.2 MalignantneoplasmoftemporallobeC71.3 MalignantneoplasmofparietallobeC71.4 MalignantneoplasmofoccipitallobeC71.5 MalignantneoplasmofcerebralventricleC71.6 MalignantneoplasmofcerebellumC71.7 MalignantneoplasmofbrainstemC71.8 MalignantneoplasmofoverlappingsitesofbrainC71.9 Malignantneoplasmofbrain,unspecifiedC72.0 MalignantneoplasmofspinalcordC72.1 MalignantneoplasmofcaudaequinaC72.20 MalignantneoplasmofunspecifiedolfactorynerveC72.21 MalignantneoplasmofrightolfactorynerveC72.22 MalignantneoplasmofleftolfactorynerveC72.30 MalignantneoplasmofunspecifiedopticnerveC72.31 MalignantneoplasmofrightopticnerveC72.32 MalignantneoplasmofleftopticnerveC72.40 MalignantneoplasmofunspecifiedacousticnerveC72.41 MalignantneoplasmofrightacousticnerveC72.42 MalignantneoplasmofleftacousticnerveC72.50 MalignantneoplasmofunspecifiedcranialnerveC72.59 MalignantneoplasmofothercranialnervesC72.9 Malignantneoplasmofcentralnervoussystem,unspecifiedC79.31 SecondarymalignantneoplasmofbrainC79.32 SecondarymalignantneoplasmofcerebralmeningesC79.40 SecondarymalignantneoplasmofunspecificpartofnervoussystemC79.49 SecondarymalignantneoplasmofotherpartsofnervoussystemD32.0 BenignneoplasmofcerebralmeningesD32.1 BenignneoplasmofspinalmeningesD32.9 Benignneoplasmofmeninges,unspecifiedD33.0 Benignneoplasmofbrain,supratentorialD33.1 Benignneoplasmofbrain,infratentorialD33.2 Benignneoplasmofbrain,unspecifiedD33.3 Benignneoplasmofcranialnerves

Page 10: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page10

Code DescriptorD33.4 BenignneoplasmofspinalcordD33.7 BenignneoplasmofothpartsofcentralnervoussystemD33.9 Benignneoplasmofcentralnervoussystem,unspecifiedD42.0 NeoplasmofuncertainbehaviorofcerebralmeningesD42.1 NeoplasmofuncertainbehaviorofspinalmeningesD42.9 Neoplasmofuncertainbehaviorofmeninges,unspecifiedD43.0 Neoplasmofuncertainbehaviorofbrain,supratentorialD43.1 Neoplasmofuncertainbehaviorofbrain,infratentorialD43.2 Neoplasmofuncertainbehaviorofbrain,unspecifiedD43.3 NeoplasmofuncertainbehaviorofcranialnervesD43.4 NeoplasmofuncertainbehaviorofspinalcordD43.8 NeoplasmofuncertainbehaviorofotherspecifiedpartsofcentralnervoussystemD43.9 Neoplasmofuncertainbehaviorofcentralnervoussystem,unspecifiedD49.6 NeoplasmofunspecifiedbehaviorofbrainHepatocellularCarcinomaC22.0 LivercellcarcinomaC22.1 IntrahepaticbileductcarcinomaC22.2 HepatoblastomaC22.3 AngiosarcomaofliverC22.4 OthersarcomasofliverC22.7 OtherspecifiedcarcinomasofliverC22.8 Malignantneoplasmofliver,primary,unspecifiedastotypeC22.9 Malignantneoplasmofliver,notspecifiedasprimaryorsecC78.7 SecondarymalignantneoplasmofliverandintrahepaticbileductC7B.02 SecondarycarcinoidtumorsofliverD01.5 Carcinomainsituofliver,gallbladderandbileductsD13.4 BenignneoplasmofliverD13.5 BenignneoplasmofextrahepaticbileductsD37.6 Neoplasmofuncertainbehaviorofliver,gallbladder&bileductHeadandNeckTumorsC00.0 MalignantneoplasmofexternalupperlipC00.1 MalignantneoplasmofexternallowerlipC00.2 Malignantneoplasmofexternallip,unspecifiedC00.3 Malignantneoplasmofupperlip,inneraspectC00.4 Malignantneoplasmoflowerlip,inneraspectC00.5 Malignantneoplasmoflip,unspecified,inneraspectC00.6 Malignantneoplasmofcommissureoflip,unspecifiedC00.8 MalignantneoplasmofoverlappingsitesoflipC00.9 Malignantneoplasmoflip,unspecifiedC01 Malignantneoplasmofbaseoftongue

Page 11: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page11

Code DescriptorC02.0 MalignantneoplasmofdorsalsurfaceoftongueC02.1 MalignantneoplasmofborderoftongueC02.2 MalignantneoplasmofventralsurfaceoftongueC02.3 Malignantneoplasmofanteriortwo-thirdsoftongue,partunspecifiedC02.4 MalignantneoplasmoflingualtonsilC02.8 MalignantneoplasmofoverlappingsitesoftongueC02.9 Malignantneoplasmoftongue,unspecifiedC03.0 MalignantneoplasmofuppergumC03.1 MalignantneoplasmoflowergumC03.9 Malignantneoplasmofgum,unspecifiedC04.0 MalignantneoplasmofanteriorfloorofmouthC04.1 MalignantneoplasmoflateralfloorofmouthC04.8 MalignantneoplasmofoverlappingsitesoffloorofmouthC04.9 Malignantneoplasmoffloorofmouth,unspecifiedC05.0 MalignantneoplasmofhardpalateC05.1 MalignantneoplasmofsoftpalateC05.2 MalignantneoplasmofuvulaC05.8 MalignantneoplasmofoverlappingsitesofpalateC05.9 Malignantneoplasmofpalate,unspecifiedC06.0 MalignantneoplasmofcheekmucosaC06.1 MalignantneoplasmofvestibuleofmouthC06.2 MalignantneoplasmofretromolarareaC06.80 MalignantneoplasmofoverlappingsitesofunspecifiedpartsofmouthC06.89 MalignantneoplasmofoverlappingsitesofotherpartsmouthC06.9 Malignantneoplasmofmouth,unspecifiedC07 MalignantneoplasmofparotidglandC08.0 MalignantneoplasmofsubmandibularglandC08.1 MalignantneoplasmofsublingualglandC08.9 Malignantneoplasmofmajorsalivarygland,unspecifiedC09.0 MalignantneoplasmoftonsillarfossaC09.1 Malignantneoplasmoftonsillarpillar(anterior)(posterior)C09.8 MalignantneoplasmofoverlappingsitesoftonsilC09.9 Malignantneoplasmoftonsil,unspecifiedC10.0 MalignantneoplasmofvalleculaC10.1 MalignantneoplasmofanteriorsurfaceofepiglottisC10.2 MalignantneoplasmoflateralwalloforopharynxC10.3 MalignantneoplasmofposteriorwalloforopharynxC10.4 MalignantneoplasmofbranchialcleftC10.8 MalignantneoplasmofoverlappingsitesoforopharynxC10.9 Malignantneoplasmoforopharynx,unspecified

Page 12: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page12

Code DescriptorC11.0 MalignantneoplasmofsuperiorwallofnasopharynxC11.1 MalignantneoplasmofposteriorwallofnasopharynxC11.2 MalignantneoplasmoflateralwallofnasopharynxC11.3 MalignantneoplasmofanteriorwallofnasopharynxC11.8 MalignantneoplasmofoverlappingsitesofnasopharynxC11.9 Malignantneoplasmofnasopharynx,unspecifiedC12 MalignantneoplasmofpyriformsinusC13.0 MalignantneoplasmofpostcricoidregionC13.1 Malignantneoplasmofaryepiglotticfold,hypopharyngealaspectC13.2 MalignantneoplasmofposteriorwallofhypopharynxC13.8 MalignantneoplasmofoverlappingsitesofhypopharynxC13.9 Malignantneoplasmofhypopharynx,unspecifiedC14.0 Malignantneoplasmofpharynx,unspecifiedC14.2 MalignantneoplasmofWaldeyer’sringC14.8 Malignantneoplasmofoverlappingsitesoflip,oralcavityandpharynxC30.0 MalignantneoplasmofnasalcavityC30.1 MalignantneoplasmofmiddleearC31.0 MalignantneoplasmofmaxillarysinusC31.1 MalignantneoplasmofethmoidalsinusC31.2 MalignantneoplasmoffrontalsinusC31.3 MalignantneoplasmofsphenoidsinusC31.8 MalignantneoplasmofoverlappingsitesofaccessorysinusesC31.9 Malignantneoplasmofaccessorysinus,unspecifiedC32.0 MalignantneoplasmofglottisC32.1 MalignantneoplasmofsupraglottisC32.2 MalignantneoplasmofsubglottisC32.3 MalignantneoplasmoflaryngealcartilageC32.8 MalignantneoplasmofoverlappingsitesoflarynxC32.9 Malignantneoplasmoflarynx,unspecifiedC43.0 MalignantmelanomaoflipC43.20 MalignantmelanomaofunspecifiedearandexternalauricularcanalC43.21 MalignantmelanomaofrightearandexternalauricularcanalC43.22 MalignantmelanomaofleftearandexternalauricularcanalC43.30 MalignantmelanomaofunspecifiedpartoffaceC43.31 MalignantmelanomaofnoseC43.39 MalignantmelanomaofotherpartsoffaceC43.4 MalignantmelanomaofscalpandneckC44.00 UnspecifiedmalignantneoplasmofskinoflipC44.01 BasalcellcarcinomaofskinoflipC44.02 Squamouscellcarcinomaofskinoflip

Page 13: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page13

Code DescriptorC44.09 OtherspecifiedmalignantneoplasmofskinoflipC44.201 Unspecifiedmalignantneoplasmskin/UnspecifiedearandexternalauricularcanalC44.202 Unspecifiedmalignantneoplasmskin/rightearandexternalauricularcanalC44.209 Unspecifiedmalignantneoplasmskin/leftearandexternalauricularcanalC44.211 Basalcellcarcinomaskin/unspecifiedearandexternalauricularcanalC44.212 Basalcellcarcinomaskin/rearandexternalauricularcanalC44.219 Basalcellcarcinomaskin/leftearandexternalauricularcanalC44.221 Squamouscellcarcinomaskin/unspecifiedearandexternalauricularcanalC44.222 Squamouscellcarcinomaskin/rearandexternalauricularcanalC44.229 Squamouscellcarcinomaskin/leftearandexternalauricularcanalC44.291 Othermalignantneoplasmskin/unspecifiedearandexternalauricularcanalC44.292 Othermalignantneoplasmskin/rightearandexternalauricularcanalC44.299 Othermalignantneoplasmskin/leftearandexternalauricularcanalC44.300 UnspecifiedmalignantneoplasmofskinofunspecifiedpartoffaceC44.301 UnspecifiedmalignantneoplasmofskinofnoseC44.309 UnspecifiedmalignantneoplasmofskinofotherpartsoffaceC44.310 BasalcellcarcinomaofskinofunspecifiedpartsoffaceC44.311 BasalcellcarcinomaofskinofnoseC44.319 BasalcellcarcinomaofskinofotherpartsoffaceC44.320 SquamouscellcarcinomaofskinofunspecifiedpartsoffaceC44.321 SquamouscellcarcinomaofskinofnoseC44.329 SquamouscellcarcinomaofskinofotherpartsoffaceC44.390 OthermalignantneoplasmofskinofunspecifiedpartsoffaceC44.391 OtherspecifiedmalignantneoplasmofskinofnoseC44.399 OthermalignantneoplasmofskinofotherpartsoffaceC44.40 UnspecifiedmalignantneoplasmofskinofscalpandneckC44.41 BasalcellcarcinomaofskinofscalpandneckC44.42 SquamouscellcarcinomaofskinofscalpandneckC44.49 OtherspecifiedmalignantneoplasmofskinofscalpandneckC46.2 Kaposi’ssarcomaofpalateC47.0 Malignantneoplasmofperipheralnervesofhead,faceandneckC49.0 Malignantneoplasmofconnectiveandsofttissueofhead,faceandneckC4A.0 MerkelcellcarcinomaoflipC4A.20 MerkelcellcarcinomaofunspecifiedearandexternalauriccanalC4A.21 MerkelcellcarcinomaofrightearandexternalauriccanalC4A.22 MerkelcellcarcinomaofleftearandexternalauriccanalC4A.30 MerkelcellcarcinomaofunspecifiedpartoffaceC4A.31 MerkelcellcarcinomaofnoseC4A.39 MerkelcellcarcinomaofotherpartsoffaceC4A.4 Merkelcellcarcinomaofscalpandneck

Page 14: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page14

Code DescriptorC76.0 Malignantneoplasmofhead,faceandneckC77.0 Secandunspecifiedmalignantneoplasmofnodesofhead,faceandneckD00.00 Carcinomainsituoforalcavity,unspecifiedsiteD00.01 CarcinomainsituoflabialmucosaandvermilionborderD00.02 CarcinomainsituofbuccalmucosaD00.03 CarcinomainsituofgingivaandedentulousalveolarridgeD00.04 CarcinomainsituofsoftpalateD00.05 CarcinomainsituofhardpalateD00.06 CarcinomainsituoffloorofmouthD00.07 CarcinomainsituoftongueD02.0 CarcinomainsituoflarynxD03.0 MelanomainsituoflipD03.20 MelanomainsituofunspecifiedearandexternalauricularcanalD03.21 MelanomainsituofrightearandexternalauricularcanalD03.22 MelanomainsituofleftearandexternalauricularcanalD03.30 MelanomainsituofunspecifiedpartoffaceD03.39 MelanomainsituofotherpartsoffaceD03.4 MelanomainsituofscalpandneckD04.0 CarcinomainsituofskinoflipD04.20 CarcinomainsituskinofunspecifiedearandexternalauricularcanalD04.21 CarcinomainsituskinofrightearandexternalauricularcanalD04.22 CarcinomainsituskinofleftearandexternalauricularcanalD04.30 CarcinomainsituofskinofunspecifiedpartoffaceD04.39 CarcinomainsituofskinofotherpartsoffaceD04.4 CarcinomainsituofskinofscalpandneckD10.0 BenignneoplasmoflipD10.1 BenignneoplasmoftongueD10.2 BenignneoplasmoffloorofmouthD10.30 BenignneoplasmofunspecifiedpartofmouthD10.39 BenignneoplasmofotherpartsofmouthD10.4 BenignneoplasmoftonsilD10.5 BenignneoplasmofotherpartsoforopharynxD10.6 BenignneoplasmofnasopharynxD10.7 BenignneoplasmofhypopharynxD10.9 Benignneoplasmofpharynx,unspecifiedD11.0 BenignneoplasmofparotidglandD11.7 BenignneoplasmofothermajorsalivaryglandsD11.9 Benignneoplasmofmajorsalivarygland,unspecifiedD14.0 Benignneoplasmofmidear,nasalcavityandaccessorysinusesD21.0 Benignneoplasmofconnective/softtissueofhead,faceandneck

Page 15: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page15

Code DescriptorD22.20 MelanocyticneviofunspecifiedearandexternalauricularcanalD22.21 MelanocyticneviofrightearandexternalauricularcanalD22.22 MelanocyticneviofleftearandexternalauricularcanalD22.30 MelanocyticneviofunspecifiedpartoffaceD22.39 MelanocyticneviofotherpartsoffaceD22.4 MelanocyticneviofscalpandneckD23.0 OtherbenignneoplasmofskinoflipD23.20 Otherbenignneoplasmskin/unspecifiedearandexternalauriccanalD23.21 Otherbenignneoplasmskin/rightearandexternalauriccanalD23.22 Otherbenignneoplasmskin/leftearandexternalauriccanalD23.30 OtherbenignneoplasmofskinofunspecifiedpartoffaceD23.39 OtherbenignneoplasmofskinofOtherpartsoffaceD23.4 OtherbenignneoplasmofskinofscalpandneckD37.01 NeoplasmofuncertainbehavioroflipD37.02 NeoplasmofuncertainbehavioroftongueD37.030 NeoplasmofuncertainbehavioroftheparotidsalivaryglandD37.031 NeoplasmofuncertainbehaviorofthesublingualsalivaryglandD37.032 NeoplasmofuncertainbehaviorofthesubmandibularsalivaryglandD37.039 Neoplasmofuncertainbehaviorofthemajorsalivarygland,unspecifiedD37.04 NeoplasmofuncertainbehavioroftheminorsalivaryglandsD37.05 NeoplasmofuncertainbehaviorofpharynxD37.09 NeoplasmofuncertainbehaviorofsitesoftheoralcavityGastrointestinalCancersC16.1 MalignantneoplasmoffundusofstomachC16.2 MalignantneoplasmofbodyofstomachC16.3 MalignantneoplasmofpyloricantrumC16.4 MalignantneoplasmofpylorusC16.5 Malignantneoplasmoflessercurvatureofstomach,unspecifiedC16.6 Malignantneoplasmofgreatercurvatureofstomach,unspecifiedC16.8 MalignantneoplasmofoverlappingsitesofstomachC16.9 Malignantneoplasmofstomach,unspecifiedC17.0 MalignantneoplasmofduodenumC17.1 MalignantneoplasmofjejunumC17.2 MalignantneoplasmofileumC17.3 Meckel’sdiverticulum,malignantC17.8 MalignantneoplasmofoverlappingsitesofsmallintestineC17.9 Malignantneoplasmofsmallintestine,unspecifiedC18.0 MalignantneoplasmofcecumC18.1 MalignantneoplasmofappendixC18.2 Malignantneoplasmofascendingcolon

Page 16: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page16

Code DescriptorC18.3 MalignantneoplasmofhepaticflexureC18.4 MalignantneoplasmoftransversecolonC18.5 MalignantneoplasmofsplenicflexureC18.6 MalignantneoplasmofdescendingcolonC18.7 MalignantneoplasmofsigmoidcolonC18.8 MalignantneoplasmofoverlappingsitesofcolonC18.9 Malignantneoplasmofcolon,unspecifiedC19 MalignantneoplasmofrectosigmoidjunctionC20 MalignantneoplasmofrectumC21.0 Malignantneoplasmofanus,unspecifiedC21.1 MalignantneoplasmofanalcanalC21.2 MalignantneoplasmofcloacogeniczoneC21.8 Malignantneoplasmofoverlappingsitesofrectum,anusandanalcanalC23. MalignantneoplasmofgallbladderC24.0 MalignantneoplasmofextrahepaticbileductC24.1 MalignantneoplasmofampullaofVaterC24.8 MalignantneoplasmofoverlappingsitesofbiliarytractC24.9 Malignantneoplasmofbiliarytract,unspecifiedC25.0 MalignantneoplasmofheadofpancreasC25.1 MalignantneoplasmofbodyofpancreasC25.2 MalignantneoplasmoftailofpancreasC25.3 MalignantneoplasmofpancreaticductC25.4 MalignantneoplasmofendocrinepancreasC25.7 MalignantneoplasmofotherpartsofpancreasC25.8 MalignantneoplasmofoverlappingsitesofpancreasC25.9 Malignantneoplasmofpancreas,unspecifiedC26.0 Malignantneoplasmofintestinaltract,partunspecifiedC26.1 MalignantneoplasmofspleenC26.9 Malignantneoplasmofill-definedsiteswithinthedigestivesystemC43.51 MalignantmelanomaofanalskinC44.500 UnspecifiedmalignantneoplasmofanalskinC44.510 BasalcellcarcinomaofanalskinC44.520 SquamouscellcarcinomaofanalskinC44.590 OtherspecifiedmalignantneoplasmofanalskinC45.1 MesotheliomaofperitoneumC46.4 Kaposi’ssarcomaofgastrointestinalsitesC47.4 MalignantneoplasmofperipheralnervesofabdomenC49.4 MalignantneoplasmofconnectiveandsofttissueofabdomenC4A.51 MerkelcellcarcinomaofanalskinC76.2 Malignantneoplasmofabdomen

Page 17: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page17

Code DescriptorC77.2 Secondaryandunspecifiedmalignantneoplasmofintra-abdominalnodesC78.4 SecondarymalignantneoplasmofsmallintestineC78.5 SecondarymalignantneoplasmoflargeintestineandrectumC78.80 SecondarymalignantneoplasmofunspecifieddigestiveorganC78.89 SecondarymalignantneoplasmofotherdigestiveorgansC7A.00 MalignantcarcinoidtumorofunspecifiedsiteC7A.010 MalignantcarcinoidtumoroftheduodenumC7A.011 MalignantcarcinoidtumorofthejejunumC7A.012 MalignantcarcinoidtumoroftheileumC7A.019 Malignantcarcinoidtumorofthesmallintestine,unspecifiedportionC7A.020 MalignantcarcinoidtumoroftheappendixC7A.021 MalignantcarcinoidtumorofthececumC7A.022 MalignantcarcinoidtumoroftheascendingcolonC7A.023 MalignantcarcinoidtumorofthetransversecolonC7A.024 MalignantcarcinoidtumorofthedescendingcolonC7A.025 MalignantcarcinoidtumorofthesigmoidcolonC7A.026 MalignantcarcinoidtumoroftherectumC7A.029 Malignantcarcinoidtumorofthelargeintestine,unspecifiedportionC7A.092 MalignantcarcinoidtumorofthestomachC7A.093 MalignantcarcinoidtumorofthekidneyC7A.094 Malignantcarcinoidtumoroftheforegut,unspecifiedC7A.095 Malignantcarcinoidtumorofthemidgut,unspecifiedC7A.096 Malignantcarcinoidtumorofthehindgut,unspecifiedD00.2 CarcinomainsituofstomachD01.0 CarcinomainsituofcolonD01.1 CarcinomainsituofrectosigmoidjunctionD01.2 CarcinomainsituofrectumD01.3 CarcinomainsituofanusandanalcanalD01.40 CarcinomainsituofunspecifiedpartofintestineD01.49 CarcinomainsituofotherpartsofintestineD01.7 CarcinomainsituofotherspecifieddigestiveorgansD01.9 Carcinomainsituofdigestiveorgan,unspecifiedD03.51 MelanomainsituofanalskinD12.0 BenignneoplasmofcecumD12.1 BenignneoplasmofappendixD12.2 BenignneoplasmofascendingcolonD12.3 BenignneoplasmoftransversecolonD12.4 BenignneoplasmofdescendingcolonD12.5 BenignneoplasmofsigmoidcolonD12.6 Benignneoplasmofcolon,unspecified

Page 18: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page18

Code DescriptorD12.7 BenignneoplasmofrectosigmoidjunctionD12.8 BenignneoplasmofrectumD12.9 BenignneoplasmofanusandanalcanalD13.1 BenignneoplasmofstomachD13.2 BenignneoplasmofduodenumD13.30 BenignneoplasmofunspecifiedpartofsmallintestineD13.39 BenignneoplasmofotherpartsofsmallintestineD13.6 BenignneoplasmofpancreasD13.7 BenignneoplasmofendocrinepancreasD13.9 Benignneoplasmofill-definedsiteswithinthedigestivesystemD17.5 Benignlipomatousneoplasmofintra-abdominalorgansD18.03 Hemangiomaofintra-abdominalstructuresD21.4 BenignneoplasmofconnectiveandothersofttissueofabdomenD37.1 NeoplasmofuncertainbehaviorofstomachD37.2 NeoplasmofuncertainbehaviorofsmallintestineD37.3 NeoplasmofuncertainbehaviorofappendixD37.4 NeoplasmofuncertainbehaviorofcolonD37.5 NeoplasmofuncertainbehaviorofrectumD37.8 NeoplasmofuncertainbehaviorofotherdigestiveorgansD37.9 Neoplasmofuncertainbehaviorofdigestiveorgan,unspecifiedD3A.00 BenigncarcinoidtumorofunspecifiedsiteD3A.010 BenigncarcinoidtumoroftheduodenumD3A.011 BenigncarcinoidtumorofthejejunumD3A.012 BenigncarcinoidtumoroftheileumD3A.019 Benigncarcinoidtumorofthesmallintestine,unspecifiedportionD3A.020 BenigncarcinoidtumoroftheappendixD3A.021 BenigncarcinoidtumorofthececumD3A.022 BenigncarcinoidtumoroftheascendingcolonD3A.023 BenigncarcinoidtumorofthetransversecolonD3A.024 BenigncarcinoidtumorofthedescendingcolonD3A.025 BenigncarcinoidtumorofthesigmoidcolonD3A.026 BenigncarcinoidtumoroftherectumD3A.029 Benigncarcinoidtumorofthelargeintestine,unspecifiedportionD3A.092 BenigncarcinoidtumorofthestomachD3A.093 BenigncarcinoidtumorofthekidneyD3A.094 Benigncarcinoidtumoroftheforegut,unspecifiedD3A.095 Benigncarcinoidtumorofthemidgut,unspecifiedD3A.096 Benigncarcinoidtumorofthehindgut,unspecifiedRetroperitonealSarcomaC48.0 Malignantneoplasmofretroperitoneum

Page 19: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page19

Code DescriptorD20.0 BenignneoplasmofsofttissueofretroperitoneumD48.3 NeoplasmofuncertainbehaviorofretroperitoneumProstateCancerC61 MalignantneoplasmofprostateD07.5 CarcinomainsituofprostateD29.1 BenignneoplasmofprostateD40.0 NeoplasmofuncertainbehaviorofprostateBreastCancerC43.52 MalignantmelanomaofskinofbreastC44.501 UnspecifiedmalignantneoplasmofskinofbreastC44.511 BasalcellcarcinomaofskinofbreastC44.521 SquamouscellcarcinomaofskinofbreastC44.591 OtherspecifiedmalignantneoplasmofskinofbreastC4A.52 MerkelcellcarcinomaofskinofbreastC50.011 Malignantneoplasmofnippleandareola,rightfemalebreastC50.012 Malignantneoplasmofnippleandareola,leftfemalebreastC50.019 Malignantneoplasmofnippleandareola,unspecifiedfemalebreastC50.021 Malignantneoplasmofnippleandareola,rightmalebreastC50.022 Malignantneoplasmofnippleandareola,leftmalebreastC50.029 Malignantneoplasmofnippleandareola,unspecifiedmalebreastC50.111 MalignantneoplasmofcentralportionofrightfemalebreastC50.112 MalignantneoplasmofcentralportionofleftfemalebreastC50.119 MalignantneoplasmofcentralportionofunspecifiedfemalebreastC50.121 MalignantneoplasmofcentralportionofrightmalebreastC50.122 MalignantneoplasmofcentralportionofleftmalebreastC50.129 MalignantneoplasmofcentralportionofunspecifiedmalebreastC50.211 Malignantneoplasmofupper-innerquadrantofrightfemalebreastC50.212 Malignantneoplasmofupper-innerquadrantofleftfemalebreastC50.219 Malignantneoplasmofupper-innerquadrantofunspecifiedfemalebreastC50.221 Malignantneoplasmofupper-innerquadrantofrightmalebreastC50.222 Malignantneoplasmofupper-innerquadrantofleftmalebreastC50.229 Malignantneoplasmofupper-innerquadrantofunspecifiedmalebreastC50.311 Malignantneoplasmoflower-innerquadrantofrightfemalebreastC50.312 Malignantneoplasmoflower-innerquadrantofleftfemalebreastC50.319 Malignantneoplasmoflower-innerquadrantofunspecifiedfemalebreastC50.321 Malignantneoplasmoflower-innerquadrantofrightmalebreastC50.322 Malignantneoplasmoflower-innerquadrantofleftmalebreastC50.329 Malignantneoplasmoflower-innerquadrantofunspecifiedmalebreastC50.411 Malignantneoplasmofupper-outerquadrantofrightfemalebreastC50.412 Malignantneoplasmofupper-outerquadrantofleftfemalebreast

Page 20: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page20

Code DescriptorC50.419 Malignantneoplasmofupper-outerquadrantofunspecifiedfemalebreastC50.421 Malignantneoplasmofupper-outerquadrantofrightmalebreastC50.422 Malignantneoplasmofupper-outerquadrantofleftmalebreastC50.429 Malignantneoplasmofupper-outerquadrantofunspecifiedmalebreastC50.511 Malignantneoplasmoflower-outerquadrantofrightfemalebreastC50.512 Malignantneoplasmoflower-outerquadrantofleftfemalebreastC50.519 Malignantneoplasmoflower-outerquadrantofunspecifiedfemalebreastC50.521 Malignantneoplasmoflower-outerquadrantofrightmalebreastC50.522 Malignantneoplasmoflower-outerquadrantofleftmalebreastC50.529 Malignantneoplasmoflower-outerquadrantofunspecifiedmalebreastC50.611 MalignantneoplasmofaxillarytailofrightfemalebreastC50.612 MalignantneoplasmofaxillarytailofleftfemalebreastC50.619 MalignantneoplasmofaxillarytailofunspecifiedfemalebreastC50.621 MalignantneoplasmofaxillarytailofrightmalebreastC50.622 MalignantneoplasmofaxillarytailofleftmalebreastC50.629 MalignantneoplasmofaxillarytailofunspecifiedmalebreastC50.811 MalignantneoplasmofoverlappingsitesofrightfemalebreastC50.812 MalignantneoplasmofoverlappingsitesofleftfemalebreastC50.819 MalignantneoplasmofoverlappingsitesofunspecifiedfemalebreastC50.821 MalignantneoplasmofoverlappingsitesofrightmalebreastC50.822 MalignantneoplasmofoverlappingsitesofleftmalebreastC50.829 MalignantneoplasmofoverlappingsitesofunspecifiedmalebreastC50.911 MalignantneoplasmofunspecifiedsiteofrightfemalebreastC50.912 MalignantneoplasmofunspecifiedsiteofleftfemalebreastC50.919 MalignantneoplasmofunspecifiedsiteofunspecifiedfemalebreastC50.921 MalignantneoplasmofunspecifiedsiteofrightmalebreastC50.922 MalignantneoplasmofunspecifiedsiteofleftmalebreastC50.929 MalignantneoplasmofunspecifiedsiteofunspecifiedmalebreastC79.81 SecondarymalignantneoplasmofbreastD03.52 Melanomainsituofbreast(skin)(softtissue)D05.00 LobularcarcinomainsituofunspecifiedbreastD05.01 LobularcarcinomainsituofrightbreastD05.02 LobularcarcinomainsituofleftbreastD05.10 IntraductalcarcinomainsituofunspecifiedbreastD05.11 IntraductalcarcinomainsituofrightbreastD05.12 IntraductalcarcinomainsituofleftbreastD05.80 OthertypeofcarcinomainsituofunspecifiedbreastD05.81 OtherspecifiedtypeofcarcinomainsituofrightbreastD05.82 OtherspecifiedtypeofcarcinomainsituofleftbreastD05.90 UnspecifiedtypeofcarcinomainsituofUnspecifiedbreast

Page 21: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page21

Code DescriptorD05.91 UnspecifiedtypeofcarcinomainsituofrightbreastD05.92 UnspecifiedtypeofcarcinomainsituofleftbreastD24.1 BenignneoplasmofrightbreastD24.2 BenignneoplasmofleftbreastD24.9 BenignneoplasmofunspecifiedbreastD48.60 NeoplasmofuncertainbehaviorofunspecifiedbreastD48.61 NeoplasmofuncertainbehaviorofrightbreastD48.62 NeoplasmofuncertainbehaviorofleftbreastD49.3 NeoplasmofunspecifiedbehaviorofbreastThoracicTumorsC15.3 MalignantneoplasmofupperthirdofesophagusC15.4 MalignantneoplasmofmiddlethirdofesophagusC15.5 MalignantneoplasmoflowerthirdofesophagusC15.8 MalignantneoplasmofoverlappingsitesofesophagusC15.9 Malignantneoplasmofesophagus,unspecifiedC16.0 MalignantneoplasmofcardiaC33. MalignantneoplasmoftracheaC34.00 MalignantneoplasmofunspecifiedmainbronchusC34.01 MalignantneoplasmofrightmainbronchusC34.02 MalignantneoplasmofleftmainbronchusC34.10 Malignantneoplasmofupperlobe,unspecifiedbronchusorlungC34.11 Malignantneoplasmofupperlobe,rightbronchusorlungC34.12 Malignantneoplasmofupperlobe,leftbronchusorlungC34.2 Malignantneoplasmofmiddlelobe,bronchusorlungC34.30 Malignantneoplasmoflowerlobe,unspecifiedbronchusorlungC34.31 Malignantneoplasmoflowerlobe,rightbronchusorlungC34.32 Malignantneoplasmoflowerlobe,leftbronchusorlungC34.80 MalignantneoplasmofoverlappingsitesofunspecifiedbronchusandlungC34.81 MalignantneoplasmofoverlappingsitesofrightbronchusandlungC34.82 MalignantneoplasmofoverlappingsitesofleftbronchusandlungC34.90 MalignantneoplasmofunspecifiedpartofunspecifiedbronchusorlungC34.91 MalignantneoplasmofunspecifiedpartofrightbronchusorlungC34.92 MalignantneoplasmofunspecifiedpartofleftbronchusorlungC37. MalignantneoplasmofthymusC38.0 MalignantneoplasmofheartC38.1 MalignantneoplasmofanteriormediastinumC38.2 MalignantneoplasmofposteriormediastinumC38.3 Malignantneoplasmofmediastinum,partunspecifiedC38.4 MalignantneoplasmofpleuraC38.8 Malignantneoplasmofoverlappingsitesofheart,mediastinumandpleura

Page 22: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page22

Code DescriptorC39.0 Malignantneoplasmofupperrespiratorytract,partunspecifiedC39.9 Malignantneoplasmoflowerrespiratorytract,partunspecifiedC45.0 MesotheliomaofpleuraC45.2 MesotheliomaofpericardiumC46.50 Kaposi’ssarcomaofunspecifiedlungC46.51 Kaposi’ssarcomaofrightlungC46.52 Kaposi’ssarcomaofleftlungC47.3 MalignantneoplasmofperipheralnervesofthoraxC49.3 MalignantneoplasmofconnectiveandsofttissueofthoraxC76.1 MalignantneoplasmofthoraxC77.1 SecondaryandunspecifiedmalignantneoplasmofintrathoracicnodesC78.00 SecondarymalignantneoplasmofunspecifiedlungC78.01 SecondarymalignantneoplasmofrightlungC78.02 SecondarymalignantneoplasmofleftlungC78.1 SecondarymalignantneoplasmofmediastinumC78.2 SecondarymalignantneoplasmofpleuraC78.30 SecondarymalignantneoplasmofunspecifiedrespiratoryorganC78.39 SecondarymalignantneoplasmofotherrespiratoryorgansC7A.090 MalignantcarcinoidtumorofthebronchusandlungC7A.091 MalignantcarcinoidtumorofthethymusC7B.04 SecondarycarcinoidtumorsofperitoneumD00.08 CarcinomainsituofpharynxD00.1 CarcinomainsituofesophagusD02.1 CarcinomainsituoftracheaD02.20 CarcinomainsituofunspecifiedbronchusandlungD02.21 CarcinomainsituofrightbronchusandlungD02.22 CarcinomainsituofleftbronchusandlungD02.3 CarcinomainsituofotherpartsofrespiratorysystemD02.4 Carcinomainsituofrespiratorysystem,unspecifiedD13.0 BenignneoplasmofesophagusD14.1 BenignneoplasmoflarynxD14.2 BenignneoplasmoftracheaD14.30 BenignneoplasmofunspecifiedbronchusandlungD14.31 BenignneoplasmofrightbronchusandlungD14.32 BenignneoplasmofleftbronchusandlungD14.4 Benignneoplasmofrespiratorysystem,unspecifiedD15.0 BenignneoplasmofthymusD15.1 BenignneoplasmofheartD15.2 BenignneoplasmofmediastinumD15.7 Benignneoplasmofotherspecifiedintrathoracicorgans

Page 23: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page23

Code DescriptorD15.9 Benignneoplasmofintrathoracicorgan,unspecifiedD17.4 BenignlipomatousneoplasmofintrathoracicorgansD19.0 BenignneoplasmofmesothelialtissueofpleuraD21.3 BenignneoplasmofconnectiveandothersofttissueofthoraxD38.0 NeoplasmofuncertainbehavioroflarynxD38.1 Neoplasmofuncertainbehavioroftrachea,bronchusandlungD38.2 NeoplasmofuncertainbehaviorofpleuraD38.3 NeoplasmofuncertainbehaviorofmediastinumD38.4 NeoplasmofuncertainbehaviorofthymusD38.5 NeoplasmofuncertainbehaviorofotherrespiratoryorgansD38.6 Neoplasmofuncertainbehaviorofrespiratoryorgan,unspecifiedD3A.090 BenigncarcinoidtumorofthebronchusandlungD3A.091 BenigncarcinoidtumorofthethymusD49.1 NeoplasmofunspecifiedbehaviorofrespiratorysystemHodgkin’sLymphomaC81.00 NodularlymphocytepredominantHodgkinlymphoma,unspecifiedsiteC81.01 NodularlymphocytepredominantHodgkinlymph,nodesofhead,face,&neckC81.02 NodularlymphocytepredominantHodgkinlymphoma,intrathoracicnodesC81.03 NodularlymphocytepredominantHodgkinlymphoma,intra-abdominalnodesC81.04 NodularlymphocytepredominantHodgkinlymph,nodesofaxillaandupperlimb

C81.05 NodularlymphocytepredominantHodgkinlymph,nodesofinguinalregion&lowlimb

C81.06 NodularlymphocytepredominantHodgkinlymphoma,intrapelvicnodesC81.07 NodularlymphocytepredominantHodgkinlymphoma,spleenC81.08 NodularlymphocytepredominantHodgkinlymphoma,nodesmultiplesiteC81.09 NodularlymphocytepredominantHodgkinlymph,extranodal&solidorgsiteC81.10 NodularsclerosisclassicalHodgkinlymphoma,unspecifiedsiteC81.11 NodularsclerosisclassicalHodgkinlymphoma,nodesofhead,face,andneckC81.12 NodularsclerosisclassHodgkinlymphoma,intrathoracicnodesC81.13 NodularsclerosisclassHodgkinlymphoma,intra-abdominalnodesC81.14 NodularsclerosisclassHodgkinlymph,nodesofaxillaandupperlimbC81.15 NodularsclerosisclassHodgkinlymph,nodesofinguinalregionandlowlimbC81.16 NodularsclerosisclassHodgkinlymphoma,intrapelvicnodesC81.17 NodularsclerosisclassicalHodgkinlymphoma,spleenC81.18 NodularsclerosisclassHodgkinlymphoma,nodesofmultiplesitesC81.19 NodularsclerosisclassHodgkinlymph,extranodalandsolidorgansitesC81.20 MixedcellularityclassicalHodgkinlymphoma,unspecifiedsiteC81.21 MixcellularclassHodgkinlymph,nodesofhead,face,andneckC81.22 MixedcellularclassicalHodgkinlymphoma,intrathoracicnodesC81.23 MixedcellularclassicalHodgkinlymphoma,intra-abdominalnodes

Page 24: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page24

Code DescriptorC81.24 MixcellularclassHodgkinlymph,nodesofaxillaandupperlimbC81.25 MixcellularclassHodgkinlymph,nodesofinguinalregionandlowlimbC81.26 MixedcellularclassicalHodgkinlymphoma,intrapelvicnodesC81.27 MixedcellularityclassicalHodgkinlymphoma,spleenC81.28 MixedcellularclassicalHodgkinlymphoma,nodesofmultiplesitesC81.29 MixcellularclassHodgkinlymph,extranodalandsolidorgsitesC81.30 LymphocytedepletedclassicalHodgkinlymphoma,unspecifiedsiteC81.31 LymphocytedepletedclassHodgkinlymph,nodesofhead,face,&neckC81.32 LymphocytedepletedclassHodgkinlymphoma,intrathoracicnodesC81.33 LymphocytedepletedclassHodgkinlymphoma,intra-abdominalnodesC81.34 LymphocytedepletedclassHodgkinlymph,nodesofaxillaandupperlimbC81.35 LymphocytedepletedclassHodgkinlymph,nodesofinguinalregion&lowlimbC81.36 LymphocytedepletedclassHodgkinlymphoma,intrapelvicnodesC81.37 LymphocytedepletedclassicalHodgkinlymphoma,spleenC81.38 LymphocytedepletedclassHodgkinlymphoma,nodesofmultiplesitesC81.39 LymphocytedepletedclassHodgkinlymph,extranodal&solidorgsiteC81.40 Lymphocyte-richclassicalHodgkinlymphoma,unspecifiedsiteC81.41 Lymphocyte-richclassHodgkinlymph,nodesofhead,face,andneckC81.42 Lymphocyte-richclassicalHodgkinlymphoma,intrathoracicnodesC81.43 Lymphocyte-richclassicalHodgkinlymphoma,intra-abdominallymphnodesC81.44 Lymphocyte-richclassHodgkinlymph,nodesofaxillaandupperlimbC81.45 Lymphocyte-richclassHodgkinlymph,nodesofinguinalregionandlowerlimbC81.46 Lymphocyte-richclassicalHodgkinlymphoma,intrapelviclymphnodesC81.47 Lymphocyte-richclassicalHodgkinlymphoma,spleenC81.48 Lymphocyte-richclassicalHodgkinlymphoma,lymphnodesofmultiplesitesC81.49 Lymphocyte-richclassHodgkinlymph,extranodalandsolidorgansitesC81.70 OtherclassicalHodgkinlymphoma,unspecifiedsiteC81.71 OtherclassHodgkinlymphoma,nodesofhead,face,andneckC81.72 OtherclassicalHodgkinlymphoma,intrathoraciclymphnodesC81.73 OtherclassicalHodgkinlymphoma,intra-abdominallymphnodesC81.74 OtherclassHodgkinlymphoma,nodesofaxillaandupperlimbC81.75 OtherclassHodgkinlymph,nodesofinguinalregionandlowerlimbC81.76 OtherclassicalHodgkinlymphoma,intrapelviclymphnodesC81.77 OtherclassicalHodgkinlymphoma,spleenC81.78 OtherclassicalHodgkinlymphoma,lymphnodesofmultiplesitesC81.79 OtherclassHodgkinlymphoma,extranodalandsolidorgansitesC81.90 Hodgkinlymphoma,unspecified,unspecifiedsiteC81.91 Hodgkinlymphoma,unspecified,lymphnodesofhead,face,andneckC81.92 Hodgkinlymphoma,unspecified,intrathoraciclymphnodesC81.93 Hodgkinlymphoma,unspecified,intra-abdominallymphnodes

Page 25: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page25

Code DescriptorC81.94 Hodgkinlymphoma,unspecified,lymphnodesofaxillaandupperlimbC81.95 Hodgkinlymphoma,unspecified,nodesofinguinalregionandlowerlimbC81.96 Hodgkinlymphoma,unspecified,intrapelviclymphnodesC81.97 Hodgkinlymphoma,unspecified,spleenC81.98 Hodgkinlymphoma,unspecified,lymphnodesofmultiplesitesC81.99 Hodgkinlymphoma,unspecified,extranodalandsolidorgansitesB-CellLymphomasC83.00 Smallcellb-celllymphoma,unspecifiedsiteC83.01 Smallcellb-celllymphoma,nodesofhead,face,andneckC83.02 Smallcellb-celllymphoma,intrathoraciclymphnodesC83.03 Smallcellb-celllymphoma,intra-abdominallymphnodesC83.04 Smallcellb-celllymphoma,nodesofaxillaandupperlimbC83.05 Smallcellb-celllymph,nodesofinguinalregionandlowerlimbC83.06 Smallcellb-celllymphoma,intrapelviclymphnodesC83.07 Smallcellb-celllymphoma,spleenC83.08 Smallcellb-celllymphoma,lymphnodesofmultiplesitesC83.09 Smallcellb-celllymphoma,extranodalandsolidorgansitesC83.30 Diffuselargeb-celllymphoma,unspecifiedsiteC83.31 Diffuselargeb-celllymphoma,nodesofhead,face,andneckC83.32 Diffuselargeb-celllymphoma,intrathoraciclymphnodesC83.33 Diffuselargeb-celllymphoma,intra-abdominallymphnodesC83.34 Diffuselargeb-celllymph,nodesofaxillaandupperlimbC83.35 Diffuselargeb-celllymph,nodesofinguinalregionandlowerlimbC83.36 Diffuselargeb-celllymphoma,intrapelviclymphnodesC83.37 Diffuselargeb-celllymphoma,spleenC83.38 Diffuselargeb-celllymphoma,lymphnodesofmultiplesitesC83.39 Diffuselargeb-celllymphoma,extranodalandsolidorgansitesC85.10 Unspecifiedb-celllymphoma,UnspecifiedsiteC85.11 Unspecifiedb-celllymphoma,lymphnodesofhead,face,andneckC85.12 Unspecifiedb-celllymphoma,intrathoraciclymphnodesC85.13 Unspecifiedb-celllymphoma,intra-abdominallymphnodesC85.14 Unspecifiedb-celllymphoma,lymphnodesofaxillaandupperlimbC85.15 Unspecifiedb-celllymphoma,nodesofingregionandlowerlimbC85.16 Unspecifiedb-celllymphoma,intrapelviclymphnodesC85.17 Unspecifiedb-celllymphoma,spleenC85.18 Unspecifiedb-celllymphoma,lymphnodesofmultiplesitesC85.19 Unspecifiedb-celllymphoma,extranodalandsolidorgansitesC85.20 Mediastinal(thymic)largeb-celllymphoma,unspecifiedsiteC85.21 Mediastinallargeb-celllymph,nodesofhead,face,andneckC85.22 Mediastinal(thymic)largeb-celllymphoma,intrathoracicnodes

Page 26: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page26

Code DescriptorC85.23 Mediastinal(thymic)largeb-celllymphoma,intra-abdominalnodesC85.24 Mediastinallargeb-celllymph,nodesofaxillaandupperlimbC85.25 Mediastinallargeb-celllymph,nodesofinguinalregionandlowerlimbC85.26 Mediastinal(thymic)largeb-celllymphoma,intrapelvicnodesC85.27 Mediastinal(thymic)largeb-celllymphoma,spleenC85.28 Mediastinal(thymic)largeb-celllymphoma,nodesofmultiplesitesC85.29 Mediastinallargeb-celllymph,extranodalandsolidorgansitesOtherCarcinomasC40.00 MalignantneoplasmofscapulaandlongbonesofunspecifiedupperlimbC40.01 MalignantneoplasmofscapulaandlongbonesofrightupperlimbC40.02 MalignantneoplasmofscapulaandlongbonesofleftupperlimbC40.10 MalignantneoplasmofshortbonesofunspecifiedupperlimbC40.11 MalignantneoplasmofshortbonesofrightupperlimbC40.12 MalignantneoplasmofshortbonesofleftupperlimbC40.20 MalignantneoplasmoflongbonesofunspecifiedlowerlimbC40.21 MalignantneoplasmoflongbonesofrightlowerlimbC40.22 MalignantneoplasmoflongbonesofleftlowerlimbC40.30 MalignantneoplasmofshortbonesofunspecifiedlowerlimbC40.31 MalignantneoplasmofshortbonesofrightlowerlimbC40.32 Malignantneoplasmofshortbonesofleftlowerlimb

C40.80 Malignantneoplasmofoverlappingsitesofbone/articularcartilageofunspecifiedlimb

C40.81 Malignantneoplasmofoverlappingsitesofbone/articularcartilageofrightlimbC40.82 Malignantneoplasmofoverlappingsitesofbone/articularcartilageofleftlimbC40.90 MalignantneoplasmofunspecifiedbonesandarticularcartilageofunspecifiedlimbC40.91 MalignantneoplasmofunspecifiedbonesandarticularcartilageofrightlimbC40.92 MalignantneoplasmofunspecifiedbonesandarticularcartilageofleftlimbC43.59 MalignantmelanomaofotherpartoftrunkC43.60 Malignantmelanomaofunspecifiedupperlimb,includingshoulderC43.61 Malignantmelanomaofrightupperlimb,includingshoulderC43.62 Malignantmelanomaofleftupperlimb,includingshoulderC43.70 Malignantmelanomaofunspecifiedlowerlimb,includinghipC43.71 Malignantmelanomaofrightlowerlimb,includinghipC43.72 Malignantmelanomaofleftlowerlimb,includinghipC43.8 MalignantmelanomaofoverlappingsitesofskinC43.9 Malignantmelanomaofskin,unspecifiedC44.509 UnspecifiedmalignantneoplasmofskinofotherpartoftrunkC44.519 BasalcellcarcinomaofskinofotherpartoftrunkC44.529 SquamouscellcarcinomaofskinofotherpartoftrunkC44.599 Othermalignantneoplasmofskinofotherpartoftrunk

Page 27: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page27

Code DescriptorC44.601 Unspecifiedmalignantneoplasmskin/Unspecifiedupperlimb,includingshoulderC44.602 Unspecifiedmalignantneoplasmskin/rightupperlimb,includingshoulderC44.609 Unspecifiedmalignantneoplasmskin/leftupperlimb,includingshoulderC44.611 Basalcellcarcinomaskin/unspecifiedupperlimb,includingshoulderC44.612 Basalcellcarcinomaskin/rightupperlimb,includingshoulderC44.619 Basalcellcarcinomaskin/leftupperlimb,includingshoulderC44.621 Squamouscellcarcinomaskin/unspecifiedupperlimb,includingshoulderC44.622 Squamouscellcarcinomaskin/rightupperlimb,includingshoulderC44.629 Squamouscellcarcinomaskin/leftupperlimb,includingshoulderC44.691 Othermalignantneoplasmskin/unspecifiedupperlimb,includingshoulderC44.692 Othermalignantneoplasmskin/rightupperlimb,includingshoulderC44.699 Othermalignantneoplasmskin/leftupperlimb,includingshoulderC44.701 Unspecifiedmalignantneoplasmskin/Unspecifiedlowerlimb,includinghipC44.702 Unspecifiedmalignantneoplasmskin/rightlowerlimb,includinghipC44.709 Unspecifiedmalignantneoplasmskin/leftlowerlimb,includinghipC44.711 Basalcellcarcinomaskin/unspecifiedlowerlimb,includinghipC44.712 Basalcellcarcinomaskin/rightlowerlimb,includinghipC44.719 Basalcellcarcinomaskin/leftlowerlimb,includinghipC44.721 Squamouscellcarcinomaskin/unspecifiedlowerlimb,includinghipC44.722 Squamouscellcarcinomaskin/rightlowerlimb,includinghipC44.729 Squamouscellcarcinomaskin/leftlowerlimb,includinghipC44.791 Othermalignantneoplasmskin/unspecifiedlowerlimb,includinghipC44.792 Othermalignantneoplasmskin/rightlowerlimb,includinghipC44.799 Othermalignantneoplasmskin/leftlowerlimb,includinghipC44.80 UnspecifiedmalignantneoplasmofoverlappingsitesofskinC44.81 BasalcellcarcinomaofoverlappingsitesofskinC44.82 SquamouscellcarcinomaofoverlappingsitesofskinC44.89 OthermalignantneoplasmofoverlappingsitesofskinC44.90 Unspecifiedmalignantneoplasmofskin,UnspecifiedC44.91 Basalcellcarcinomaofskin,unspecifiedC44.92 Squamouscellcarcinomaofskin,unspecifiedC44.99 Otherspecifiedmalignantneoplasmofskin,unspecifiedC45.7 MesotheliomaofothersitesC45.9 Mesothelioma,unspecifiedC46.0 Kaposi’ssarcomaofskinC46.1 Kaposi’ssarcomaofsofttissueC46.3 Kaposi’ssarcomaoflymphnodesC46.7 Kaposi’ssarcomaofothersitesC46.9 Kaposi’ssarcoma,unspecified

Page 28: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page28

Code Descriptor

C47.10 Malignantneoplasmofperipheralnervesofunspecifiedupperlimb,includingshoulder

C47.11 Malignantneoplasmofperipheralnervesofrightupperlimb,includingshoulderC47.12 Malignantneoplasmofperipheralnervesofleftupperlimb,includingshoulderC47.20 Malignantneoplasmofperipheralnervesofunspecifiedlowerlimb,includinghipC47.21 Malignantneoplasmofperipheralnervesofrightlowerlimb,includinghipC47.22 Malignantneoplasmofperipheralnervesofleftlowerlimb,includinghipC47.5 MalignantneoplasmofperipheralnervesofpelvisC47.6 Malignantneoplasmofperipheralnervesoftrunk,unspecified

C47.8 Malignantneoplasmofoverlappingsitesofperipheralnervesandautonomicnervoussystem

C47.9 Malignantneoplasmofperipheralnervesandautonomicnervoussystem,unspecified

C48.1 MalignantneoplasmofspecifiedpartsofperitoneumC48.2 Malignantneoplasmofperitoneum,unspecifiedC48.8 Malignantneoplasmofoverlappingsitesofretroperitoneumandperitoneum

C49.10 Malignantneoplasmofconnectiveandsofttissueofunspecifiedupperlimb,includingshoulder

C49.11 Malignantneoplasmofconnectiveandsofttissueofrightupperlimb,includingshoulder

C49.12 Malignantneoplasmofconnectiveandsofttissueofleftupperlimb,includingshoulder

C49.20 Malignantneoplasmofconnectiveandsofttissueofunspecifiedlowlimb,includinghip

C49.21 Malignantneoplasmofconnectiveandsofttissueofrightlowlimb,includinghipC49.22 Malignantneoplasmofconnectiveandsofttissueofleftlowlimb,includinghipC49.5 MalignantneoplasmofconnectiveandsofttissueofpelvisC49.6 Malignantneoplasmofconnandsofttissueoftrunk,unspecifiedC49.8 MalignantneoplasmofoverlappingsitesofconnectiveandsofttissueC49.9 Malignantneoplasmofconnectiveandsofttissue,unspecifiedC4A.59 MerkelcellcarcinomaofotherpartoftrunkC4A.60 Merkelcellcarcinomaofunspecifiedupperlimb,includingshoulderC4A.61 Merkelcellcarcinomaofrightupperlimb,includingshoulderC4A.62 Merkelcellcarcinomaofleftupperlimb,includingshoulderC4A.70 Merkelcellcarcinomaofunspecifiedlowerlimb,includinghipC4A.71 Merkelcellcarcinomaofrightlowerlimb,includinghipC4A.72 Merkelcellcarcinomaofleftlowerlimb,includinghipC4A.8 MerkelcellcarcinomaofoverlappingsitesC4A.9 Merkelcellcarcinoma,unspecifiedC51.0 MalignantneoplasmoflabiummajusC51.1 Malignantneoplasmoflabiumminus

Page 29: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page29

Code DescriptorC51.2 MalignantneoplasmofclitorisC51.8 MalignantneoplasmofoverlappingsitesofvulvaC51.9 Malignantneoplasmofvulva,unspecifiedC52. MalignantneoplasmofvaginaC53.0 MalignantneoplasmofendocervixC53.1 MalignantneoplasmofexocervixC53.8 MalignantneoplasmofoverlappingsitesofcervixuteriC53.9 Malignantneoplasmofcervixuteri,unspecifiedC54.0 MalignantneoplasmofisthmusuteriC54.1 MalignantneoplasmofendometriumC54.2 MalignantneoplasmofmyometriumC54.3 MalignantneoplasmoffundusuteriC54.8 MalignantneoplasmofoverlappingsitesofcorpusuteriC54.9 Malignantneoplasmofcorpusuteri,unspecifiedC55. Malignantneoplasmofuterus,partunspecifiedC56.1 MalignantneoplasmofrightovaryC56.2 MalignantneoplasmofleftovaryC56.9 MalignantneoplasmofunspecifiedovaryC57.00 MalignantneoplasmofunspecifiedfallopiantubeC57.01 MalignantneoplasmofrightfallopiantubeC57.02 MalignantneoplasmofleftfallopiantubeC57.10 MalignantneoplasmofunspecifiedbroadligamentC57.11 MalignantneoplasmofrightbroadligamentC57.12 MalignantneoplasmofleftbroadligamentC57.20 MalignantneoplasmofunspecifiedroundligamentC57.21 MalignantneoplasmofrightroundligamentC57.22 MalignantneoplasmofleftroundligamentC57.3 MalignantneoplasmofparametriumC57.4 Malignantneoplasmofuterineadnexa,unspecifiedC57.7 MalignantneoplasmofotherspecifiedfemalegenitalorgansC57.8 MalignantneoplasmofoverlappingsitesoffemalegenitalorgansC57.9 Malignantneoplasmoffemalegenitalorgan,unspecifiedC58. MalignantneoplasmofplacentaC60.0 MalignantneoplasmofprepuceC60.1 MalignantneoplasmofglanspenisC60.2 MalignantneoplasmofbodyofpenisC60.8 MalignantneoplasmofoverlappingsitesofpenisC60.9 Malignantneoplasmofpenis,unspecifiedC62.00 MalignantneoplasmofunspecifiedundescendedtestisC62.01 Malignantneoplasmofundescendedrighttestis

Page 30: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page30

Code DescriptorC62.02 MalignantneoplasmofundescendedlefttestisC62.10 MalignantneoplasmofunspecifieddescendedtestisC62.11 MalignantneoplasmofdescendedrighttestisC62.12 MalignantneoplasmofdescendedlefttestisC62.90 Malignantneoplasmofunspecifiedtestis,unspecifieddescendedorundescendedC62.91 Malignantneoplasmofrighttestis,unspecifieddescendedorundescendedC62.92 Malignantneoplasmoflefttestis,unspecifieddescendedorundescendedC63.00 MalignantneoplasmofunspecifiedepididymisC63.01 MalignantneoplasmofrightepididymisC63.02 MalignantneoplasmofleftepididymisC63.10 MalignantneoplasmofunspecifiedspermaticcordC63.11 MalignantneoplasmofrightspermaticcordC63.12 MalignantneoplasmofleftspermaticcordC63.2 MalignantneoplasmofscrotumC63.7 MalignantneoplasmofotherspecifiedmalegenitalorgansC63.8 MalignantneoplasmofoverlappingsitesofmalegenitalorgansC63.9 Malignantneoplasmofmalegenitalorgan,unspecifiedC64.1 Malignantneoplasmofrightkidney,exceptrenalpelvisC64.2 Malignantneoplasmofleftkidney,exceptrenalpelvisC64.9 Malignantneoplasmofunspecifiedkidney,exceptrenalpelvisC65.1 MalignantneoplasmofrightrenalpelvisC65.2 MalignantneoplasmofleftrenalpelvisC65.9 MalignantneoplasmofunspecifiedrenalpelvisC66.1 MalignantneoplasmofrightureterC66.2 MalignantneoplasmofleftureterC66.9 MalignantneoplasmofunspecifiedureterC67.0 MalignantneoplasmoftrigoneofbladderC67.1 MalignantneoplasmofdomeofbladderC67.2 MalignantneoplasmoflateralwallofbladderC67.3 MalignantneoplasmofanteriorwallofbladderC67.4 MalignantneoplasmofposteriorwallofbladderC67.5 MalignantneoplasmofbladderneckC67.6 MalignantneoplasmofuretericorificeC67.7 MalignantneoplasmofurachusC67.8 MalignantneoplasmofoverlappingsitesofbladderC67.9 Malignantneoplasmofbladder,unspecifiedC68.0 MalignantneoplasmofurethraC68.1 MalignantneoplasmofparaurethralglandsC68.8 MalignantneoplasmofoverlappingsitesofurinaryorgansC68.9 Malignantneoplasmofurinaryorgan,unspecified

Page 31: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page31

Code DescriptorC73. MalignantneoplasmofthyroidglandC74.00 MalignantneoplasmofcortexofunspecifiedadrenalglandC74.01 MalignantneoplasmofcortexofrightadrenalglandC74.02 MalignantneoplasmofcortexofleftadrenalglandC74.10 MalignantneoplasmofmedullaofunspecifiedadrenalglandC74.11 MalignantneoplasmofmedullaofrightadrenalglandC74.12 MalignantneoplasmofmedullaofleftadrenalglandC74.90 MalignantneoplasmofunspecifiedpartofunspecifiedadrenalglandC74.91 MalignantneoplasmofunspecifiedpartofrightadrenalglandC74.92 MalignantneoplasmofunspecifiedpartofleftadrenalglandC75.0 MalignantneoplasmofparathyroidglandC75.1 MalignantneoplasmofpituitaryglandC75.2 MalignantneoplasmofcraniopharyngealductC75.3 MalignantneoplasmofpinealglandC75.4 MalignantneoplasmofcarotidbodyC75.5 MalignantneoplasmofaorticbodyandotherparagangliaC75.8 Malignantneoplasmwithpluriglandularinvolvement,unspecifiedC75.9 Malignantneoplasmofendocrinegland,unspecifiedC76.3 MalignantneoplasmofpelvisC76.40 MalignantneoplasmofunspecifiedupperlimbC76.41 MalignantneoplasmofrightupperlimbC76.42 MalignantneoplasmofleftupperlimbC76.50 MalignantneoplasmofunspecifiedlowerlimbC76.51 MalignantneoplasmofrightlowerlimbC76.52 MalignantneoplasmofleftlowerlimbC76.8 Malignantneoplasmofotherspecifiedill-definedsitesC77.3 SecandunspecifiedmalignantneoplasmofaxillaandupperlimbnodesC77.4 SecandunspecifiedmalignantneoplasmofinguinalandlowerlimbnodesC77.5 SecondaryandunspecifiedmalignantneoplasmofintrapelvicnodesC77.8 SecandunspecifiedmalignantneoplasmofnodesofmultipleregionsC77.9 Secondaryandunspecifiedmalignantneoplasmoflymphnode,unspecifiedC78.6 SecondarymalignantneoplasmofretroperitoneumandperitoneumC79.00 SecondarymalignantneoplasmofunspecifiedkidneyandrenalpelvisC79.01 SecondarymalignantneoplasmofrightkidneyandrenalpelvisC79.02 SecondarymalignantneoplasmofleftkidneyandrenalpelvisC79.10 SecondarymalignantneoplasmofunspecifiedurinaryorgansC79.11 SecondarymalignantneoplasmofbladderC79.19 SecondarymalignantneoplasmofotherurinaryorgansC79.2 SecondarymalignantneoplasmofskinC79.51 Secondarymalignantneoplasmofbone

Page 32: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page32

Code DescriptorC79.52 SecondarymalignantneoplasmofbonemarrowC79.60 SecondarymalignantneoplasmofunspecifiedovaryC79.61 SecondarymalignantneoplasmofrightovaryC79.62 SecondarymalignantneoplasmofleftovaryC79.70 SecondarymalignantneoplasmofunspecifiedadrenalglandC79.71 SecondarymalignantneoplasmofrightadrenalglandC79.72 SecondarymalignantneoplasmofleftadrenalglandC79.82 SecondarymalignantneoplasmofgenitalorgansC79.89 SecondarymalignantneoplasmofotherspecifiedsitesC79.9 SecondarymalignantneoplasmofunspecifiedsiteC7A.098 MalignantcarcinoidtumorsofothersitesC7A.1 MalignantpoorlydifferentiatedneuroendocrinetumorsC7A.8 OthermalignantneuroendocrinetumorsC7B.00 Secondarycarcinoidtumors,unspecifiedsiteC7B.01 SecondarycarcinoidtumorsofdistantlymphnodesC7B.03 SecondarycarcinoidtumorsofboneC7B.09 SecondarycarcinoidtumorsofothersitesC7B.1 SecondaryMerkelcellcarcinomaC7B.8 OthersecondaryneuroendocrinetumorsC80.0 Disseminatedmalignantneoplasm,unspecifiedC80.1 Malignant(primary)neoplasm,unspecifiedC80.2 MalignantneoplasmassociatedwithtransplantedorganC82.00 FollicularlymphomagradeI,unspecifiedsiteC82.01 FollicularlymphomagradeI,nodesofhead,face,andneckC82.02 FollicularlymphomagradeI,intrathoraciclymphnodesC82.03 FollicularlymphomagradeI,intra-abdominallymphnodesC82.04 FollicularlymphomagradeI,nodesofaxillaandupperlimbC82.05 FollicularlymphomagradeI,nodesofinguinalregionandlowerlimbC82.06 FollicularlymphomagradeI,intrapelviclymphnodesC82.07 FollicularlymphomagradeI,spleenC82.08 FollicularlymphomagradeI,lymphnodesofmultiplesitesC82.09 FollicularlymphomagradeI,extranodalandsolidorgansitesC82.10 FollicularlymphomagradeII,unspecifiedsiteC82.11 FollicularlymphomagradeII,nodesofhead,face,andneckC82.12 FollicularlymphomagradeII,intrathoraciclymphnodesC82.13 FollicularlymphomagradeII,intra-abdominallymphnodesC82.14 FollicularlymphomagradeII,nodesofaxillaandupperlimbC82.15 FollicularlymphomagradeII,nodesofinguinalregionandlowerlimbC82.16 FollicularlymphomagradeII,intrapelviclymphnodesC82.17 FollicularlymphomagradeII,spleen

Page 33: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page33

Code DescriptorC82.18 FollicularlymphomagradeII,lymphnodesofmultiplesitesC82.19 FollicularlymphomagradeII,extranodalandsolidorgansitesC82.20 FollicularlymphomagradeIII,unspecified,unspecifiedsiteC82.21 FollicularlymphgradeIII,unspecified,nodesofhead,face,andneckC82.22 FollicularlymphomagradeIII,unspecified,intrathoraciclymphnodesC82.23 FollicularlymphomagradeIII,unspecified,intra-abdominallymphnodesC82.24 FollicularlymphgradeIII,unspecified,nodesofaxillaandupperlimbC82.25 FollicularlymphgradeIII,unspecified,nodesofinguinalregionandlowlimbC82.26 FollicularlymphomagradeIII,unspecified,intrapelviclymphnodesC82.27 FollicularlymphomagradeIII,unspecified,spleenC82.28 FollicularlymphomagradeIII,unspecified,lymphnodesofmultiplesitesC82.29 FollicularlymphomagradeIII,unspecified,extranodalandsolidorgsitesC82.30 FollicularlymphomagradeIIIa,unspecifiedsiteC82.31 FollicularlymphomagradeIIIa,nodesofhead,face,andneckC82.32 FollicularlymphomagradeIIIa,intrathoraciclymphnodesC82.33 FollicularlymphomagradeIIIa,intra-abdominallymphnodesC82.34 FollicularlymphomagradeIIIa,nodesofaxillaandupperlimbC82.35 FollicularlymphomagradeIIIa,nodesofinguinalregionandlowerlimbC82.36 FollicularlymphomagradeIIIa,intrapelviclymphnodesC82.37 FollicularlymphomagradeIIIa,spleenC82.38 FollicularlymphomagradeIIIa,lymphnodesofmultiplesitesC82.39 FollicularlymphomagradeIIIa,extranodalandsolidorgansitesC82.40 FollicularlymphomagradeIIIb,unspecifiedsiteC82.41 FollicularlymphomagradeIIIb,nodesofhead,face,andneckC82.42 FollicularlymphomagradeIIIb,intrathoraciclymphnodesC82.43 FollicularlymphomagradeIIIb,intra-abdominallymphnodesC82.44 FollicularlymphomagradeIIIb,nodesofaxillaandupperlimbC82.45 FollicularlymphomagradeIIIb,nodesofinguinalregionandlowerlimbC82.46 FollicularlymphomagradeIIIb,intrapelviclymphnodesC82.47 FollicularlymphomagradeIIIb,spleenC82.48 FollicularlymphomagradeIIIb,lymphnodesofmultiplesitesC82.49 FollicularlymphomagradeIIIb,extranodalandsolidorgansitesC82.50 Diffusefolliclecenterlymphoma,unspecifiedsiteC82.51 Diffusefolliclecenterlymphoma,nodesofhead,face,andneckC82.52 Diffusefolliclecenterlymphoma,intrathoraciclymphnodesC82.53 Diffusefolliclecenterlymphoma,intra-abdominallymphnodesC82.54 Diffusefolliclecenterlymphoma,nodesofaxillaandupperlimbC82.55 Diffusefolliclecenterlymphoma,nodesofinguinalregionandlowerlimbC82.56 Diffusefolliclecenterlymphoma,intrapelviclymphnodesC82.57 Diffusefolliclecenterlymphoma,spleen

Page 34: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page34

Code DescriptorC82.58 Diffusefolliclecenterlymphoma,lymphnodesofmultiplesitesC82.59 Diffusefolliclecenterlymphoma,extranodalandsolidorgansitesC82.60 Cutaneousfolliclecenterlymphoma,unspecifiedsiteC82.61 Cutaneousfolliclecenterlymphoma,nodesofhead,face,andneckC82.62 Cutaneousfolliclecenterlymphoma,intrathoraciclymphnodesC82.63 Cutaneousfolliclecenterlymphoma,intra-abdominallymphnodesC82.64 Cutaneousfolliclecenterlymphoma,nodesofaxillaandupperlimbC82.65 Cutaneousfolliclecenterlymphoma,nodesofinguinalregionandlowerlimbC82.66 Cutaneousfolliclecenterlymphoma,intrapelviclymphnodesC82.67 Cutaneousfolliclecenterlymphoma,spleenC82.68 Cutaneousfolliclecenterlymphoma,lymphnodesofmultiplesitesC82.69 Cutaneousfolliclecenterlymphoma,extranodalandsolidorgansitesC82.80 Othertypesoffollicularlymphoma,unspecifiedsiteC82.81 Othertypesoffollicularlymphoma,nodesofhead,face,andneckC82.82 Othertypesoffollicularlymphoma,intrathoraciclymphnodesC82.83 Othertypesoffollicularlymphoma,intra-abdominallymphnodesC82.84 Othertypesoffollicularlymphoma,nodesofaxillaandupperlimbC82.85 Othertypesoffollicularlymphoma,nodesofinguinalregionandlowerlimbC82.86 Othertypesoffollicularlymphoma,intrapelviclymphnodesC82.87 Othertypesoffollicularlymphoma,spleenC82.88 Othertypesoffollicularlymphoma,lymphnodesofmultiplesitesC82.89 Othertypesoffollicularlymphoma,extranodalandsolidorgansitesC82.90 Follicularlymphoma,unspecified,unspecifiedsiteC82.91 Follicularlymphoma,unspecified,nodesofhead,face,andneckC82.92 Follicularlymphoma,unspecified,intrathoraciclymphnodesC82.93 Follicularlymphoma,unspecified,intra-abdominallymphnodesC82.94 Follicularlymphoma,unspecified,nodesofaxillaandupperlimbC82.95 Follicularlymphoma,unspecified,nodesofinguinalregionandlowerlimbC82.96 Follicularlymphoma,unspecified,intrapelviclymphnodesC82.97 Follicularlymphoma,unspecified,spleenC82.98 Follicularlymphoma,unspecified,lymphnodesofmultiplesitesC82.99 Follicularlymphoma,unspecified,extranodalandsolidorgansitesC83.10 Mantlecelllymphoma,unspecifiedsiteC83.11 Mantlecelllymphoma,lymphnodesofhead,face,andneckC83.12 Mantlecelllymphoma,intrathoraciclymphnodesC83.13 Mantlecelllymphoma,intra-abdominallymphnodesC83.14 Mantlecelllymphoma,lymphnodesofaxillaandupperlimbC83.15 Mantlecelllymphoma,nodesofinguinalregionandlowerlimbC83.16 Mantlecelllymphoma,intrapelviclymphnodesC83.17 Mantlecelllymphoma,spleen

Page 35: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page35

Code DescriptorC83.18 Mantlecelllymphoma,lymphnodesofmultiplesitesC83.19 Mantlecelllymphoma,extranodalandsolidorgansitesC83.50 Lymphoblastic(diffuse)lymphoma,unspecifiedsiteC83.51 Lymphoblasticlymphoma,nodesofhead,face,andneckC83.52 Lymphoblastic(diffuse)lymphoma,intrathoraciclymphnodesC83.53 Lymphoblastic(diffuse)lymphoma,intra-abdominallymphnodesC83.54 Lymphoblasticlymphoma,nodesofaxillaandupperlimbC83.55 Lymphoblasticlymphoma,nodesofinguinalregionandlowerlimbC83.56 Lymphoblastic(diffuse)lymphoma,intrapelviclymphnodesC83.57 Lymphoblastic(diffuse)lymphoma,spleenC83.58 Lymphoblastic(diffuse)lymphoma,lymphnodesofmultiplesitesC83.59 Lymphoblasticlymphoma,extranodalandsolidorgansitesC83.70 Burkittlymphoma,unspecifiedsiteC83.71 Burkittlymphoma,lymphnodesofhead,face,andneckC83.72 Burkittlymphoma,intrathoraciclymphnodesC83.73 Burkittlymphoma,intra-abdominallymphnodesC83.74 Burkittlymphoma,lymphnodesofaxillaandupperlimbC83.75 Burkittlymphoma,nodesofinguinalregionandlowerlimbC83.76 Burkittlymphoma,intrapelviclymphnodesC83.77 Burkittlymphoma,spleenC83.78 Burkittlymphoma,lymphnodesofmultiplesitesC83.79 Burkittlymphoma,extranodalandsolidorgansitesC83.80 Othernon-follicularlymphoma,unspecifiedsiteC83.81 Othernon-follicularlymphoma,lymphnodesofhead,face,andneckC83.82 Othernon-follicularlymphoma,intrathoraciclymphnodesC83.83 Othernon-follicularlymphoma,intra-abdominallymphnodesC83.84 Othernon-follicularlymphoma,nodesofaxillaandupperlimbC83.85 Othernon-follicularlymphoma,nodesofinguinalregionandlowerlimbC83.86 Othernon-follicularlymphoma,intrapelviclymphnodesC83.87 Othernon-follicularlymphoma,spleenC83.88 Othernon-follicularlymphoma,lymphnodesofmultiplesitesC83.89 Othernon-follicularlymphoma,extranodalandsolidorgansitesC83.90 Non-follicular(diffuse)lymphoma,unspecified,unspecifiedsiteC83.91 Non-follicularlymphoma,unspecified,nodesofhead,face,andneckC83.92 Non-follicular(diffuse)lymphoma,unspecified,intrathoraciclymphnodesC83.93 Non-follicular(diffuse)lymphoma,unspecified,intra-abdominallymphnodesC83.94 Non-follicularlymphoma,unspecified,nodesofaxillaandupperlimbC83.95 Non-follicularlymph,unspecified,nodesofinguinalregionandlowerlimbC83.96 Non-follicular(diffuse)lymphoma,unspecified,intrapelviclymphnodesC83.97 Non-follicular(diffuse)lymphoma,unspecified,spleen

Page 36: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page36

Code DescriptorC83.98 Non-follicular(diffuse)lymphoma,unspecified,lymphnodesofmultiplesitesC83.99 Non-follicularlymphoma,unspecified,extranodalandsolidorgansitesC84.00 Mycosisfungoides,unspecifiedsiteC84.01 Mycosisfungoides,lymphnodesofhead,face,andneckC84.02 Mycosisfungoides,intrathoraciclymphnodesC84.03 Mycosisfungoides,intra-abdominallymphnodesC84.04 Mycosisfungoides,lymphnodesofaxillaandupperlimbC84.05 Mycosisfungoides,nodesofinguinalregionandlowerlimbC84.06 Mycosisfungoides,intrapelviclymphnodesC84.07 Mycosisfungoides,spleenC84.08 Mycosisfungoides,lymphnodesofmultiplesitesC84.09 Mycosisfungoides,extranodalandsolidorgansitesC84.10 Sezarydisease,unspecifiedsiteC84.11 Sezarydisease,lymphnodesofhead,face,andneckC84.12 Sezarydisease,intrathoraciclymphnodesC84.13 Sezarydisease,intra-abdominallymphnodesC84.14 Sezarydisease,lymphnodesofaxillaandupperlimbC84.15 Sezarydisease,nodesofinguinalregionandlowerlimbC84.16 Sezarydisease,intrapelviclymphnodesC84.17 Sezarydisease,spleenC84.18 Sezarydisease,lymphnodesofmultiplesitesC84.19 Sezarydisease,extranodalandsolidorgansitesC84.40 Peripheralt-celllymphoma,notclassified,unspecifiedsiteC84.41 Peripheralt-celllymph,notclass,nodesofhead,face,andneckC84.42 Peripheralt-celllymphoma,notclass,intrathoracicnodesC84.43 Peripheralt-celllymphoma,notclassified,intra-abdominalnodesC84.44 Peripheralt-celllymph,notclass,nodesofaxillaandupperlimbC84.45 Peripheralt-celllymph,notclass,nodesofinguinalregionandlowlimbC84.46 Peripheralt-celllymphoma,notclassified,intrapelvicnodesC84.47 Peripheralt-celllymphoma,notclassified,spleenC84.48 Peripheralt-celllymphoma,notclassified,nodesofmultiplesitesC84.49 Peripheralt-celllymph,notclass,extranodalandsolidorgansitesC84.60 Anaplasticlargecelllymphoma,ALK-positive,unspecifiedsiteC84.61 Anaplasticlargecelllymph,ALK-positive,nodesofhead,face,andneckC84.62 Anaplasticlargecelllymphoma,ALK-positive,intrathoracicnodesC84.63 Anaplasticlargecelllymphoma,ALK-positive,intra-abdominalnodesC84.64 Anaplasticlargecelllymph,ALK-positive,nodesofaxillaandupperlimbC84.65 Anaplasticlargecelllymph,ALK-positive,nodesofinguinalregion&lowlimbC84.66 Anaplasticlargecelllymphoma,ALK-positive,intrapelvicnodesC84.67 Anaplasticlargecelllymphoma,ALK-positive,spleen

Page 37: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page37

Code DescriptorC84.68 Anaplasticlargecelllymphoma,ALK-positive,nodesofmultiplesitesC84.69 Anaplasticlargecelllymph,ALK-positive,extranodalandsolidorgsitesC84.70 Anaplasticlargecelllymphoma,ALK-negative,unspecifiedsiteC84.71 Anaplasticlargecelllymph,ALK-negative,nodesofhead,face,andneckC84.72 Anaplasticlargecelllymphoma,ALK-negative,intrathoracicnodesC84.73 Anaplasticlargecelllymphoma,ALK-negative,intra-abdominalnodesC84.74 Anaplasticlargecelllymph,ALK-negative,nodesofaxillaandupperlimbC84.75 Anaplasticlargecelllymph,ALK-negative,nodesofinguinalregion&lowlimbC84.76 Anaplasticlargecelllymphoma,ALK-negative,intrapelvicnodesC84.77 Anaplasticlargecelllymphoma,ALK-negative,spleenC84.78 Anaplasticlargecelllymphoma,ALK-negative,nodesofmultiplesitesC84.79 Anaplasticlargecelllymph,ALK-negative,extranodalandsolidorgsitesC84.90 MatureT/NK-celllymphomas,unspecified,unspecifiedsiteC84.91 MatureT/NK-celllymph,unspecified,nodesofhead,face,andneckC84.92 MatureT/NK-celllymphomas,unspecified,intrathoraciclymphnodesC84.93 MatureT/NK-celllymphomas,unspecified,intra-abdominallymphnodesC84.94 MatureT/NK-celllymph,unspecified,nodesofaxillaandupperlimbC84.95 MatureT/NK-celllymph,unspecified,nodesofinguinalregionandlowlimbC84.96 MatureT/NK-celllymphomas,unspecified,intrapelviclymphnodesC84.97 MatureT/NK-celllymphomas,unspecified,spleenC84.98 MatureT/NK-celllymphomas,unspecified,lymphnodesofmultiplesitesC84.99 MatureT/NK-celllymph,unspecified,extranodalandsolidorgansitesC84.A0 Cutaneoust-celllymphoma,unspecified,unspecifiedsiteC84.A1 Cutaneoust-celllymphoma,unspecifiednodesofhead,face,andneckC84.A2 Cutaneoust-celllymphoma,unspecified,intrathoraciclymphnodesC84.A3 Cutaneoust-celllymphoma,unspecified,intra-abdominallymphnodesC84.A4 Cutaneoust-celllymphoma,unspecified,nodesofaxillaandupperlimbC84.A5 Cutaneoust-celllymph,unspecified,nodesofinguinalregionandlowerlimbC84.A6 Cutaneoust-celllymphoma,unspecified,intrapelviclymphnodesC84.A7 Cutaneoust-celllymphoma,unspecified,spleenC84.A8 Cutaneoust-celllymphoma,unspecified,lymphnodesofmultiplesitesC84.A9 Cutaneoust-celllymphoma,unspecified,extranodalandsolidorgansitesC84.Z0 OthermatureT/NK-celllymphomas,unspecifiedsiteC84.Z1 OthermatureT/NK-celllymph,nodesofhead,face,andneckC84.Z2 OthermatureT/NK-celllymphomas,intrathoraciclymphnodesC84.Z3 OthermatureT/NK-celllymphomas,intra-abdominallymphnodesC84.Z4 OthermatureT/NK-celllymph,nodesofaxillaandupperlimbC84.Z5 OthermatureT/NK-celllymph,nodesofinguinalregionandlowerlimbC84.Z6 OthermatureT/NK-celllymphomas,intrapelviclymphnodesC84.Z7 OthermatureT/NK-celllymphomas,spleen

Page 38: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page38

Code DescriptorC84.Z8 OthermatureT/NK-celllymphomas,lymphnodesofmultiplesitesC84.Z9 OthermatureT/NK-celllymph,extranodalandsolidorgansitesC85.80 Othertypesofnon-Hodgkinlymphoma,unspecifiedsiteC85.81 Othertypesofnon-Hodgkinlymph,nodesofhead,face,andneckC85.82 Othertypesofnon-Hodgkinlymphoma,intrathoraciclymphnodesC85.83 Othertypesofnon-Hodgkinlymphoma,intra-abdominallymphnodesC85.84 Othertypesofnon-Hodgkinlymph,nodesofaxillaandupperlimbC85.85 Othertypesofnon-Hodgkinlymph,nodesofinguinalregionandlowerlimbC85.86 Othertypesofnon-Hodgkinlymphoma,intrapelviclymphnodesC85.87 Otherspecifiedtypesofnon-Hodgkinlymphoma,spleenC85.88 Othertypesofnon-Hodgkinlymphoma,lymphnodesofmultiplesitesC85.89 Othertypesofnon-Hodgkinlymph,extranodalandsolidorgansitesC85.90 Non-Hodgkinlymphoma,unspecified,unspecifiedsiteC85.91 Non-Hodgkinlymphoma,unspecified,nodesofhead,face,andneckC85.92 Non-Hodgkinlymphoma,unspecified,intrathoraciclymphnodesC85.93 Non-Hodgkinlymphoma,unspecified,intra-abdominallymphnodesC85.94 Non-Hodgkinlymphoma,unspecified,nodesofaxillaandupperlimbC85.95 Non-Hodglymphoma,unspecified,nodesofingregionandlowerlimbC85.96 Non-Hodgkinlymphoma,unspecified,intrapelviclymphnodesC85.97 Non-Hodgkinlymphoma,unspecified,spleenC85.98 Non-Hodgkinlymphoma,unspecified,lymphnodesofmultiplesitesC85.99 Non-Hodgkinlymphoma,unspecified,extranodalandsolidorgansitesC86.0 ExtranodalNK/T-celllymphoma,nasaltypeC86.1 HepatosplenicT-celllymphomaC86.2 Enteropathy-type(intestinal)T-celllymphomaC86.3 Subcutaneouspanniculitis-likeT-celllymphomaC86.4 BlasticNK-celllymphomaC86.5 AngioimmunoblasticT-celllymphomaC86.6 Primarycutaneouscd30-positiveT-cellproliferationsC88.0 WaldenstrommacroglobulinemiaC88.2 HeavychaindiseaseC88.3 Immunoproliferativesmallintestinaldisease

C88.4 Extranodalmarginalzoneb-celllymphomamucosa-associatedlymphoidtissue(MALT-lymphoma)

C88.8 OthermalignantimmunoproliferativediseasesC88.9 Malignantimmunoproliferativedisease,unspecifiedC90.00 MultiplemyelomanothavingachievedremissionC90.01 MultiplemyelomainremissionC90.02 MultiplemyelomainrelapseC90.10 Plasmacellleukemianothavingachievedremission

Page 39: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page39

Code DescriptorC90.11 PlasmacellleukemiainremissionC90.12 PlasmacellleukemiainrelapseC90.20 ExtramedullaryplasmacytomanothavingachievedremissionC90.21 ExtramedullaryplasmacytomainremissionC90.22 ExtramedullaryplasmacytomainrelapseC90.30 SolitaryplasmacytomanothavingachievedremissionC90.31 SolitaryplasmacytomainremissionC90.32 SolitaryplasmacytomainrelapseC91.00 AcutelymphoblasticleukemianothavingachievedremissionC91.01 Acutelymphoblasticleukemia,inremissionC91.02 Acutelymphoblasticleukemia,inrelapseC91.10 Chroniclymphocyticleukemiaofb-celltypenotachieveremissionC91.11 Chroniclymphocyticleukemiaofb-celltypeinremissionC91.12 Chroniclymphocyticleukemiaofb-celltypeinrelapseC91.30 Prolymphocyticleukemiaofb-celltypenotachieveremissionC91.31 Prolymphocyticleukemiaofb-celltype,inremissionC91.32 Prolymphocyticleukemiaofb-celltype,inrelapseC91.40 HairycellleukemianothavingachievedremissionC91.41 Hairycellleukemia,inremissionC91.42 Hairycellleukemia,inrelapseC91.50 Adultt-celllymphoma/leukemia(htlv-1-assoc)notachieveremissionC91.51 Adultt-celllymphoma/leukemia(htlv-1-assoc),inremissionC91.52 Adultt-celllymphoma/leukemia(htlv-1-assoc),inrelapseC91.60 Prolymphocyticleukemiaoft-celltypenotachieveremissionC91.61 Prolymphocyticleukemiaoft-celltype,inremissionC91.62 Prolymphocyticleukemiaoft-celltype,inrelapseC91.90 Lymphoidleukemia,unspecifiednothavingachievedremissionC91.91 Lymphoidleukemia,unspecified,inremissionC91.92 Lymphoidleukemia,unspecified,inrelapseC91.A0 Matureb-cellleukemiaBurkitt-typenotachieveremissionC91.A1 Matureb-cellleukemiaBurkitt-type,inremissionC91.A2 Matureb-cellleukemiaBurkitt-type,inrelapseC91.Z0 OtherlymphoidleukemianothavingachievedremissionC91.Z1 Otherlymphoidleukemia,inremissionC91.Z2 Otherlymphoidleukemia,inrelapseC92.00 Acutemyeloblasticleukemia,nothavingachievedremissionC92.01 Acutemyeloblasticleukemia,inremissionC92.02 Acutemyeloblasticleukemia,inrelapseC92.10 Chronicmyeloidleukemia,bcr/abl-positive,nothavingachievedremissionC92.11 Chronicmyeloidleukemia,bcr/abl-positive,inremission

Page 40: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page40

Code DescriptorC92.12 Chronicmyeloidleukemia,bcr/abl-positive,inrelapseC92.20 Atypicalchronicmyeloidleukemia,bcr/abl-negative,nothavingachievedremissionC92.21 Atypicalchronicmyeloidleukemia,bcr/abl-negative,inremissionC92.22 Atypicalchronicmyeloidleukemia,bcr/abl-negative,inrelapseC92.30 Myeloidsarcoma,nothavingachievedremissionC92.31 Myeloidsarcoma,inremissionC92.32 Myeloidsarcoma,inrelapseC92.40 Acutepromyelocyticleukemia,nothavingachievedremissionC92.41 Acutepromyelocyticleukemia,inremissionC92.42 Acutepromyelocyticleukemia,inrelapseC92.50 Acutemyelomonocyticleukemia,nothavingachievedremissionC92.51 Acutemyelomonocyticleukemia,inremissionC92.52 Acutemyelomonocyticleukemia,inrelapseC92.60 Acutemyeloidleukemiaw11q23-abnormalitynothavingachievedremissionC92.61 Acutemyeloidleukemiawith11q23-abnormalityinremissionC92.62 Acutemyeloidleukemiawith11q23-abnormalityinrelapseC92.90 Myeloidleukemia,unspecified,nothavingachievedremissionC92.91 Myeloidleukemia,unspecifiedinremissionC92.92 Myeloidleukemia,unspecifiedinrelapseC92.A0 Acutemyeloidleukemiawithmultilineagedysplasia,nothavingachievedremissionC92.A1 Acutemyeloidleukemiawithmultilineagedysplasia,inremissionC92.A2 Acutemyeloidleukemiawithmultilineagedysplasia,inrelapseC92.Z0 OthermyeloidleukemianothavingachievedremissionC92.Z1 Othermyeloidleukemia,inremissionC92.Z2 Othermyeloidleukemia,inrelapseC93.00 Acutemonoblastic/monocyticleukemia,nothavingachievedremissionC93.01 Acutemonoblastic/monocyticleukemia,inremissionC93.02 Acutemonoblastic/monocyticleukemia,inrelapseC93.10 ChronicmyelomonocyticleukemianothavingachievedremissionC93.11 Chronicmyelomonocyticleukemia,inremissionC93.12 Chronicmyelomonocyticleukemia,inrelapseC93.30 Juvenilemyelomonocyticleukemia,nothavingachievedremissionC93.31 Juvenilemyelomonocyticleukemia,inremissionC93.32 Juvenilemyelomonocyticleukemia,inrelapseC93.90 Monocyticleukemia,unsp,nothavingachievedremissionC93.91 Monocyticleukemia,unspecifiedinremissionC93.92 Monocyticleukemia,unspecifiedinrelapseC93.Z0 Othermonocyticleukemia,nothavingachievedremissionC93.Z1 Othermonocyticleukemia,inremissionC93.Z2 Othermonocyticleukemia,inrelapse

Page 41: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page41

Code DescriptorC94.00 Acuteerythroidleukemia,nothavingachievedremissionC94.01 Acuteerythroidleukemia,inremissionC94.02 Acuteerythroidleukemia,inrelapseC94.20 AcutemegakaryoblasticleukemianothavingachievedremissionC94.21 Acutemegakaryoblasticleukemia,inremissionC94.22 Acutemegakaryoblasticleukemia,inrelapseC94.30 MastcellleukemianothavingachievedremissionC94.31 Mastcellleukemia,inremissionC94.32 Mastcellleukemia,inrelapseC94.40 AcutepanmyelosiswithmyelofibrosisnothavingachievedremissionC94.41 Acutepanmyelosiswithmyelofibrosis,inremissionC94.42 Acutepanmyelosiswithmyelofibrosis,inrelapseC94.6 Myelodysplasticdisease,notclassifiedC94.80 OtherspecifiedleukemiasnothavingachievedremissionC94.81 Otherspecifiedleukemias,inremissionC94.82 Otherspecifiedleukemias,inrelapseC95.00 AcuteleukemiaofunspecifiedcelltypenothavingachievedremissionC95.01 Acuteleukemiaofunspecifiedcelltype,inremissionC95.02 Acuteleukemiaofunspecifiedcelltype,inrelapseC95.10 ChronicleukemiaofunspecifiedcelltypenothavingachievedremissionC95.11 Chronicleukemiaofunspecifiedcelltype,inremissionC95.12 Chronicleukemiaofunspecifiedcelltype,inrelapseC95.90 Leukemia,unspecifiednothavingachievedremissionC95.91 Leukemia,unspecified,inremissionC95.92 Leukemia,unspecified,inrelapseC96.0 Multifocalandmultisystemic(disseminated)Langerhans-cellhistiocytosisC96.2 MalignantmastcelltumorC96.4 Sarcomaofdendriticcells(accessorycells)C96.5 MultifocalandunisystemicLangerhans-cellhistiocytosisC96.6 UnifocalLangerhans-cellhistiocytosisC96.9 Malignantneoplasmoflymphoid,hematopoieticandrelatedtissue,unspecifiedC96.A HistiocyticsarcomaC96.Z Otherspecifiedmalignantneoplasmsoflymphoid,hematopoieticandrelatedtissueD03.59 MelanomainsituofotherpartoftrunkD03.60 Melanomainsituofunspecifiedupperlimb,includingshoulderD03.61 Melanomainsituofrightupperlimb,includingshoulderD03.62 Melanomainsituofleftupperlimb,includingshoulderD03.70 Melanomainsituofunspecifiedlowerlimb,includinghipD03.71 Melanomainsituofrightlowerlimb,includinghipD03.72 Melanomainsituofleftlowerlimb,includinghip

Page 42: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page42

Code DescriptorD03.8 MelanomainsituofothersitesD03.9 Melanomainsitu,unspecifiedD04.5 CarcinomainsituofskinoftrunkD04.60 Carcinomainsituskinofunspecifiedupperlimb,includingshoulderD04.61 Carcinomainsituskinofrightupperlimb,includingshoulderD04.62 Carcinomainsituskinofleftupperlimb,includingshoulderD04.70 Carcinomainsituofskinofunsplowerlimb,includinghipD04.71 Carcinomainsituofskinofrightlowerlimb,includinghipD04.72 Carcinomainsituofskinofleftlowerlimb,includinghipD04.8 CarcinomainsituofskinofothersitesD04.9 Carcinomainsituofskin,unspecifiedD06.0 CarcinomainsituofendocervixD06.1 CarcinomainsituofexocervixD06.7 CarcinomainsituofotherpartsofcervixD06.9 Carcinomainsituofcervix,unspecifiedD07.0 CarcinomainsituofendometriumD07.1 CarcinomainsituofvulvaD07.2 CarcinomainsituofvaginaD07.30 CarcinomainsituofunspecifiedfemalegenitalorgansD07.39 CarcinomainsituofotherfemalegenitalorgansD07.4 CarcinomainsituofpenisD07.60 CarcinomainsituofunspecifiedmalegenitalorgansD07.61 CarcinomainsituofscrotumD07.69 CarcinomainsituofothermalegenitalorgansD09.0 CarcinomainsituofbladderD09.10 CarcinomainsituofunspecifiedurinaryorganD09.19 CarcinomainsituofotherurinaryorgansD09.3 CarcinomainsituofthyroidandotherendocrineglandsD09.8 CarcinomainsituofotherspecifiedsitesD09.9 Carcinomainsitu,unspecifiedD16.00 BenignneoplasmofscapulaandlongbonesofunspecifiedupperlimbD16.01 BenignneoplasmofscapulaandlongbonesofrightupperlimbD16.02 BenignneoplasmofscapulaandlongbonesofleftupperlimbD16.10 BenignneoplasmofshortbonesofunspecifiedupperlimbD16.11 BenignneoplasmofshortbonesofrightupperlimbD16.12 BenignneoplasmofshortbonesofleftupperlimbD16.20 BenignneoplasmoflongbonesofunspecifiedlowerlimbD16.21 BenignneoplasmoflongbonesofrightlowerlimbD16.22 BenignneoplasmoflongbonesofleftlowerlimbD16.30 Benignneoplasmofshortbonesofunspecifiedlowerlimb

Page 43: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page43

Code DescriptorD16.31 BenignneoplasmofshortbonesofrightlowerlimbD16.32 BenignneoplasmofshortbonesofleftlowerlimbD17.0 Benignlipomatousneoplasmofskin,subcutaneoustissueofhead,faceandneckD17.1 Benignlipomatousneoplasmofskin,subcutaneoustissueoftrunkD17.20 Benignlipomatousneoplasmofskin,subcutaneoustissueofunspecifiedlimbD17.21 Benignlipomatousneoplasmofskin,subcutaneoustissueofrightarmD17.22 Benignlipomatousneoplasmofskin,subcutaneoustissueofleftarmD17.23 Benignlipomatousneoplasmofskin,subcutaneoustissueofrightlegD17.24 Benignlipomatousneoplasmofskin,subcutaneoustissueofleftlegD17.30 Benignlipomatousneoplasmofskin,subcutaneoustissueofunspecifiedsitesD17.39 Benignlipomatousneoplasmofskin,subcutaneoustissueofsitesD17.6 BenignlipomatousneoplasmofspermaticcordD17.71 BenignlipomatousneoplasmofkidneyD17.72 BenignlipomatousneoplasmofothergenitourinaryorganD17.79 BenignlipomatousneoplasmofothersitesD17.9 Benignlipomatousneoplasm,unspecifiedD18.00 HemangiomaunspecifiedsiteD18.01 HemangiomaofskinandsubcutaneoustissueD18.02 HemangiomaofintracranialstructuresD18.09 HemangiomaofothersitesD18.1 Lymphangioma,anysiteD19.1 BenignneoplasmofmesothelialtissueofperitoneumD19.7 BenignneoplasmofmesothelialtissueofothersitesD19.9 Benignneoplasmofmesothelialtissue,unspecifiedD20.1 Benignneoplasmofsofttissueofperitoneum

D21.10 Benignneoplasmofconnective/softtissueofunspecifiedupperlimb,includingshoulder

D21.11 Benignneoplasmofconnective/softtissueofrightupperlimb,includingshoulderD21.12 Benignneoplasmofconnective/softtissueofleftupperlimb,includingshoulderD21.20 Benignneoplasmofconnective/softtissueofunspecifiedlowerlimb,includinghipD21.21 Benignneoplasmofconnective/softtissueofrightlowerlimb,includinghipD21.22 Benignneoplasmofconnective/softtissueofleftlowerlimb,includinghipD21.5 BenignneoplasmofconnectiveandothersofttissueofpelvisD21.6 Benignneoplasmofconnective/softtissueoftrunk,unspecifiedD21.9 Benignneoplasmofconnectiveandothersofttissue,unspecifiedD22.0 MelanocyticnevioflipD22.5 MelanocyticnevioftrunkD22.60 Melanocyticneviofunspecifiedupperlimb,includingshoulderD22.61 Melanocyticneviofrightupperlimb,includingshoulderD22.62 Melanocyticneviofleftupperlimb,includingshoulder

Page 44: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page44

Code DescriptorD22.70 Melanocyticneviofunspecifiedlowerlimb,includinghipD22.71 Melanocyticneviofrightlowerlimb,includinghipD22.72 Melanocyticneviofleftlowerlimb,includinghipD22.9 Melanocyticnevi,unspecifiedD23.5 OtherbenignneoplasmofskinoftrunkD23.60 Otherbenignneoplasmskin/unspecifiedupperlimb,includingshoulderD23.61 Otherbenignneoplasmskin/rightupperlimb,includingshoulderD23.62 Otherbenignneoplasmskin/leftupperlimb,includingshoulderD23.70 Otherbenignneoplasmskin/unspecifiedlowerlimb,includinghipD23.71 Otherbenignneoplasmskin/rightlowerlimb,includinghipD23.72 Otherbenignneoplasmskin/leftlowerlimb,includinghipD23.9 Otherbenignneoplasmofskin,unspecifiedD25.0 SubmucousleiomyomaofuterusD25.1 IntramuralleiomyomaofuterusD25.2 SubserosalleiomyomaofuterusD25.9 Leiomyomaofuterus,unspecifiedD26.0 OtherbenignneoplasmofcervixuteriD26.1 OtherbenignneoplasmofcorpusuteriD26.7 OtherbenignneoplasmofOtherpartsofuterusD26.9 Otherbenignneoplasmofuterus,unspecifiedD27.0 BenignneoplasmofrightovaryD27.1 BenignneoplasmofleftovaryD27.9 BenignneoplasmofunspecifiedovaryD28.0 BenignneoplasmofvulvaD28.1 BenignneoplasmofvaginaD28.2 BenignneoplasmofuterinetubesandligamentsD28.7 BenignneoplasmofotherspecifiedfemalegenitalorgansD28.9 Benignneoplasmoffemalegenitalorgan,unspecifiedD29.0 BenignneoplasmofpenisD29.20 BenignneoplasmofunspecifiedtestisD29.21 BenignneoplasmofrighttestisD29.22 BenignneoplasmoflefttestisD29.30 BenignneoplasmofunspecifiedepididymisD29.31 BenignneoplasmofrightepididymisD29.32 BenignneoplasmofleftepididymisD29.4 BenignneoplasmofscrotumD29.8 BenignneoplasmofotherspecifiedmalegenitalorgansD29.9 Benignneoplasmofmalegenitalorgan,unspecifiedD30.00 BenignneoplasmofunspecifiedkidneyD30.01 Benignneoplasmofrightkidney

Page 45: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page45

Code DescriptorD30.02 BenignneoplasmofleftkidneyD30.10 BenignneoplasmofunspecifiedrenalpelvisD30.11 BenignneoplasmofrightrenalpelvisD30.12 BenignneoplasmofleftrenalpelvisD30.20 BenignneoplasmofunspecifiedureterD30.21 BenignneoplasmofrightureterD30.22 BenignneoplasmofleftureterD30.3 BenignneoplasmofbladderD30.4 BenignneoplasmofurethraD30.8 BenignneoplasmofotherspecifiedurinaryorgansD30.9 Benignneoplasmofurinaryorgan,unspecifiedD34 BenignneoplasmofthyroidglandD35.00 BenignneoplasmofunspecifiedadrenalglandD35.01 BenignneoplasmofrightadrenalglandD35.02 BenignneoplasmofleftadrenalglandD35.1 BenignneoplasmofparathyroidglandD35.2 BenignneoplasmofpituitaryglandD35.3 BenignneoplasmofcraniopharyngealductD35.4 BenignneoplasmofpinealglandD35.5 BenignneoplasmofcarotidbodyD35.6 BenignneoplasmofaorticbodyandotherparagangliaD35.7 BenignneoplasmofotherspecifiedendocrineglandsD35.9 Benignneoplasmofendocrinegland,unspecifiedD36.0 BenignneoplasmoflymphnodesD36.10 Benignneoplasmofperipheralnervesandautonomicnervoussys,unspecifiedD36.11 Benneoplasmofperipheralnervesandautonomicnervoussystemofface/head/neck

D36.12 Benneoplasmofperipheralnerves&autonomicnervoussystem,upperlimb,includingshoulder

D36.13 Benneoplasmofperipheralnerves&autonomicnervoussystemoflowlimb,includinghip

D36.14 BenignneoplasmofperipheralnervesandautonomicnervoussystemofthoraxD36.15 BenignneoplasmofperipheralnervesandautonomicnervoussystemofabdominalD36.16 Benignneoplasmofperipheralnervesandautonomicnervoussystemofpelvis

D36.17 Benignneoplasmofperipheralnervesandautonomicnervoussystemoftrunk,unspecified

D36.7 BenignneoplasmofotherspecifiedsitesD36.9 Benignneoplasm,unspecifiedsiteD39.0 NeoplasmofuncertainbehaviorofuterusD39.10 NeoplasmofuncertainbehaviorofunspecifiedovaryD39.11 Neoplasmofuncertainbehaviorofrightovary

Page 46: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page46

Code DescriptorD39.12 NeoplasmofuncertainbehaviorofleftovaryD39.2 NeoplasmofuncertainbehaviorofplacentaD39.8 NeoplasmofuncertainbehaviorofotherfemalegenitalorgansD39.9 Neoplasmofuncertainbehavioroffemalegenitalorgan,unspecifiedD3A.098 BenigncarcinoidtumorsofothersitesD3A.8 OtherbenignneuroendocrinetumorsD40.10 NeoplasmofuncertainbehaviorofunspecifiedtestisD40.11 NeoplasmofuncertainbehaviorofrighttestisD40.12 NeoplasmofuncertainbehavioroflefttestisD40.8 NeoplasmofuncertainbehaviorofothermalegenitalorgansD40.9 Neoplasmofuncertainbehaviorofmalegenitalorgan,unspecifiedD41.00 NeoplasmofuncertainbehaviorofunspecifiedkidneyD41.01 NeoplasmofuncertainbehaviorofrightkidneyD41.02 NeoplasmofuncertainbehaviorofleftkidneyD41.10 NeoplasmofuncertainbehaviorofunspecifiedrenalpelvisD41.11 NeoplasmofuncertainbehaviorofrightrenalpelvisD41.12 NeoplasmofuncertainbehaviorofleftrenalpelvisD41.20 NeoplasmofuncertainbehaviorofunspecifiedureterD41.21 NeoplasmofuncertainbehaviorofrightureterD41.22 NeoplasmofuncertainbehaviorofleftureterD41.3 NeoplasmofuncertainbehaviorofurethraD41.4 NeoplasmofuncertainbehaviorofbladderD41.8 NeoplasmofuncertainbehaviorofotherurinaryorgansD41.9 NeoplasmofuncertainbehaviorofunspecifiedurinaryorganD44.0 NeoplasmofuncertainbehaviorofthyroidglandD44.10 NeoplasmofuncertainbehaviorofunspecifiedadrenalglandD44.11 NeoplasmofuncertainbehaviorofrightadrenalglandD44.12 NeoplasmofuncertainbehaviorofleftadrenalglandD44.2 NeoplasmofuncertainbehaviorofparathyroidglandD44.3 NeoplasmofuncertainbehaviorofpituitaryglandD44.4 NeoplasmofuncertainbehaviorofcraniopharyngealductD44.5 NeoplasmofuncertainbehaviorofpinealglandD44.6 NeoplasmofuncertainbehaviorofcarotidbodyD44.7 NeoplasmofuncertainbehaviorofaorticbodyandotherparagangliaD44.9 NeoplasmofuncertainbehaviorofunspecifiedendocrineglandD45. PolycythemiaveraD46.0 Refractoryanemiawithoutringsideroblasts,sostatedD46.1 RefractoryanemiawithringsideroblastsD46.20 Refractoryanemiawithexcessofblasts,unspecifiedD46.21 Refractoryanemiawithexcessofblasts1

Page 47: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page47

Code DescriptorD46.22 Refractoryanemiawithexcessofblasts2D46.4 Refractoryanemia,unspecifiedD46.9 Myelodysplasticsyndrome,unspecifiedD46.A RefractorycytopeniawithmultilineagedysplasiaD46.B RefractorycytopeniawithmultilineagedysplasiaandringsideroblastsD46.C Myelodysplasticsyndromewithisolateddel(5q)chromosomalabnormalityD46.Z OthermyelodysplasticsyndromesD47.0 HistiocyticandmastcelltumorsofuncertainbehaviorD47.1 ChronicmyeloproliferativediseaseD47.2 MonoclonalgammopathyD47.3 Essential(hemorrhagic)thrombocythemiaD47.4 Osteomyelofibrosis

D47.9 Neoplasmofuncertainbehavioroflymphoid,hematopoieticandrelatedtissue,unspecified

D47.Z1 Post-transplantlymphoproliferativedisorder(PTLD)

D47.Z9 Otherspecifiedneoplasmsofuncertainbehavioroflymphoid,hematopoieticandrelatedtissue

D48.0 Neoplasmofuncertainbehaviorofbone/articularcartilageD48.1 Neoplasmofuncertainbehaviorofconnective/softtissueD48.2 NeoplasmofuncertainbehaviorofperipheralnervesandautonomicnervoussystemD48.4 NeoplasmofuncertainbehaviorofperitoneumD48.5 NeoplasmofuncertainbehaviorofskinD48.7 NeoplasmofuncertainbehaviorofotherspecifiedsitesD48.9 Neoplasmofuncertainbehavior,unspecifiedD49.0 NeoplasmofunspecifiedbehaviorofdigestivesystemD49.2 Neoplasmofunspecifiedbehaviorofbone,softtissue,andskinD49.4 NeoplasmofunspecifiedbehaviorofbladderD49.5 NeoplasmofunspecifiedbehaviorofothergenitourinaryorgansD49.7 NeoplasmofunspecifiedbehaviorofendoglandsandotherpartsofnervoussystemD49.89 NeoplasmofunspecifiedbehaviorofotherspecifiedsitesD49.9 Neoplasmofunspecifiedbehaviorofunspecifiedsite

Itistheprovider’sresponsibilitytoselectcodescarriedouttothehighestlevelofspecificityandselectedfromtheICD-10-CMcodebookappropriatetotheyearinwhichtheserviceisrenderedfortheclaim(s)submitted.Iftheindicationsofthispolicyhavebeensatisfied,thenthefollowingICD-10-CMcodesmayberelevant.

OTHERINFORMATION

DocumentationRequirements

Page 48: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page48

1. Alldocumentationmustbemaintainedinthepatient’smedicalrecordandavailabletothecontractor/payeruponrequest.

2. Every page of the recordmust be legible and include appropriate patient identificationinformation (e.g., complete name, dates of service(s)). The record must include thephysicianornon-physicianpractitionerresponsibleforandprovidingthecareofthepatient.

3. ThesubmittedmedicalrecordshouldsupporttheuseoftheselectedICD-10-CMcode(s).ThesubmittedCPT®/HCPCScodeshoulddescribetheserviceperformed.

4. EachclaimmustbesubmittedwiththeICD-10-CMcode(s)thatreflecttheconditionofthepatient,andindicatethereason(s)forwhichtheservicewasperformed.ClaimssubmittedwithoutICD-10-CMcodeswillbereturned.

5. Documentationinthepatientmedicalrecordmustsupport:

a. The reasonable and necessary requirements as outlined under the coverage andlimitationssectionsofthispolicyandmustbeavailabletothecontractor/payerforreviewuponrequest.

b. Documentation must include the planned course of therapy, type and delivery oftreatment,levelofclinicalmanagementinvolvedandongoingdocumentationofanychanges in the course of treatment, and DHV as noted in the covered indicationssection.

APPENDIX2–SCIENTIFICLITERATUREREFERENCES

BREAST

1. AresC,KhanS,MacartainAM,etal.Postoperativeprotonradiotherapyforlocalizedandlocoregionalbreastcancer:potentialforclinicallyrelevantimprovements?IntJRadiatOncolBiolPhys.2010Mar1;76(3):685-97.

2. BradleyJA,DaganR,HoMW,etal.Initialreportofaprospectivedosimetricandclinicalfeasibilitytrialdemonstratesthepotentialofprotonstoincreasethetherapeuticratioinbreastcancercomparedwithphotons.IntJRadiatOncolBiolPhys.2016May1;95(1):411-21.

3. BushDA,DoS, LumS,etal.Partialbreast radiation therapywithprotonbeam:5-year resultswithcosmeticoutcomes.IntJRadiatOncolBiolPhys.2014;90(3):501-505.

4. BushDA,SlaterJD,GarberoglioC,etal.Atechniqueofpartialbreastirradiationutilizingprotonbeamradiotherapy:comparisonwithconformalx-raytherapy.CancerJ.2007;13(2):114-118.

5. BushDA,SlaterJD,GarberoglioC,etal.Partialbreastirradiationdeliveredwithprotonbeam:resultsofaphaseIItrial.ClinBreastCancer.2011;11(4):241-245.

6. BushDA,TeichmanSL,DoSY,etal.Long-TermQualityofLifeOutcomesofProtonBeamPBIComparedWithPhotonWholeBreastRadiationTherapy.IntJRadiatOncolBiolPhys.2017October1;99(2):E5.

7. ChangJH,LeeNK,KimJY,etal.PhaseIItrialofprotonbeamacceleratedpartialbreastirradiationinbreastcancer.RadiotherOncol.2013;108(2):209-214.

8. ChoiJI,ChangAL.Excellentacutetoxicityoutcomeswithprotontherapyforpartialbreastirradiationinearlystagebreastcancer:Initialresultsofamulti-institutionalphaseIItrial[abstract].CancerRes.2018;78(4).

Page 49: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page49

9. CuaronJJ,ChonB,TsaiH,etal.Earlytoxicityinpatientstreatedwithpostoperativeprotontherapyforlocallyadvancedbreastcancer.IntJRadiatOncolBiolPhys.2015Jun1;92(2):284-291.

10. DarbySC,EwertzM,McGaleP,etal.Riskofischemicheartdiseaseinwomenafterradiotherapyforbreastcancer.NEngJMed.2013;368(11):987-998.

11. FaraceP,DeiddaM,AmichettiM.Axillary irradiationomittingaxillarydissection inbreastcancer: istherearoleforshoulder-sparingprotontherapy.BrJRadiol.2015October;88(1054):20150274

12. FegaR,VargasCE,HartsellWF,etal.ClinicalOutcomesofBreastProtonRadiationTherapy:AMulti-institutional Analysis of the Proton Collaborative Group Registry. Int J Radiat Oncol Biol Phys.2017;99(2S):S214.

13. Hansen TM, Bartless GK, Mannina EM, et al. Dosimetric comparison of treatment techniques:brachytherapy,intensity-modulatedradiationtherapy,andprotonbeaminpartialbreastirradiation.IntJPartTher.2015;2(2):376-384.

14. JimenezRB,GomaC,NyamwandaJ,etal. Intensitymodulatedprotontherapy forpostmastectomyradiationofbilateralimplantreconstructedbreasts:atreatmentplanningstudy.RadiotherOncol.2013May;107(2):213-217.

15. KanemotoA, IshikawaH,MizumotoM,etal.Protonbeamtherapy for livermetastasis frombreastcancer:fivecasereportsandareviewoftheliterature.IntCancConfJ.2012;1(4):210-214.

16. Kozak KR, Katz A, Adams J, et al. Dosimetric comparison of proton and photon three-dimensional,conformal,externalbeamacceleratedpartialbreastirradiationtechniques.IntJRadiatOncolBiolPhys.2006,65(5):1572-1578.

17. KozakKR,SmithBL,AdamsJ,etal.Acceleratedpartial-breast irradiationusingprotonbeams: initialclinicalexperience.IntJRadiatOncolBiolPhys.2006;66(3):691-698.

18. Lin LL, Vennarini S, DimofteA, et al. Proton beam versus photon beamdose to the heart and leftanteriordescendingarteryforleft-sidedbreastcancer.ActaOncol.2015Jul;54(7):1032-1039.

19. Lischalk JW,ChenH,RepkaMC,et al.Definitivehypofractionated radiation therapy forearly stagebreastcancer:dosimetricfeasibilityofstereotacticablativeradiotherapyandprotonbeamtherapyforintactbreasttumors.AdvRadiatOncol.2018;3(3):447-457.

20. LomaxAJ,CellaL,WeberD,etal.Potentialroleof intensitymodulatedphotonsandprotons inthetreatmentofthebreastandregionalnodes.IntJRadiatOncolBiolPhys.2003;55(3):785-792.

21. Lundkvist J, EkmanM, Ericsson SR, et al. Economic evaluation of proton radiation therapy in thetreatmentofbreastcancer.RadiotherOncol.2005a;75(2):179-185.

22. Luo L, Cuaron J, Braunstein L, et al. Early outcomes of breast cancer patients treated with post-mastectomyuniformscanningprotontherapy.RadiotherOncol.2018.

23. MacDonaldSM,Patel SA,HickeyS,etal.Proton therapy forbreast canceraftermastectomy:earlyoutcomesofaprospectiveclinicaltrial.IntJRadiatOncolBiolPhys.2013;86(3):484-490.

24. MailhotVR,IshaqO,RaldowA,etal.Establishingcost-effectiveallocationofprotontherapyforbreastirradiation.IntJRadiatOncolBiolPhys.2016May1;95(1):11-18.

25. MastME,VredeveldEJ,CredoeHM,etal.Wholebreastprotonirradiationformaximalreductionofheartdoseinbreastcancerpatients.BreastCancerReseTreat.2014November;148(1):33-39.

Page 50: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page50

26. McGee LA, Iftekaruddin Z, Chang JHC, et al. PostmastectomyChestWall ReirradiationWithProtonTherapyforBreastCancer.IntJRadiatOncolBiolPhys.2017;99(2S):E34.

27. NiskaJR,ThorpeC,BrusoME,etal.Protonbeamtherapyforisolatedlocoregionalrecurrenceofbreastcanceraftermastectomywithoutpriorradiationtherapy:prospectivePCGregistryanalysis.IntJRadiatOncolBiolPhys.2018.

28. Orecchia R, Fossati P, Zurrida S, KrengliM.New frontiers in proton therapy: applications in breastcancer.CurrOpinOncol.2015;26(6):427-432.

29. Smith N, Jethwa KR, Gonuguntla K, et al. Early toxicity and patient reported outcomes of post-mastectomypencil-beamscanningprotontherapyinwomenwithimmediatetissueexpanderbreastreconstruction.IntJRadiatOncolBiolPhys.2018;102(3):e573-574.

30. Stick LB, Yu J, Maraldo MV, et al. Joint estimation of cardiac toxicity and recurrence risks aftercomprehensive nodal photon vs. proton therapy for breast cancer. Int J Radiat Oncol Biol Phys.2016;97(4):754-761.

31. TaghianAG,KozakKR,KatzA,etal.Acceleratedpartialbreastirradiationusingprotonbeams:initialdosimetricexperience.IntJRadiatOncolBiolPhys.2006;65(5):1404-1410.

32. TanT,ChinJ,LuHM,etal.Assessmentofcardiacfunctionfollowingprotonradiationinacohortofpostmastectomypatientswithlocallyadvancedbreastcancer.JAmCollCardiol.2015;65(10_S).

33. Taylor CW,Wang Z,Macaulay E, et al. Exposureof theheart in breast cancer radiation therapy: asystematic review of heart doses published during 2003-2013. Int J Radiat Oncol Biol Phys. 2015Nov;93(4):845-853.

34. TeichmanSL,DoS,LumS,etal.Improvedlong-termpatient-reportedhealthandwell-beingoutcomesofearly-stagebreastcancertreatedwithpartialbreastprotontherapy.CancerMedicine.2018;7:6064-6076.

35. ThorpeC,NiskaJR,BrusoME,etal.Protonbeamtherapyreirradiationforrecurrentbreastcancer:multi-institutionalprospectivePCGregistryanalysis.IntJRadiatOncolBiolPhys.2018.

36. VegaRM,IshaqO,RaldowA,etal.Establishingcost-effectiveallocationofprotontherapyforbreastirradiation.IntJRadiatOncolBiolPhys.2016May1;95(1):11-18.

37. VermaV,IftekaruddinZ,BadarN,etal.Protonbeamradiotherapyaspartofcomprehensiveregionalnodalirradiationforlocallyadvancedbreastcancer.RadiotherOncol.2017May;123(2):294-298.

38. VermaV,ShahC,MehtaMP.Clinicaloutcomesandtoxicityofprotonradiotherapyforbreastcancer.ClinBreastCancer.2016Jun;16(3):145-154.

39. WeberDC,AresC,LomaxAJ,KurtzJM.Radiationtherapyplanningwithphotonsandprotonsforearlyandadvancedbreastcancer:anoverview.RadiatOncol.2006;1:22.

40. XuN,HoMW,LiZ,etal.Canprotontherapyimprovethetherapeuticratioinbreastcancerpatientsatriskfornodaldisease?AmJClinOncol.2014Dec;37(6):568-574.

41. YuJ,ParkSS,HermanMG,etal.Freebreathingversusbreath-holdscanningbeamprotontherapyandcardiacsparinginbreastcancer.IntJPartTher.2016;3(3):407-413.

CENTRALNERVOUSSYSTEM

Page 51: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page51

42. AjithkumarT,MazhariA-L,Stickan-VerfürthM,etal.ProtonTherapyforCraniopharyngioma—AnEarlyReportfromaSingleEuropeanCentre.ClinOncol.2018:pii:S0936-6555(18)30043-8.

43. AmelioD,ScartoniD,FaraceP,etal.P01.084Re-irradiationinrecurrentglioblastoma:protontherapywithorwithoutchemotherapy.Neuro-Oncology.2018;20(3).

44. AmsbaughMJ,GrosshansDR,McAleerMF,etal.Protontherapyforspinalependymomas:planning,acutetoxicities,andpreliminaryoutcomes.IntJRadiatOncolBiolPhys.2012;83(5):1419-1424.

45. AtkinsKM,Pashtan IM,BussiereMR,etal.Protonstereotacticradiosurgery forbrainmetastases:asingle institution analysis of 370 patients. Int J Radiat Oncol Biol Phys. 2018;https://doi.org/10.1016/j.ijrobp.2018.03.056.

46. BarkerFGII,ButlerWE,LyonsS,etal.Dose-volumepredictionofradiation-relatedcomplicationsafterprotonbeamradiosurgeryforcerebralarteriovenousmalformations.JNeurosurg.2003;99(2):254-263.

47. BarnesCJ,BushDA,GroveRI,etal.Fractionatedprotonbeamtherapyforacousticneuromas:tumorcontrolandhearingpreservation.IntJPartTher.2018.

48. BaumertBG,LomaxAJ.AComparisonofDoseDistributionsofProtonandPhotonBeamsinStereotacticConformalRadiotherapyofBrainLesions.IntJRadiatOncolBiolPhys.2001;49(5):1439-1449.

49. BaumertBG,NortonIA,LomaxAJ,etal.Doseconformationofintensity-modulatedstereotacticphotonbeams, proton beams, and intensity-modulated proton beams for intracranial lesions. Int J RadiatOncolBiolPhys.2004;60:1314–1324

50. BhattacharyyaN,ThorntonAF,JosephMP,etal.Successfultreatmentofesthesioneuroblastomaandneuroendocrinecarcinomawithcombinedchemotherapyandprotonradiation.Resultsin9cases.ArchOtolaryngolHeadNeckSurg.1997;123(1):34-40.

51. Bronk JK, Guha-Thakurta N, Allen PK, et al. Analysis of pseudoprogression after proton or photontherapyof99patientswith lowgradeandanaplasticglioma.ClinTranslatRadiatOncol. 2018.doi:https://doi.org/10.1016/j.ctro.2018.01.002.

52. BrowerJV,GansS,HartsellWF,etal.Protontherapyandhelicaltomothrapyresultinreduceddosedepositiontothepancreasinthesettingofcranio-spinalirradiationformedulloblastoma:implicationsforreducedriskofdiabetesmellitusinlong-termsurvivors.ActaOncol.2015;54(4):522-526.

53. BrownAP,BarneyCL,GrosshansDR,etal.Protonbeamcraniospinalirradiationreducesacutetoxicityforadultswithmedulloblastoma.IntJRadiatOncolBiolPhys.2013;86(2):277-284.

54. BushDA,McAllisterCJ,LoredoLN,etal.Fractionatedprotonbeamradiotherapyforacousticneuroma.Neurosurgery.2002;50(2):270-273.

55. CombsSE,WelzelT,HabermehlD,etal.Prospectiveevaluationofearlytreatmentoutcomeinpatientswith meningiomas treated with particle therapy based on target volume definition with MRI and68Ga-DOTATOC-PET.ActaOncol.2013;52(3):514-520.

56. CombsSE.DoesprotontherapyhaveafutureinCNStumors?CurrTreatOptionsNeurol.2017.

57. CombsSE.Protonandcarbon ion therapyof intracranialgliomas.Progress inNeurologicalSurgery.2018;32:57-65.

58. DeAmorimBernstein K, Sethi R, Trofimov, et al. Early clinical outcomesusingproton radiation forchildrenwithcentralnervoussystematypicalteratoidrhabdoidtumors.IntJRadiatOncolBiolPhys.2013;86(1):114-120.

Page 52: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page52

59. DeLaney TF. Long term results of Phase II study of high dose photon/proton radiotherapy in themanagement of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol.2014;110(2):115-122.

60. DinhJ,StokerJ,GeorgesRH,etal.Comparisonofprotontherapytechniquesfortreatmentofthewholebrainasacomponentofcraniospinalradiation.RadiatOncol.2013;8:289.

61. Eaton BR, Esiashvili N, Kim S, et al. Endocrine outcomeswith proton and photon radiotherapy forstandardriskmedulloblastoma.NeuroOncol.2016Jun;18(6):881-887.

62. Fitzek MM, Linggood RM, Adams J, Munzenrider JE. Combined proton and photon irradiation forcraniopharyngioma: long-term results of the early cohort of patients treated at Harvard CyclotronLaboratoryandMassachusettsGeneralHospital.IntJRadiatOncolBiolPhys.2006;64(5):1348-1354.

63. Fitzek MM, Thornton AF, Harsh G, et al. Dose-escalation with proton/photon irradiation forDaumas-Duportlower-gradeglioma:resultsofaninstitutionalphaseI/IItrial.IntJRadiatOncolBiolPhys.2001;51(1):131-137.

64. FitzekMM,ThorntonAF,RabinovJD,etal.Acceleratedfractionatedproton/photonirradiationto90cobaltgrayequivalentforglioblastomamultiforme:resultsofaphaseIIprospectivetrial.JNeurosurg.1999;91(2):251-260.

65. GiantsoudiD,SethiRV,YeapBY,etal.IncidenceofCNSInjuryforaCohortof111PatientsTreatedWithProtonTherapyforMedulloblastoma:LETandRBEAssociationsforAreasofInjury.IntJRadiatOncolBiolPhys.2016;95(1):287-296.

66. Gridley DS, Grover RS, Loredo LM, et al. Proton beam therapy for tumors of the CNS. Expert RevNeurother.2010Feb;10(2):319-330.

67. Gunther JR, Rahman AR, Dong W, et al. Craniospinal irradiation prior to stem cell transplant forhematologicmalignancieswith CNS involvement: Effectiveness and toxicity after photonor protontreatment.PracRadiatOncol.2017Nov;7(6):e401-e408.

68. Harrabi SB, Bougatf N,Mohr A, et al. Dosimetric advantages of proton therapy over conventionalradiotherapywithphotons inyoungpatientsandadultswith low-gradeglioma.StrahlentherOnkol.2016Nov;192(11):759-769.

69. Harsh GR, Thornton AF, Chapman PH, et al. Proton beam stereotactic radiosurgery of vestibularschwannomas.IntJRadiatOncolBiolPhys.2002;54(1):3544.

70. Hattangadi JA, Chapman PH, Bussière MR, et al. Planned two-fraction proton beam stereotacticradiosurgery for high-risk inoperable cerebral arteriovenousmalformations. Int J Radiat Oncol BiolPhys.2012;83(2):533-541.

71. HauswaldH,RiekenS,EckerS,etal.Firstexperiencesintreatmentoflow-gradegliomagradeIandIIwithprotontherapy.RadiatOncol.2012;7:189.

72. HugEB,DeVriesA,ThorntonAF,etal.Managementofatypicalandmalignantmeningiomas:roleofhigh-dose,3D-conformalradiationtherapy.JNeurooncol.2000;48(2):151-160.

73. ItoY,OkumuraT,SuzukiK,etal.Longtermoutcomeofprotonbeamradiosurgeryforarteriovenousmalformationslargerthan30mmindiameter.NeurolMedChir(Tokyo).2011;51(9):624629.

74. JhaveriJ,ChengE,BuchwaldZS,etal.Protonversusphotonradiationtherapyforprimarygliomas:ananalysisoftheNationalCancerDataBase.FrontOncol.2018.

Page 53: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page53

75. Johnson WD, Loredo LN, Chung A, et al. Surgery and radiotherapy: complementary tools in themanagementofbenignintracranialtumors.NeurosurgFocus.2008;24(5):E2.

76. KahnJ,LoefflerJS,NiemierkoA,etal.Long-termoutcomesofpatientswithspinalcordgliomastreatedbymodernconformalradiationtechniques.IntJRadiatOncolBiolPhys.2011;81(1):232-238.

77. KamranSC,DworkinML,NiemierkoA,etal.PatternsofFailureandRiskFactorsforRecurrenceAmongLow-GradeGliomaPatientsTreatedWithProtonRadiationTherapy.IntJRadiatOncolBiolPhys.2017Oct1;99(2):E83.

78. KangKH,SchapiraE,NiemierkoA,etal.Theroleofprotonbeamtherapyincentralneurocytoma:asingle-institutionexperience.PractRadiatOncol.2018.https://doi.org/10.1016/j.prro.2018.02.005

79. KjellbergRN,SweetWH,PrestonWM,KoehlerAM.TheBraggpeakofaprotonbeaminintracranialtherapyoftumors.TransAmNeurolAssoc.1962;87:216-218.

80. McDonaldMW, Plankenhorn DA,McMullen KP, et al. Proton therapy for atypical meningiomas. JNeurooncol.2015;123(1):123-128.

81. MizumotoM,OkumuraT, IshikawaE,etal.Reirradiation for recurrentmalignantbrain tumorwithradiotherapy or proton beam therapy. Technical considerations based on experience at a singleinstitution.StrahlentherOnkol.2013August;189(8):656-663.

82. MizumotoM,TsuboiK, IgakiH,etal.PhaseI/IItrialofhyperfractionatedconcomitantboostprotonradiotherapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys.2010;77(1):98-105.

83. Mizumoto M, Yamamoto T, Ishikawa E, et al, Tsuboi K. Proton beam therapy with concurrentchemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride andtemozolomide.JNeurooncol.2016Oct;130(1):165-170.

84. MoignierA,Gelover E,WangD, et al. Theoretical Benefits ofDynamicCollimation in Pencil BeamScanningProtonTherapyforBrainTumors:DosimetricandRadiobiologicalMetrics.IntJRadiatOncolBiolPhys.2016;95(1):171-180.

85. Murray FR, Snider JW, Bolsi A, et al. Long-term clinical outcomes of Pencil Beam Scanning ProtonTherapyforbenignandnon-benignintracranialmeningiomas.IntJRadiatOncolBiolPhys.2017,doi:10.1016/j.ijrobp.2017.08.005.

86. Nakai Y, Ito Y, Sato M, et al. Multimodality treatment for cerebral arteriovenous malformations.Complementaryroleofprotonbeamradiotherapy.NeurolMedChir(Tokyo).2012;52(12):859-864.

87. NoëlG,BolletMA,CalugaruV,etal.Functionaloutcomeofpatientswithbenignmeningiomatreatedby3Dconformalirradiationwithacombinationofphotonsandprotons.IntJRadiatOncolBiolPhys.2005;62(5):1412-1422.

88. Noël G, Habrand JL, Mammar H, et al. Highly conformal therapy using proton component in themanagementofmeningiomas.StrahlentherOnkol.2002;178(9):480-485.

89. Oshiro Y, Mizumoto M, Okumura T, et al. Clinical results of proton beam therapy for advancedneuroblastoma.RadiatOncol.2013;8(1):142.

90. ParkJ,ParkY,LeeSU, etal.Differentialdosimetricbenefitofprotonbeamtherapyover intensity-modulatedradiotherapyforavarietyoftargetsinpatientswithintracranialgermcelltumors.RadiatOncol.2015June;10:135.

Page 54: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page54

91. Petit JH, Biller BMK, Yock TI, et al. Proton stereotactic radiotherapy for persistentadrenocorticotropin-producingadenomas.JClinEndocrinolMetab.2008;93(2):393-399.

92. RonsonBB,SchulteRW,HanKP,etal.Fractionatedprotonbeamirradiationofpituitaryadenomas.IntJRadiatOncolBiolPhys.2006;64(2):425-434.

93. ScartoniD,AmelioD,LorentiniS,etal.P05.58Activebeamscanningprotontherapyforlargeskullbasebenignmeningiomas:earlyoutcomes.Neuro-Oncology.2018;20(3).

94. Shih HA, Sherman JC, Nachtigall LB, et al. Proton therapy for low-grade gliomas: Results from aprospectivetrial.Cancer.2015May15;121(10):1712-1719.

95. SilanderH,PellettieriL,EnbladP,etal.Fractionated,stereotacticprotonbeamtreatmentofcerebralarteriovenousmalformations.ActaNeurolScand.2004;109(2):85-90.

96. SmithGL,RahmanAR,DongW,etal.ProtonVersusPhotonCraniospinalIrradiationforHematologicMalignanciesInvolvingtheCNS:EffectivenessandToxicityintheSettingofStemCellTransplant.IntJRadiatOncolBiolPhys.2016Oct1;96(2S):E496.

97. SniderJW,SchneiderRA,Poelma-TapD,etal.Long-TermOutcomesandPrognosticFactorsFollowingPencil-BeamScanningProtonRadiotherapyforSpinalChordomas:ALarge,Single-InstitutionCohort.IntJRadiatOncolBiolPhys.2018.https://doi.org/10.1016/j.ijrobp.2018.01.060.

98. TabriziS,YeapBY,ShermanJC,etal.Long-TermOutcomesofaProspectiveTrialonProtonTherapyforLow-GradeGlioma.IntJRadiatOncolBiolPhys.2017Oct1;99(2):S189.

99. Vernimmen FJ, Mohamed Z, Slabbert JP, et al. Long term results of stereotactic proton beamradiotherapyforacousticneuromas.RadiotherOncol.2009;90(2):208-212.

100. Vernimmen FJAI, Slabbert JP, Wilson JA, et al. Stereotactic proton beam therapy for intracranialarteriovenousmalformations.IntJRadiatOncolBiolPhys.2005;62(1):44-52.

101. Vlachogiannis P, Gudjonsson O, Montelius A, et al. Hypofractionated high-energy proton-beamirradiation is an alternative treatment for WHO grade I meningiomas. Acta Neurochir. 2017Dec;159(12):2391-2400.

102. WattsonDA,YanquturiSK,SpiegelDY,etal.Outcomesofprotontherapyforpatientswithfunctionalpituitaryadenomas.IntJRadiatOncolBiolPhys.2014Nov1;90(3):532-539.

103. WeberDC,ChanAW,BussiereMR,etal.Protonbeamradiosurgeryforvestibularschwannoma:tumorcontrolandcranialnervetoxicity.Neurosurgery.2003;53(3):577-586.

104. WeberDC,LomaxAJ,RutzHP,etal.Spot-scanningprotonradiationtherapyforrecurrent,residualoruntreatedintracranialmeningiomas.RadiotherOncol.2004;71(3):251-258.

105. Weber DC, Schneider R, Goitein G, et al. Spot scanning-based proton therapy for intracranialmeningioma: long-term results from the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys.2012;83(3):865-871.

106. Wenkel E, Thornton AF, Finkelstein D, et al. Benignmeningioma: partially resected, biopsied, andrecurrent intracranial tumors treatedwith combined proton and photon radiotherapy. Int J RadiatOncolBiolPhys.2000;48(5):1363-1370.

107. WilkinsonB,MorganH,GondiV,etal.LowLevelsofAcuteToxicityAssociatedWithProtonTherapyforLow-Grade Glioma: A Proton Collaborative Group Study. Int J Radiat Oncol Biol Phys. 2016 Oct1;96(2S):E135.

Page 55: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page55

108. YerramilliD,BussiereMR,LoefflerJS,etal.Protonbeamtherapy(forCNStumors).AdultsIn:ChangE.,BrownP.,LoS.,SahgalA.,SuhJ.(eds)AdultCNSRadiationOncology.Springer,Cham

109. YockTI,WeymanEA,GoldbergS,etal.HRQoLinmedulloblastomapatientsenrolledonaprospectivephaseIIstudyofprotonradiation.JClinOncol.2015;33(15):e21029.

110. ZhuS,RotondoR,MendenhallWM,et al. Long-termoutcomesof fractionated stereotactic protontherapyforvestibularschwannoma:acaseseries.IntJPartTher.2018.

GASTROINTESTINAL

Anus

111. AnandA,BuesMWG,KeoleSR,etal.Scanningprotonbeamtherapyreducesnormaltissueexposureinpelvicradiotherapyforanalcancer.RadiotheOncol.2015Dec;117(3):505-508.

112. Ojerholm E, KirkML, Thompson RF, et al. Pencil-beam scanning proton therapy for anal cancer: adosimetriccomparisonwithintensity-modulatedradiotherapy.ActaOncol.2015;54(8):1209-1217.

Esophagus

113. ChuongMD,HallemeierCL,JabbourSK,YuJ,BadiyanS,MerrellKW,MishraMV,LiH,VermaV,LinSH.Improvingoutcomesforesophagealcancerusingprotonbeamtherapy.IntJRadiatOncolBiolPhys.2015;availableonline.

114. Cooper JS,GuoMD,HerskovicA,etal.Chemoradiotherapyof locallyadvancedesophageal cancer:long-termfollow-upofaprospectiverandomizedtrial.JAMA.1999May5;281(17):1623-7.

115. EcheverriaAE,McCurdyM,CastilloR,etal.Protontherapyradiationpneumonitislocaldoseresponseinesophaguscancerpatients.RadiotherOncol.2013;106(1):124-129.

116. Fang P, Shiraishi Y, Jiang W, et al. Lymphocyte-sparing effect of proton therapy in patients withesophagealcancer.IntJRadiatOncolBiolPhys.2017;98(2):e6.

117. FernandesA,BermanAT,MickR,etal.Aprospectivestudyofprotonbeamreirradiationforesophagealcancer.IntJRadiatOncolBiolPhys.2016May1;95(1):483-487.

118. Gajjar SR,AllenPK,He L, et al. Reduced Incidenceof SevereAcuteToxicities inEsophagealCancerTreatedwithProtonTherapy.IntJPartTher.2015;2(2).

119. Gayed IW, Liu HH, Yusuf SW, et al. The prevalence of myocardial ischemia after concurrentchemoradiation therapy as detected by gated myocardial perfusion imaging in patients withesophagealcancer.JNuclMed.2006Nov;47(11):1756-62.

120. HaqueW,VermaV,ButlerEB,TheBS.Utilizationofneoadjuvantintensity-modulatedradiationtherapyand proton beam therapy for esophageal cancer in the United States. J Gastrointest Oncol. 2018.http://jgo.amegroups.com/article/view/18383.

121. HiranoY,OnozawaM,HojoH,etal.Dosimetriccomparisonbetweenprotonbeamtherapyandphotonradiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol.2018;13(23).

Page 56: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page56

122. Ishikawa H, Hashimoto T, Moriwaki T, et al. Proton beam therapy combined with concurrentchemotherapyforesophagealcancer.AnticancerRes.2015Mar;35(3):1757-1762.

123. KoyamaS,TsujiiH,YokotaH,etal.Protonbeamtherapyforpatientswithesophagealcarcinoma.JpnJClinOncol.1994;24(3):144-153.

124. Koyama S, Tsujii H. Proton beam therapy with high-dose irradiation for superficial and advancedesophagealcarcinomas.ClinCancerRes.2003;9(10Pt1):3571-3577.

125. LesterSC,LinSH,ChuongM,etal.AMulti-institutionalAnalysisofTrimodalityTherapyforEsophagealCancerinElderlyPatients.IntJRadiatOncolBiolPhys.2017;98(4):820-828.

126. LinSH,HallemeierCL,ChuongM.Protonbeamtherapyforthetreatmentofesophagealcancer.ChinClinOncol.2016Aug;5(4):53.doi:10.21037/cco.2016.07.04.PubMedPMID:27558254.

127. LinSH,KomakiR, LiaoZ,etal.Protonbeamtherapyandconcurrentchemotherapy foresophagealcancer.IntJRadiatOncolBiolPhys.2012;83(3):e345-e351.

128. LinSH,MerrellKW,ShenJ,etal.Multi-institutionalanalysisofradiationmodalityuseandpostoperativeoutcomesofneoadjuvantchemoradiationforesophagealcancer.RadiotherOncol.2017;123(3):376-381.

129. LingTC,SlaterJM,NookalaP,etal.Analysisofintensity-modulatedradiationtherapy(IMRT),protonand3Dconformalradiotherapy(3D-CRT)forreducingperioperativecardiopulmonarycomplicationsinesophagealcancerpatients.Cancers.2014;6(4):2356-2368.

130. Makishima H, Ishikawa H, Terunuma T, et al. Comparison of adverse effects of proton and X-raychemoradiotherapyforesophagealcancerusinganadaptivedosevolumehistogramanalysis.JRadiatRes.2015May;56(3):568-576.

131. MizumotoM,SugaharaS,NakayamaH,etal.Clinicalresultsofproton-beamtherapyforlocoregionallyadvancedesophagealcancer.StrahlentherOnkol.2010;186(9):482-488.

132. Mizumoto M, Sugahara S, Okumura T, et al. Hyperfractionated concomitant boost proton beamtherapyforesophagealcarcinoma.IntJRadiatOncolBiolPhys.2011;81(4):e601-e606.

133. PatelSA,EdgingtonSK,AdamsJ,etal.Noveluseofprotonbeamtherapyforneoadjuvantthreatmentofradiation-associatedsquamouscellcarcinomaoftheesophagus.JGastrointestOncol.2018.

134. Prayongrat A, Xu C, Li H, Lin SH. Clinical outcomes of intensity-modulated proton therapy andconcurrent chemotherapy in esophageal carcinoma: a single institutional experience. Adv RadiatOncol.2017Jun13:2(3):301-307.

135. SugaharaS,TokuuyeK,OkumuraT,etal.Clinical resultsofprotonbeamtherapy forcancerof theesophagus.IntJRadiatOncolBiolPhys.2005;61(1):76-84.

136. TakadaA,NakamuraT,TakayamaK,etal.PreliminarytreatmentresultsofprotonbeamtherapywithchemoradiotherapyforstageI-IIIesophagealcancer.CancerMed.2016Mar;5(3):506-515.

137. WangJ,WeiC,TuckerSL,etal.Predictorsofpostoperativecomplicationsaftertrimodalitytherapyforesophagealcancer.IntJRadiatOncolBiolPhys.2013;86(5):885-891.

138. WarrenS,HurtCH,CrosbyT,etal.Thepotentialofprotontherapytoreduceacutehaematologicaltoxicity in concurrent chemoradiotherapy for oesophageal cancer. Int J Radiation Oncol Biol Phys.2017;99(3):729-737.

Page 57: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page57

139. XiM,XuC,LiaoZ,etal.ComparativeOutcomesafterDefinitiveChemoradiotherapyusingProtonBeamTherapyversusIntensity-ModulatedRadiationTherapyforEsophagealCancer:ARetrospectiveSingle-InstitutionalAnalysis.RadiatOncol.2017.DOI:10.1016/j.ijrobp.2017.06.2450

140. Zhang X, Zhao KL, Guerrero TM, et al. Four-dimensional computed tomography–based treatmentplanningforintensity-modulatedradiationtherapyandprotontherapyfordistalesophagealcancer.IntJRadiatOncolBiolPhys.2008Sep1;72(1):278-287.

Liver

141. Abei M, Okumura T, Fukuda K, et al. A phase I study on combined therapy with proton-beamradiotherapyandinsitutumorvaccinationfor locallyadvancedrecurrenthepatocellularcarcinoma.RadiatOncol.2013;8:239.

142. AhmadiT,OkumuraT,OnayaH,etal.Preservationofhypervascularity inhepatocellularcarcinomaaftereffectiveproton-beamradiotherapy–CTobservation.ClinRadiol.1999;54(4):253-256.

143. ApisarnthanaraxS,YeungR,BowenS,ChapmanTR.ProtonBeamTherapyforHepaticMalignancies.GastrointestinalMalignancies.2017:171-195.

144. BushDA,HillebrandDJ,Slater JM,Slater JD.High-doseprotonbeamradiotherapyofhepatocellularcarcinoma:preliminaryresultsofaphaseIItrial.Gastroenterology.2004;127(5Suppl1):S189-S193.

145. BushDA,KayaliZ,GroveR,SlaterJD.Thesafetyandefficacyofhigh-doseprotonbeamradiotherapyforhepatocellularcarcinoma:aphase2prospectivetrial.Cancer.2011;117(13):3053-3059.

146. BushDA,SmithJC,SlaterJD,etal.Randomizedclinicaltrialcomparingprotonbreamradiationtherapywithtransarterialchemoembolizationforhepatocellularcarcinoma:resultsofaninterimanalysis.IntJRadiatOncolBiolPhys.2016May;95(1):477-82.

147. Chadha AS, Gunther JR, Minsky BD, et al. Proton Therapy Outcomes for Localized, UnresectableHepatocellularCarcinoma.IntJRadiatOncolBiolPhys.2016Oct1;96(2S):E181-E182.

148. Chiba T, Tokuuye K, Matsuzaki Y, et al. Proton beam therapy for hepatocellular carcinoma: aretrospectivereviewof162patients.ClinCancerRes.2005;11(10):3799-3805.

149. ChuongMD,etal.Protonbeamtherapyforlivercanceriswelltolerated:outcomesfromtheProtonCollaborativeGroupREG001-09trial.JClinOncol.2017.

150. ColbertLE,CloydJM,KoayEJ,etal.Protonbeamradiationassalvagetherapyforbilateralcolorectallivermetastasesnotamenabletosecond-stagehepatectomy.Surgery.2017Jun;161(6):1543-1548

151. DionisiF,Ben-JosefE.Theuseofprotontherapy in thetreatmentofgastrointestinalcancers: liver.CancerJ.2014;20(6):371-7.

152. DionisiF,WidesottL,LorentiniS,AmichettiM.Istherearoleforprotontherapyinthetreatmentofhepatocellularcarcinoma?Asystematicreview.RadiotherOncol.2014April;111(1):1-10.

153. DyerMA,McDonnellEI,YeapBY,etal.ChangeinPlateletCountandNormalLiverDosimetryinPatientsReceiving Proton Radiation Therapy for Unresectable Hepatocellular Carcinoma or IntrahepaticCholangiocarcinoma.IntJRadiatOncolBiolPhys.2016Oct1;96(2S):E174-E175.

154. FukumitsuN,HashimotoT,OkumuraT,etal.Investigationofthegeometricaccuracyofprotonbeamirradiationintheliver.IntJRadiatOncolBiolPhys.2012;82(2):826-833.

Page 58: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page58

155. FukumitsuN,OkumuraT,NumajiriH, et al. Follow-up studyof livermetastasis frombreast cancertreatedbyprotonbeamtherapy.MolClinOncol.2017;7(1):56-60.

156. FukumitsuN,OkumuraT,TakizawaD,etal.Protonbeamtherapyformetastaticlivertumors.RadiotherOncol.2015November;117(2):322-7.

157. FukumitsuN,SugaharaS,NakayamaH,etal.Aprospectivestudyofhypofractionatedprotonbeamtherapyforpatientswithhepatocellularcarcinoma.IntJRadiatOncolBiolPhys.2009;74(3):831-836.

158. FukumitsuN,OkumuraT,TakizawaD,etal.Protonbeamtherapy for livermetastases fromgastriccancer.JRadiatRes.2016;1-6.

159. GandhiSJ,LiangX,DingX,etal.Clinicaldecisiontool foroptimaldeliveryof liverstereotacticbodyradiationtherapy:photonsversusprotons.PractRadiatOncol.2015July-August;5(4):209-18.

160. HashimotoS,OginoH,IwataH,etal.EfficacyofProtonBeamTherapyforHepatocellularCarcinomaWithPortalVeinorInferiorVenaCavaTumorThrombosis.IntJRadiatOncolBiolPhys.2017October1;99(2):E152-153.

161. Hashimoto T, Tokuuye K, Fukumitsu N, et al. Repeated proton beam therapy for hepatocellularcarcinoma.IntJRadiatOncolBiolPhys.2006;65(1):196-202.

162. HataM, Tokuuye K, Sugahara S, et al. Proton beam therapy for aged patientswith hepatocellularcarcinoma.IntJRadiatOncolBiolPhys.2007;69(3):805-812.

163. HataM,TokuuyeK,SugaharaS,etal.Protonbeamtherapyforhepatocellularcarcinomapatientswithseverecirrhosis.StrahlentherOnkol.2006b;182(12):713-720.

164. HataM,TokuuyeK,SugaharaS,etal.Protonbeamtherapyforhepatocellularcarcinomawithlimitedtreatmentoptions.Cancer.2006a;107(3):591-598.

165. HataM,TokuuyeK,SugaharaS,etal.Protonbeamtherapyforhepatocellularcarcinomawithportalveintumorthrombus.Cancer.2005;104(4):794-801.

166. HataM,TokuuyeK,SugaharaS,etal.Protonirradiationinasinglefractionforhepatocellularcarcinomapatientswithuncontrollableascites.StrahlentherOnkol.2007;183(8):411-416.

167. HongTS,DelaneyTF,MamonHJetal.Aprospectivefeasibilitystudyofrespiratorygatedprotonbeamtherapy.PractRadiatOncol.2014;4(5):316-322.

168. HongTS,GrassbergerC,YeapBY,etal.HepatocyteGrowthFactorisAssociatedWithLiverDysfunctionand Survival: Biomarker Results of a Phase 2 Study of Proton Beam Therapy in Patients withHepatocellularCarcinomaandIntrahepaticCholangiocarcinoma.IntJRadiatOncolBiolPhys.2017Oct1;99(2):S89.

169. HongTS,WoJY,BorgerDR,etal.PhaseIIStudyofProton-BasedStereotacticBodyRadiationTherapyforLiverMetastases:ImportanceofTumorGenotype.JNatlCancerInst.2017;109(9):djx031.

170. HongTS,WoJY,YeapBY,etal.Multi-institutionalphaseIIstudyofhigh-dosehypofractionatedprotonbeam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepaticcholangiocarcinoma.JClinOncol.2016;34(5):460-468.

171. Hsieh CE, Hong JH, Lin CC, et al. Complete response of unresectable icteric-type hepatocellularcarcinomatohypofractionatedprotonbeamtherapywithconcurrentplusadjuvantsorafenib:acasereport.TherRadiolOncol.2018.

Page 59: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page59

172. Kanemoto A, Mizumoto M, Okumura T, et al. Dose-volume histogram analysis for risk factors ofradiation-induced rib fracture after hypofractionated proton beam therapy for hepatocellularcarcinoma.ActaOncol.2013;52(3):538-544.

173. KangJI,SufficoolDC,HsuehCT,etal.AphaseItrialofprotonstereotacticbodyradiationtherapyforlivermetastases.JGastrointestOncol.2018.

174. KawashimaM, Furuse J,Nishio T, et al. Phase II studyof radiotherapyemployingprotonbeam forhepatocellularcarcinoma.JClinOncol.2005;23(9):1839-1846.

175. KawashimaM,KohnoR,NakachiK,etal.Dose-volumehistogramanalysisofthesafetyofprotonbeamtherapyforunresectablehepatocellularcarcinoma.IntJRadiatOncolBiolPhys.2011;79(5):1479-1486.

176. KimJY,etal.Normalliversparingbyprotonbeamtherapyforhepatocellularcarcinoma:Comparisonwithhelicalintensitymodulatedradiotherapyandvolumetricmodulatedarctherapy.ActaOncologica.2015;54(10):1827-1832.

177. Kim TH, Park JW, Kim BH, et al. Optimal time of tumour response evaluation and effectiveness ofhypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma.Oncotarget.2017;9(3):4034-4043.

178. KimTH,ParkJW,KimYJ,etal.PhaseIdose-escalationstudyofprotonbeamtherapyforinoperablehepatocellularcarcinoma.CancerResTreat.2015January;47(1):34-45.

179. Kimura K, Nakamura T, Ono T, et al. Clinical results of proton beam therapy for hepatocellularcarcinomaover5cm.HepatolRes.2017February14.doi:10.1111/hepr.12874.

180. Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and futureopportunities.IntJRadiatOncolBiolPhys.2013Sep1;87(1):22-32.

181. KobashiK,PrayongratA,KimotoT,etal.Assessing theuncertainty inanormal tissuecomplicationprobabilitydifference(∆NTCP):radiation-inducedliverdisease(RILD)inlivertumourpatientstreatedwithprotonvsX-raytherapy.JRadiatRes.2018.doi:10.1093/jrr/rry018.

182. Komatsu S, Fukumoto T,Demizu Y, et al. Clinical results and risk factors of proton and carbon iontherapyforhepatocellularcarcinoma.Cancer.2011;117(21):4890-4904.

183. KomatsuS,FukumotoT,DemizuY,etal.Theeffectivenessofparticleradiotherapyforhepatocellularcarcinomaassociatedwithinferiorvenacavatumorthrombus.JGastroenterol.2011;46(7):913-920.

184. LeeCH,HungSP,HongJH,etal.Howsmallistoosmall?Newliverconstraintisneeded–protontherapyofhepatocellularcarcinomapatientswithsmallnormalliver.PLoSOne.2018;13(9).

185. LeungHWC,ChanALF.Cost-utilityofstereotacticradiationtherapyversusprotonbeamtherapyforinoperableadvancedhepatocellularcarcinoma.Oncotarget.2017Apr21.doi:10.18632/oncotarget.

186. Ling TC, Kang JI, Bush DA, et al. Proton therapy for hepatocellular carcinoma. Chin J Cancer Res.2012;24(4):361-367.

187. Masato A, Okumura T, Fukuda K, et al. A phase I study on combined therapy with proton-beamradiotherapyandinsitutumorvaccinationfor locallyadvancedrecurrenthepatocellularcarcinoma.RadiatOncol.2013;8(239).

188. MatsuzakiY,OsugaT,ChibaT,etal.New,effectivetreatmentusingprotonirradiationforunresectablehepatocellularcarcinoma.InternMed.1995;34(4):302-304.

Page 60: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page60

189. MizumotoM,OkumuraT,HashimotoT,etal.Evaluationofliverfunctionafterprotonbeamtherapyforhepatocellularcarcinoma.IntJRadiatOncolBiolPhys.2012;82(3):e529-e535.

190. MizumotoM,OkumuraT,HashimotoT,etal.Protonbeamtherapyforhepatocellularcarcinoma:acomparisonofthreetreatmentprotocols.IntJRadiatOncolBiolPhys.2011;81(4):1039-1045.

191. MizumotoM,OshiroY,OkumuraT,etal.Protonbeamtherapyforhepatocellularcarcinoma:areviewoftheUniversityofTsukubaexperience.IntJPartTher.2016:571-578.

192. MizumotoM,TokuuyeK,SugaharaS,etal.Protonbeamtherapyforhepatocellularcarcinomaadjacenttotheportahepatis.IntJRadiatOncolBiolPhys.2008;71(2):462-467.

193. MizumotoM,TokuuyeK,SugaharaS,etal.Protonbeamtherapyforhepatocellularcarcinomawithinferiorvenacavatumorthrombus:reportofthreecases.JpnJClinOncol.2007;37(6):459-462.

194. MondlaneG,GubanskiM,LindPA,etal.Comparativestudyofthecalculatedriskofradiation-inducedcancerafterphoto-andproton-beambasedradiosurgeryof livermetastases.EurJMedPhys.2017Oct;42:263-270.

195. Mondlane G, Ureba A, Michael G, et al. Evaluation of the risk for radiation-induced liver diseasefollowing photon- or proton-beam radiosurgery of liver metastases. Radiat Oncol. 2018,http://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-158223.

196. NakayamaH,SugaharaS,FukudaK,etal.Protonbeamtherapyforhepatocellularcarcinomalocatedadjacenttothealimentarytract.IntJRadiatOncolBiolPhys.2011;80(4):992-995.

197. NakayamaH, Sugahara S, TokitaM, et al. Proton beam therapy for hepatocellular carcinoma. TheUniversityofTsukubaexperience.Cancer.2009;115(23):5499-5506.

198. NiizawaG, Ikegami T,Matsuzaki Y, et al.Monitoringof hepatocellular carcinoma, followingprotonradiotherapy, with contrast-enhanced color Doppler ultrasonography. J Gastroenterol.2005;40(3):283-290.

199. OharaK,OkumuraT,TsujiH,etal.Clearanceofparenchymaltumorsfollowingradiotherapy:analysisofhepatocellularcarcinomastreatedbyprotonbeams.RadiotherOncol.1996;41(3):233-236.

200. OharaK,OkumuraT,TsujiH,etal.Radiationtoleranceofcirrhoticliversinrelationtothepreservedfunctionalcapacity:analysisofpatientswithhepatocellularcarcinomatreatedbyfocusedprotonbeamradiotherapy.IntJRadiatOncolBiolPhys.1997;38(2):367-372.

201. Ohkawa A, Mizumoto M, Ishikawa H, et al. Proton beam therapy for unresectable intrahepaticcholangiocarcinoma.JGastroenterolHepatol.2015May;30(5):957-63.

202. OshiroY,MizumotoM,OkumuraT,etal.Analysisofrepeatedprotonbeamtherapyforpatientswithhepatocellularcarcinoma.RadiotherOncol.2017May;123(2):240-245.

203. OtsukaM,OharaK,TakadaY,etal.Radiationtherapyforintrahepaticrecurrenceafterhepatectomyforhepatocellularcarcinoma.IntJClinOncol.2003;8(3):151-155.

204. Petersen JB, Lassen Y,HansenAT, et al.Normal liver tissue sparing by intensity-modulated protonstereotacticbodyradiotherapyforsolitarylivertumours.ActaOncol.2011Aug;50(6):823-828.

205. QiWX,ShenF,QingZ,Xiao-MaoG.Chargedparticletherapyversusphotontherapyforpatientswithhepatocellularcarcinoma:asystematicreviewandmeta-analysis.RadiatOncol.2015;114:289-295.

206. SchlachtermanA,CraftWWJr,HilgenfeldtE,etal.Currentandfuturetreatmentsforhepatocellularcarcinoma.WorldJGastroenterol.2015July;21(28):8478-8491

Page 61: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page61

207. ShibataS,TakamatsuS,YamamotoK,etal.ProtonBeamTherapywithoutFiducialMarkersUsingFour-Dimensional CT Planning for Large Hepatocellular Carcinomas. Cancers. 2018; 10(3), 71;doi:10.3390/cancers10030071.

208. Sugahara S, Nakayama H, Fukuda K, et al. Proton-beam therapy for hepatocellular carcinomaassociatedwithportalveintumorthrombosis.StrahlentherOnkol.2009;185(12):782-788.

209. SugaharaS,OshiroY,NakayamaH,etal.Protonbeamtherapyforlargehepatocellularcarcinoma.IntJRadiatOncolBiolPhys.2010;76(2):460-466.

210. TaddeiPJ,HowellRM,KrishnanS,etal.Riskofsecondmalignantneoplasmfollowingprotonversusintensity-modulated photon radiotherapies for hepatocellular carcinoma. Phys Med Biol.2010;55(23):7055-65.

211. WangX,KrishnanS,ZhangX,etal.Protonradiotherapyforlivertumors:dosimetricadvantagesoverphotonplans.MedDosim.2008Winter;33(4):259-67.

212. YeungR,BowenSR,MullenTD,etal.ChestWallToxicityinHypofractionatedProtonBeamTherapyforLiverMalignancies.IntJRadiatOncolBiolPhys.2017;99(2):E202.

213. Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S. Proton beam therapy for hepatocellularcarcinoma.ExpertRevAnticancerTher.2017Oct;17(10):911-924.

214. YoshidaM,OginoH,IwataH,etal.TransientIncreasesofSerumAFPandPIVKA-IILevelsAfterProtonTherapyDoNotNecessarilyIndicateProgressionofHepatocellularCarcinoma.IntJRadiatOncolBiolPhys.2017;99(2S):E203.

Pancreas

215. Hitchcock K, Nichols R, Morris C, et al. Feasibility of pancreatectomy following high-dose protontherapyforunresectablepancreaticcancer.WorldJGastrointestSurg.2017Apr27;9(4):103–108.

216. HongTS,RyanDP,BlaszkowskyLS,etal.PhaseIstudyofpreoperativeshort-coursechemoradiationwithprotonbeamtherapyandcapecitabineforresectablepancreaticductaladenocarcinomaofthehead.IntJRadiatOncolBiolPhys.2011;79(1):151-157.

217. Maemura K, Mataki Y, Kurahara H, et al. Comparison of proton beam radiotherapy and hyper-fractionatedacceleratedchemoradiotherapy for locallyadvancedpancreaticcancer.Pancreatology.2017Sep–Oct;17(5):833-838.

218. Nichols RC Jr, George TJ, Zaiden RA Jr, et al. Proton therapy with concomitant capecitabine forpancreaticandampullarycancersisassociatedwithalowincidenceofgastrointestinaltoxicity.ActaOncol.2013;52(3):498-505.

219. NicholsRCJr,HuhS,LiZ,RutenbergM.Protontherapy forpancreaticcancer.World JGastrointestOncol.2015Sep;7(9):141-147.

220. Nichols RC Jr, Huh SN, Prado KL, et al. Protons offer reduced normal-tissue exposure for patientsreceivingpostoperativeradiotherapyforresectedpancreaticheadcancer.IntJRadiatOncolBiolPhys.2012May1;83(1):158-163.

221. Nichols RC Jr, Morris CG, Hoppe BS, Rutenberg MS. A phase II trial of escalated dose protonradiotherapy with elective nodal irradiation and concomitant chemotherapy for patients withunresectable,borderlineresectable,ormedicallyinoperablepancreaticadenocarcinoma.JClinOncol.2017;35(4).

Page 62: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page62

222. NicholsRCJr,MorrisCG,PrabhuK,etal.PostoperativeprotontherapyforpancreaticcancerpatientsenrolledontheProtonCollaborativeGroup(PCG)registry.JClinOncol.2018;36(4):513.

223. NicholsRCJr,MorrisCG,TottenhamL,etal.ProtonTherapyforPancreaticandAmpullaryCarcinoma.IntJRadiatOncolBiolPhys.2017;99(2):E176-177.

224. Sio TT,Merrell KW, Beltran CJ, et al. Spot-scanned pancreatic stereotactic body proton therapy: adosimetricfeasibilityandrobustnessstudy.PhysMed.2016Feb;32(2):331-42.

225. Takatori K, Terashima K, Yoshida R, et al. Upper gastrointestinal complications associated withgemcitabine-concurrentprotonradiotherapyforinoperablepancreaticcancer.JGastroenterol.2014Jun;49(6):1074-1080.

226. Terashima K, Demizu Y, Hashimoto N, et al. A phase I/II study of gemcitabine-concurrent protonradiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol.2012;103(1):25-31.

227. ThompsonRF,etal.Adosimetriccomparisonofprotonandphotontherapyinunresectablecancersoftheheadofpancreas.MedPhys.2014Aug;41(8):081711.

Rectus

228. Colaco RJ, Nichols RC, Huh S, et al. Protons offer reduced bonemarrow, small bowel, and urinarybladder exposure for patients receiving neoadjuvant radiotherapy for resectable rectal cancer. JGastrointestOncol.2014;5(1):3-8.

229. RaduC,NorrlidO,BraendengenM,etal.Integratedperipheralboostinpreoperativeradiotherapyforthelocallymostadvancednon-resectablerectalcancerpatients.ActaOncol.2013;52(3):528-537.

230. WolffHA,WagnerDM,ConradiL,etal. Irradiationwithprotonsforthe individualizedtreatmentofpatientswith locally advanced rectal cancer: A planning studywith clinical implications. RadiotherOncol.2012;102(1):30-37.

OtherGastrointestinal

231. Plastaras JP,Dionisi F,Wo JY.Gastrointestinal cancer: non-liver proton therapy for gastrointestinalcancers.CancerJournal.2014;20(6):387-86.

GENITOURINARY

232. ChooR,KazembaB,ChooCS,LesterSC,WhitakerT.ProtontherapyforstageIIA-Bseminoma:anewstandardofcarefortreatingretroperitonealnodes.IntJPartTher.2018.In-Press.

233. HataM,MiyanagaN,TokuuyeK,etal.Protonbeamtherapyforinvasivebladdercancer:aprospectivestudyofbladder-preservingtherapywithcombinedradiotherapyandintraarterialchemotherapy.IntJRadiatOncolBiolPhys.2006;64(5):1371-1379.

GYNECOLOGY

234. ArimotoT,KitagawaT,TsujiiH,OhharaK.High-energyprotonbeamradiationtherapyforgynecologicmalignancies.Potentialofprotonbeamasanalternativetobrachytherapy.Cancer.1991;68(1):79-83.

Page 63: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page63

235. ClivioA,KlugeA,CozziL,etal.Intensitymodulatedprotonbeamradiationforbrachytherapyinpatientswithcervicalcarcinoma.IntJRadiatOncolBiolPhys.2013December1;87(5):897-903.

236. KageiK,TokuuyeK,OkumuraT,etal.Long-temresultsofprotonbeamtherapyforcarcinomaoftheuterinecervix.IntJRadiatOncolBiolPhys.2003;55(5):1265-1271.

237. Marnitz S,WlodarczykW, NeumannO, et al.Which technique for radiation ismost beneficial forpatientswith locallyadvancedcervicalcancer? Intensitymodulatedprotontherapyversus intensitymodulatedphotontreatment,helicaltomotherapyandvolumetricarctherapyforprimaryradiation–anintraindividualcomparison.RadiatOncol.2015;10:91.

238. VermaV,SimoneCB,WahlAO,etal.Protonradiotherapyforgynecologicneoplasms.ActaOncol.2016Nov;55(11):1257-1265.

HEADANDNECK

239. BlanchardP,FrankSJ.Protontherapyforheadandneckcancers.CancerRadiother.2017;21:515-520.

240. BlanchardP,FrankSJ.SP-016:thevalueofprotontherapyforheadandneckmalignancies:reducingsideeffectsandimprovingoutcomes.RadiotherOncol.2017;122(2):12.

241. BlanchardP,WongAJ,GunnGB, et al. Towardamodel-basedpatient selection strategy forprotontherapy:Externalvalidationofphoton-derivednormaltissuecomplicationprobabilitymodelsinaheadandneckprotontherapycohort.RadiotherOncol.2016Dec;121(3):381-386.

242. ChanA,LiebschN.Protonradiationtherapyforheadandneckcancer.JSurgOncol.2008;97(8):697-700.

243. ChengQ,RoelofsE,RamaekersBLT,etal.Developmentandevaluationofanonlinethree-levelprotonvsphotondecisionsupportprototypeforheadandneckcancer–comparisonofdose,toxicity,andcost-effectiveness.RadiotherOncol.2016;118(2):281-285.

Nasopharynx

244. BrownAP, UrieMM, Chisin R, et al. Proton therapy for carcinoma of the nasopharynx: a study incomparativetreatmentplanning.IntJRadiatOncolBiolPhys.1989;16:1607–1614.

245. ChanA,AdamsJA,WeymanE,etal.APhaseIITrialofProtonRadiationTherapywithChemotherapyforNasopharyngealCarcinoma.IntJRadiatOncolBiolPhys.2012;84:S151–S152

246. ChanA,LiebschL,DeschlerD,etal.ProtonradiotherapyforT4nasopharyngealcarcinoma.JClinOncol.2004;22:5574

247. HojoH,ZendaS,AkimotoT,etal.Impactofearlyradiologicalresponseevaluationonradiotherapeuticoutcomes in thepatientswith nasal cavity andparanasal sinusmalignancies. J Radiat Res (Tokyo).2012;53(5):704-709.

248. Holliday EB, Frank SJ. Proton Therapy for Nasopharyngeal Carcinoma. Chin Clin Oncol. 2016April;5(2):25.

249. HollidayEB,GardenAS,RosenthalDI,etal.Protontherapyreduces treatment-relatedtoxicities forpatients with nasopharyngeal cancer: a case-match control study of intensity-modulated protontherapyandintensity-modulatedphotontherapy.IntJPartTher.2015;2(1):1-10.

Page 64: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page64

250. LewisGD,Holliday EB, Kocak-Uzel E, et al. Intensity-modulatedproton therapy for nasopharyngealcarcinoma:decreasedradiationdosetonormalstructuresandencouragingclinicaloutcomes.HeadNeck.2016Apr;38Suppl1:E1886-1895.

251. Lin R, Slater JD, Yonemoto LT, et al. Nasopharyngeal carcinoma: repeat treatmentwith conformalprotontherapy–dose-volumehistogramanalysis.Radiology.1999;213(2):489-494.

252. LiuS-W,LiJ-M,ChangJ-Y,etal.Atreatmentplanningcomparisonbetweenprotonbeamtherapyandintensity-modulated x-ray therapy for recurrent nasopharyngeal carcinoma. J X-Ray Sci Technol.2010;18:443–450.

253. LomaxAJ,GoiteinM,AdamsJ. Intensitymodulation inradiotherapy:Photonsversusprotons intheparanasalsinus.RadiotherOncol.2003;66:11–18.

254. McDonaldMW, Liu Y, MooreMG, Johnstone PA. Acute toxicity in comprehensive head and neckradiation fornasopharynxandparanasal sinus cancers: cohort comparisonof3Dconformalprotontherapyandintensitymodulatedradiationtherapy.RadiatOncol.2016;11:32.

255. MockU,GeorgD,BognerJ,etal.Treatmentplanningcomparisonofconventional,3Dconformal,andintensity-modulatedphoton (IMRT) andproton therapy for paranasal sinus carcinoma. Int J RadiatOncolBiolPhys.2004;58:147–154.

256. NicholsAC,ChanAW,CurryWT,etal.Esthesioneuroblastoma:theMassachusettsEyeandEarInfirmaryandMassachusettsGeneralHospitalexperiencewithcraniofacial resection,protonbeamradiation,andchemotherapy.SkullBase.2008.18;(5):327-336.

257. NishimuraH,OginoT,KawashimaM,etal.Proton-beamtherapyforolfactoryneuroblastoma. Int JRadiatOncolBiolPhys.2007;68(3):758-762.

258. OkanoS,TaharaM,ZendaS,etal.Inductionchemotherapywithdocetaxel,cisplatinandS-1followedbyprotonbeamtherapyconcurrentwithcisplatininpatientswithT4bnasalandinonasalmalignancies.JpnJClinOncol.2012;42(8):691-696.

259. PatelSH,WangZ,WongWW,etal.Chargedparticletherapyversusphotontherapyforparanasalsinusand nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol. 2014Aug;15(9):1028-1038.

260. RussoAL,AdamsJA,WeymanEA,etal.Long-termoutcomesafterprotonbeamtherapyforsinonasalsquamouscellcarcinoma.IntJRadiatOncolBiolPhys.2016;95(1):368-376.

261. Slater JD, Loredo LN, Chung A, et al. Fractionated proton radiotherapy for benign cavernous sinusmeningiomas.IntJRadiatOncolBiolPhys.2012;83(5):e633-e637.

262. Taheri-KadkhodaZ,Björk-ErikssonT,NillS,etal.Intensity-modulatedradiotherapyofnasopharyngealcarcinoma:acomparativetreatmentplanningstudyofphotonsandprotons.RadiatOncol.2008;3:4.

263. Truong MT, Kamat UR, Liebsch NJ, et al. Proton radiation therapy for primary sphenoid sinusmalignancies:treatmentoutcomeandprognosticfactors.HeadNeck.2009;31(10):1297-308.

264. WeberDC,ChanAW,LessellS,etal.Visualoutcomeofacceleratedfractionatedradiationforadvancedsinonasalmalignanciesemployingphotons/protons.RadiotherOncol.2006;81(3):243-249.

265. WidesottL,PierelliA,FiorinoC,etal.Intensity-modulatedprotontherapyversushelicaltomotherapyinnasopharynxcancer:PlanningcomparisonandNTCPevaluation.IntJRadiatOncolBiolPhys.2008Oct1;72(2):589-596.

Page 65: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page65

266. ZendaS,KohnoR,KawashimaM,etal.Protonbeamtherapyforunresectablemalignanciesofthenasalcavityandparanasalsinuses.IntJRadiatOncolBiolPhys.2011;81(5):1473-1478.

Oropharynx

267. ArtsT,BreedveldS,deJongMA,etal.Theimpactoftreatmentaccuracyonprotontherapypatientselection for oropharyngeal cancer patients. Radiother Oncol. 2017 October 23.https://doi.org/10.1016/j.radonc.2017.09.028.

268. BagleyAF,YeR,HernandezM,FrankSJ.(P30)ProspectiveOutcomesofXerostomia-RelatedqualityofLifeinOropharyngealCarcinomaPatientsTreatedWithProtonTherapy.IntJRadiatOncolBiolPhys.2018;101(2):E32-E33.

269. Blanchard P, Garden AS, Gunn GB, et al. Intensity-modulated proton beam therapy (IMPT) versusintensity-modulated photon therapy (IMRT) for patientswith oropharynx cancer - A casematchedanalysis.RadiotherOncol.2016Jul;120(1):48-55.

270. FrankSJ,BlanchardP, Lee JJ, et al. Comparing Intensity-ModulatedProtonTherapyWith Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept toActivation.SeminRadiatOncol.2018.doi:10.1016/j.semradonc.2017.12.002.

271. FrankSJ,RosenthalDI,AngK,etal.Gastrostomytubesdecreasebyover50%withintensitymodulatedprotontherapy(IMPT)duringthetreatmentoforopharyngealcancerpatients:acase-controlstudy.IntJRadiatOncolBiolPhys.2013October1;87(2):S144.

272. GunnGB,BlanchardP,GardenAS,etal.Clinicaloutcomesandpatternsofdiseaserecurrencefollowingintensity modulated proton therapy for oropharyngeal squamous carcinoma: results from singleinstitutionprospectiveregistrystudies.IntJRadiatOncolBiolPhys.2016May1;95(1):360-367.

273. GunnGB, Frank SJ. Advances in radiation oncology for themanagement of oropharyngeal tumors.OtolaryngolClinNorthAm.2013Aug;46(4):629-643.

274. HayashiY,NakamuraT,MitsudoK,etal.Retrogradeintra-arterialchemotherapyanddailyconcurrentprotonbeamtherapyforrecurrentoralcavitysquamouscellcarcinoma:analysisoftherapeuticresultsin46cases.HeadNeck.2016Aug;38(8):1145-1151.

275. HollidayEB,FrankSJ.Dosimetricadvantagesofintensitymodulatedprotontherapyfororopharyngealcancercomparedwith intensity-modulated radiation:Acase-matchedcontrolanalysis.MedDosim.2016;41(3):189-194.

276. KutchesonK,LewinJS,GardenAS,etal.EarlyexperiencewithIMPTforthetreatmentoforopharyngealtumors:acutetoxicitiesandswallowing-relatedoutcomes.IntJRadiatOncolBiolPhys.2013;87:S604.

277. RwigemaJC,LangendijkJA,vanderLaanHP,etal.ProtonTherapyImprovesToxicityforOropharyngealCancer: An Outcomes and Predictive Model-based Approach. Int J Radiat Oncol Biol Phys.2017;99(2S):S135.

278. SharmaS,ZhouO,ThompsonR,GabrielP,ChalianA,RassekhC,WeinsteinGS,O’MalleyBW,AggarwalC, Bauml J, Cohen RB, Lukens N, Swisher-McClure S, Ghiam AF, Ahn PH, Lin A. Quality of life ofpostoperativephotonversusprotonradiationtherapyfororopharynxcancer.IntJPartTher.2018.In-press.

279. SioTT, LinHK,ShiQ,etal. Intensitymodulatedproton therapyversus intensitymodulatedphotonradiationtherapyfororopharyngealcancer:firstcomparativeresultsofpatient-reportedoutcomes.IntJRadiatOncolBiolPhys.2016Jul15;95(4):1107-1114.

Page 66: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page66

280. SlaterJD,YonemotoLT,MantikDW,etal.Protonradiationfortreatmentofcanceroftheoropharynx:earlyexperienceatLomaLindaUniversityMedicalCenterusingaconcomitantboosttechnique.IntJRadiatOncolBiolPhys.2005;62(2):494-500.

281. VandeWaterTA,LomaxAJ,BijlHP,etal.Potentialbenefitsofscannedintensity-modulatedprotontherapyversusadvancedphotontherapywithregardtosparingofthesalivaryglandsinoropharyngealcancer.IntJRadiatOncolBiolPhys.2011,79(4):1216-1224.

282. VandeWaterTA,LomaxAJ,BijlHP,etal.Usingareducedspotsizeforintensity-modulatedprotontherapypotentially improves salivarygland-sparing inoropharyngeal cancer. Int JRadiatOncolBiolPhys.2012;82:e313–319.

ParanasalSinuses

283. CheraBS,MalyapaR, LouisD,etal.Proton therapy formaxillary sinuscarcinoma.AmJClinOncol.2009;32:296–303.

284. DaganR,BryantC,LiZ,etal.Outcomesofsinonasalcancertreatedwithprotontherapy.IntJRadiatOncolBiolPhys.2016;95(1):377-385.

285. FitzekMM,ThorntonAF,VarvaresM,etal.Neuroendocrinetumorsofthesinonasaltract.Resultsofaprospectivestudy incorporatingchemotherapy,surgery,andcombinedprotonphotonradiotherapy.Cancer.2002;94(10):2623-2634.

286. FujiH,YoshikawaS,KasamiM,etal.High-doseprotonbeamtherapyforsinonasalmucosalmalignantmelanoma.RadiatOncol.2014July23;9:162.

287. Fukumitsu N, Okumura T,MizumotoM, et al. Outcome of T4 (International Union Against CancerStaging System, 7th edition) or recurrent nasal cavity and paranasal sinus carcinoma treatedwithprotonbeam.IntJRadiatOncolBiolPhys.2012;83(2):704-711.

OtherHeadandNeck

288. BhattasaliO,HollidayEB,KiesMS,etal.Definitiveprotonradiationtherapyandconcurrentcisplatinforunresectableheadandneckadenoidcysticcarcinoma:Aseriesof9casesandacriticalreviewoftheliterature.HeadandNeck.2016April;38(Suppl1):E1472-E1480.

289. Cozzi L, FogliataA, LomaxA, Bolsi A. A Treatment Planning Comparisonof 3DConformal Therapy,PhotonTherapy,andProtonTherapyforTreatmentofAdvancedHeadandNeckTumors.RadiotherOncol.2001Dec;61(3):287-297.

290. DemizuY,FujiiO,TerashimaK,etal.Particletherapyformucosalmelanomaoftheheadandneck.Asingle-institution retrospective comparison of proton and carbon ion therapy. Strahlenther Onkol.2014;190(2):186-191.

291. DemizuY,MurakamiM,MiyawakiD,etal.Analysisofvision losscausedbyradiation-inducedopticneuropathyafterparticletherapyforhead-and-neckandskull-basetumorsadjacenttoopticnerves.IntJRadiatOncolBiolPhys.2009;75(5):1487-1492.

292. El-SawyT,FrankSJ,HannaE,etal.Multidisciplinarymanagementof lacrimalsac/nasolacrimalductcarcinomas.OphthalPlastReconstrSurg.2013Nov-Dec;29(6):454-7.

293. EndoH,TakayamaK,MitsudoK,etal.Protonbeamtherapyincombinationwithintra-arterialinfusionchemotherapyforT4squamouscellcarcinomaofthemaxillarygingiva.Cancers.2018;10(9).

Page 67: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page67

294. FrankSJ,CoxJD,GillinM,etal.Multifieldoptimizationintensitymodulatedprotontherapyforheadandnecktumors:atranslationtopractice.IntJRadiatOncolBiolPhys.2014Jul15;89(4):846-853.

295. HarrellLM,PaulinoAC,MahajanA,etal.ClinicalOutcomesandToxicityFollowingProtonRadiationTherapyforHeadandNeckRhabdomyosarcoma.IntJRadiatOncolBiolPhys.2016Oct1;96(2S):E549-E550.

296. HollidayEB,BhattasaliO,KiesMS,etal.EffectiveuseofIntensity-ModulatedProtonTherapyforRobustDeliveryofPost-operativeRadiationforHeadandNeckAdenoidCysticCarcinoma.IntJPartTher.2016;2(4):533-543.

297. HollidayEB,BhattasaliO,KiesMS,etal.Postoperativeintensity-modulatedprotontherapyforheadandneckadenoidcysticcarcinoma.IntJPartTher.2016.doi:10.14338/IJPT-15-00032.1.

298. HollidayEB,FrankSJ.Currentapplicationsofprotonbeamradiationforthetreatmentofheadandnecktumors.Otorinolaringo.2014;64(1):1-11.

299. Holliday EB, Frank SJ. Proton radiation therapy for head and neck cancer: a review of the clinicalexperiencetodate.IntJRadiatOncolBiolPhys.2014;89(2):292-302.

300. Jakobi A, Stützer K, Bandurska-LuqueA, et al.NTCP reduction for advancedhead andneck cancerpatientsusingprotontherapyforcompleteorsequentialboosttreatmentversusphotontherapy.ActaOncologica.2015;54(9):1658-1664.

301. Kandula S, Zhu X, Garden AS, et al. Spot-scanning beam proton therapy vs intensity-modulatedradiationtherapyforipsilateralheadandneckmalignancies.MedDosim.2013Winter;38(4):390-394.

302. Leeman JE, Romesser PB, Zhou Y, et al. Proton therapy for head and neck cancer: expanding thetherapeuticwindow.LancetOncol.2017;18(5):e254-265.

303. LintonOR,MooreMG,BriganceJS,etal.Protontherapyforheadandneckadenoidcysticcarcinoma:initialclinicaloutcomes.HeadNeck.2015;37(1):117-124.

304. LiuW,FrankSJ,LiX,etal.Effectivenessofrobustoptimizationinintensity-modulatedprotontherapyplanningforheadandneckcancers.MedicalPhysics.2013;40(5):051711.

305. Ludmir EB, PaulinoAC,GrosshansDR,McAleerMF,McGovern SL,HuhWW,OkcuMF,Harrell LM,MahajanA.Patternsoffailurewithprotontherapyforheadandneckrhabdomyosarcoma.IntJRadiatOncolBiolPhys.2018July15;101(4):1007.

306. Lukens JN, Lin A, Hahn SM. Proton therapy for head and neck cancer. Curr Opin Oncol. 2015May;27(3):165-171.

307. MalyapaRS,WeberDC,SchneiderR,etal.Pencilbeamscanningintensitymodulatedprotontherapyforheadandneckcancersinvolvingskullbase.JNeurolSurgB.2016;77-A087.

308. McKeeverMR,SioTT,GunnGB,etal.Reducedacutetoxicityand improvedefficacyfromintensity-modulatedprotontherapy(IMPT)forthemanagementofheadandneckcancer.ChinClinOncol.2016Aug;5(4):54.

309. MiralbellR,CrowellC, SuitHD.Potential improvementof threedimension treatmentplanningandprotontherapyintheoutcomeofmaxillarysinuscancer.IntJRadiatOncolBiolPhys.1992;22:305–310.

310. PhanJ,SioTT,NguyenTP,etal.Reirradiationofheadandneckcancerswithprotontherapy:outcomesandanalyses.IntJRadiatOncolBiolPhys.2016Sep1;96(1):30-41.

Page 68: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page68

311. RamaekersBL,GruttersJPC,Pijls-JohannesmaM,etal.Protonsinheadandneckcancer:bridgingthegapofevidence.IntJRadiatOncolBiolPhys.2013;85(5):1282-1288.

312. Ramaekers BL, Pijls-Johannesma M, Joore MA, et al. Systematic review and meta-analysis ofradiotherapy invariousheadandneckcancers:comparingphoton,carbonionsandprotons.CancerTreatRev.2011;37(3):185-201.

313. RomesserPB,CahlonO,ScherE,etal.Protonbeamradiationtherapyresultsinsignificantlyreducedtoxicitycomparedwithintensity-modulatedradiationtherapyforheadandnecktumorsthatrequireipsilateralradiation.RadiotherOncol.2016Feb;118(2):286-292.

314. RomesserPB,CahlonO,ScherE,etal.Protonbeamre-irradiationforrecurrentheadandneckcancer:multi-institutional report on feasibility and early outcomes. Int J Radiat Oncol Biol Phys.2016;95(1):386-395.

315. ScandurraD,KierkelsRGJ,GeldermanM,etal.EP-1542Canprotontherapyforheadandneckcancerreducesideeffectswhilemaintainingtargetrobustness?RadiotherOncol.2017May;123(1):S1-S1077.

316. Sheu T, Garden AS, Fuller CD, et al. ReirradiationUtilizing Proton Radiation TherapyMay ImproveToxicityFreeSurvival inPatientsWithSmall-Volume,RecurrentHeadAndNeckCancer. Int JRadiatOncolBiolPhys.2016Oct1;96(2S):E331.

317. Simone CB, Ly D, Dan TD, et al. Comparison of intensity-modulated radiotherapy, adaptiveradiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locallyadvancedheadandneckcancer.RadiotherOncol.2011Dec;101(3):376-382.

318. StenekerM,LomaxA,SchneiderU.Intensitymodulatedphotonandprotontherapyforthetreatmentofheadandnecktumors.RadiotherOncol.2006;80:263–267.

319. ThakerNG,FrankSJ,FeeleyTW.Comparativecostsofadvancedprotonandphotonradiationtherapies:lessonsfromtime-drivenactivity-basedcostinginheadandneckcancer.JCompEffRes.2015;4(4):297-301.

320. Tokuuye K, Akine Y, Kagei K, et al. Proton therapy for head and neck malignancies at Tsukuba.StrahlentherOnkol.2004;180(2):96-101.

321. VandeWaterTA,BijlHP,SchilstraC,etal.ThePotentialBenefitofRadiotherapywithProtonsinHeadandNeckCancerwithRespecttoNormalTissueSparing:ASystematicReviewofLiterature.Oncologist.2011;16(3):366-377.

322. VanderLaanHP,vandeWaterTA,vanHerptHE,etal.Thepotentialofintensity-modulatedprotonradiotherapytoreduceswallowingdysfunctioninthetreatmentofheadandneckcancer.ActaOncol.2013Apr;52(3):561-569.

323. WaddleMR, HeckmanM, Diehl NN, et al. Survival After Proton and Photon Radiation Therapy inPatientsWithHeadandNeckCancers:AStudyoftheNationalCancerDatabase.IntJRadiatOncolBiolPhys.2018;100(5):1330.

324. YehB,HollidayEB,FrankSJ.IsAdaptivePlanningNecessaryforIntensityModulatedProtonTherapyforHeadandNeckCancer?SubmittedtoMedDosim;Nov2015.

325. ZendaS,KawashimaM,NishioT,etal.Protonbeamtherapyasanonsurgicalapproachtomucosalmelanomaoftheheadandneck:apilotstudy.IntJRadiatOncolBiolPhys.2011;81(1):135-139.

LYMPHOMA

Page 69: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page69

326. Andolino DL, Hoene T, Xiao L, et al. Dosimetric comparison of involved-field three-dimensionalconformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin’slymphomainfemalepediatricpatients.IntJRadiatOncolBiolPhys.2011Nov15;81(4):e667-71.

327. BellardiniJA,BajwaA,SeeramV,etal.Effectsofprotontherapyonpulmonaryfunction inHodgkinlymphomapatients.AmJRespirCritCareMed.2016;193:A6037.

328. CellaL,ConsonM,PresselloMC,etal.Hodgkin'slymphomaemergingradiationtreatmenttechniques:trade-offs between late radio-induced toxicities and secondarymalignant neoplasms. RadiatOncol2013;8:22.

329. Chera BS, Rodriguez C, Morris CG, et al. Dosimetric comparison of three different involved nodalirradiationtechniquesforstageIIHodgkin'slymphomapatients:conventionalradiotherapy,intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys2009;75:1173-1180.

330. GuzhvaL,MendenhallNP,MorrisCG,etal.EvaluatingCardiacBiomarkersafterChemotherapyandProtonTherapyforMediastinalHodgkinLymphoma.IntJPartTher.2017;DOI10.14338/IJPT-D-17-00022.

331. HoppeBS,FlampouriS,LynchJ,etal.ImprovingtheTherapeuticRatioinHodgkinLymphomaThroughtheUseofProtonTherapy.Oncology(WillistonPark).2012;26(5):456-459,462-65.

332. Hoppe BS, Flampouri S, Su Z, et al. Consolidated Involved-Node Proton Therapy for Stage IA-IIIBMediastinalHodgkinLymphoma:PreliminaryDosimetricOutcomesFromaPhaseIIStudy.IntJRadiatOncolBiolPhys.2012;83(1):260-267.

333. Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protonscomparedwith3DCRTandIMRTinmediastinalHodgkinlymphoma.IntJRadiatOncolBiolPhys.2012Oct1;84(2):449-455

334. HoppeBS,FlampouriS,ZaidenR,etal.Involved-nodeprotontherapyincombinedmodalitytherapyforHodgkinlymphoma:resultsofaphase2study.IntJRadiatOncolBiolPhys.2014Aug1;89(5):1053-1059.

335. HoppeBS,Hill-KayserCE,TsengYD,etal.ConsolidativeprotontherapyafterchemotherapyforpatientswithHodgkinlymphoma.AnnOncol.2017Sep1;28(9):2179-2184.

336. HoppeBS,Hill-KayserCE, TsengYD,et al. TheUseofConsolidativeProtonTherapyAfter First-LineTherapyAmongPatientsWithHodgkinLymphomaatAcademicandCommunityProtonCenters.IntJRadiatOncolBiolPhys2016;96:S39.

337. HoppeBS,MendenhallNP,LouisD,etal.ComparingBreathHoldandFreeBreathingduringIntensity-ModulatedRadiationTherapyandProtonTherapyinPatientswithMediastinalHodgkinLymphoma.IntJPartTher.2017Spring;3(4):492-496.

338. HoppeBS,TsaiH, LarsonG,etal.Proton therapypatterns-of-careandearlyoutcomes forHodgkinlymphoma:resultsfromtheProtonCollaborativeGroupRegistry.ActaOncol.2016;55:1378-1380.

339. Horn S, Fournier-Bidoz N, Pernin V, et al. Comparison of passive-beam proton therapy, helicaltomotherapyand3Dconformal radiationtherapy inHodgkin’s lymphomafemalepatientsreceivinginvolved-fieldorinvolvedsiteradiationtherapy.CancerRadiother.2016Apr;20(2):98-103.

340. JorgensenAY,MaraldoMV,BrodinNP, et al. The effect on esophagus after different radiotherapytechniquesforearlystageHodgkin'slymphoma.ActaOncol2013;52:1559-1565.

Page 70: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page70

341. KnauslB,Lutgendorf-CaucigC,HopfgartnerJ,etal.CantreatmentofpediatricHodgkin'slymphomabeimprovedbyPETimagingandprotontherapy?StrahlentherOnkol2013;189:54-61.

342. Li J, Dabaja B, Reed V, et al. Rationale for and preliminary results of proton beam therapy formediastinallymphoma.IntJRadiatOncolBiolPhys.2011;81(1):167-174.

343. MaraldoMV, Brodin NP, AznarMC, et al. Estimated risk of cardiovascular disease and secondarycancerswithmodernhighlyconformalradiotherapyforearly-stagemediastinalHodgkin lymphoma.AnnOncol2013;24:2113-2118.

344. MohindraP,TsengYD,BadiyanSN,etal.ProtonTherapyforLymphoma:AMulti-institutionalPatternsofCareStudy.IntJRadiatOncolBiolPhys.2017Oct1;99(2):E433.

345. PlastarasJP,MaityA,FlampouriS,etal.Bi-institutionalreportonconsolidativeprotontherapyafterinitial chemotherapy for mediastinal diffuse large B-cell and primary mediastinal large B-celllymphomas.IntJRadiatOncolBiolPhys.2018;102(3).

346. PlastarasJP,VogelJ,ElmongyH,etal.FirstClinicalReportofPencilBeamScannedProtonTherapyforMediastinalLymphoma.IntJRadiatOncolBiolPhys2016;96:E497.

347. RechnerLA,MaraldoMV,VogeliusIR,etal.LifeyearslostattributabletolateeffectsafterradiotherapyforearlystageHodgkinlymphoma:Theimpactofprotontherapyand/ordeepinspirationbreathhold.RadiotherOncol.2017;125(1):41-47.

348. Ricardi U, Dabaja B, Hodgson DC. Proton therapy inmediastinal Hodgkin lymphoma:moving fromdosimetricpredictiontoclinicalevidence.AnnOncol.2017Sep1;28(9):2049-2050.

349. RutenbergMS,Flampouri,HoppeBS.ProtontherapyforHodgkinlymphoma.CurrHematolMaligRep.2014Sep;9(3):203-211

350. SachsmanS,FlampouriS,LiZ,etal.Protontherapyinthemanagementofnon-Hodgkinlymphoma.LeukLymphoma.2015;56(9):2608-2612

351. ToltzA,ShinN,MitrouE,etal.LateradiationtoxicityinHodgkinlymphomapatients:protontherapy’spotential.JApplClinMedPhys.2015Sep8;16(5):167-178.

352. TsengYD,HoppeBS,MillerD,etal.RatesofToxicityandOutcomesAfterMediastinalProtonTherapyForRelapsed/RefractoryLymphoma.IntJRadiatOncolBiolPhys2017;99:S62-S63.

353. Winkfield KM, Gallotto S, Adams JA, et al. Proton Therapy forMediastinal Lymphomas: An 8-yearSingle-institutionReport.IntJRadiatOncolBiolPhys2015;93:E461.

354. ZengC,PlastarasJP,JamesP,etal.Protonpencilbeamscanningformediastinallymphoma:treatmentplanningandrobustnessassessment.ActaOncol.2016Sep-Oct;55(9-10):1132-1138.

OCULAR

355. AgarwalA,ThakerNG,TawkB,etal.Theevolutionofradiationtherapyforretinoblastoma:theMDAndersonCancerCenterexperience.IntJPartTher.2016;2(4):490-498.

356. ArvoldND,LessellS,BussiereM,etal.Visualoutcomeandtumorcontrolafterconformalradiotherapyforpatientswithopticnervesheathmeningioma.IntJRadiatOncolBiolPhys.2009;75(4):1166-1172.

357. Aziz S, Taylor A, McConnachie A, et al. Proton beam radiotherapy in the management of uvealmelanoma:clinicalexperienceinScotland.ClinOphthalmol.2009;3(1):49-55.

Page 71: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page71

358. Bellmann C, Lumbroso-Le Rouic L, Levy C, et al. Uveal melanoma: management and outcome ofpatientswithextraocularspread.BrJOphthalmol.2010;94(5):569-574.

359. BellocqD,PascalR,LaurentK,etal.20-yearassessmentofmetastaticlatencyandsubsequenttimetodeathafterprotontherapyforuvealmelanomas.MelanomaResearch.2018.

360. BuiM,FrankSJ,NasserQJ,etal.Multidisciplinarymanagementofprimaryadenoidcysticcarcinomaoftheeyelidwithperineuralinvasion.OphthalPlastReconstrSurg.2013Nov-Dec;29(6):e143-6.

361. BuschC,LöwenJ,PilgerD,etal.Quantificationofradiationretinopathyafterbeamprotonirradiationin centrally located choroidal melanoma. Graefes Arch Clin Exp Ophthalmol. 2018.https://doi.org/10.1007/s00417-018-4036-3.

362. CaujolleJ-P,MammarH,ChamoreyE,etal.ProtonbeamradiotherapyforuvealmelanomasatNiceteachinghospital:16years’experience.IntJRadiatOncolBiolPhys.2010;78(1):98-103.

363. CaujolleJ-P,PaoliV,ChamoreyE,etal.Localrecurrenceafteruvealmelanomaprotonbeamtherapy:recurrencetypesandprognosticconsequences.IntJRadiatOncolBiolPhys.2013;85(5):1218-1224.

364. Chang JW, Yu YS, Kim JY, et al. The clinical outcomes of proton beam radiation therapy forretinoblastomas that were resistant to chemotherapy and focal treatment. Korean J Ophthalmol.2011;25(6):387-393.

365. Chappell MC, Char DH, Cole TB, et al. Uveal melanoma: molecular pattern, clinical features, andradiationresponse.AmJOphthalmol.2012;154(2):227-232.

366. Char DH, Bove R, Phillips TL. Laser and proton radiation to reduce uveal melanoma-associatedexudativeretinaldetachments.TransAmOphthalmolSoc.2003;101:53-56.

367. Conway RM, Poothullil AM, Daftari IK, et al. Estimates of ocular and visual retention followingtreatment of extra-large uveal melanomas by proton beam ratiotherapy. Arch Ophthalmol.2006;124(6):838-843.

368. CourdiA,CaujolleJP,GrangeJD,etal.ResultsofprotontherapyofuvealmelanomastreatedinNice.IntJRadiatOncolBiolPhys.1999;45(1):5-11.

369. Damato B, Kacperek A, Chopra M, et al. Proton beam radiotherapy of choroidal melanoma: theLiverpool-Clatterbridgeexperience.IntJRadiatOncolBiolPhys.2005;62(5):1405-1411.

370. DamatoB,KacperekA,ChopraM,etal.Protonbeamradiotherapyofirismelanoma.IntJRadiatOncolBiolPhys.2005;63(1):109-115.

371. DendaleR,Lumbroso-LeRouicL,NoelG,etal.Protonbeamradiotherapyforuvealmelanoma:resultsofCurieInstitut-Orsayprotontherapycenter(ICPO).IntJRadiatOncolBiolPhys.2006,65(3):780-787.Epub2006May2.

372. Desjardins L, Lumbroso-LeRouic L, Levy-Gabriel C, et al. Combinedprotonbeam radiotherapy andtranspupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients.OphthalmicRes.2006;38(5):255-260.

373. EggerE,SchalenbourgA,ZografosL,etal.Maximizing localtumorcontrolandsurvivalafterprotonbeamradiotherapyofuvealmelanoma.IntJRadiatOncolBiolPhys.2001,51(1):138-147.

374. EggerE, Zografos L, SchalenbourgA, et al. Eye retentionafterprotonbeam radiotherapy foruvealmelanoma.IntJRadiatOncolBiolPhys.2003;55(4):867-80.

Page 72: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page72

375. FussM, Loredo LN, Blacharski PA, et al. Proton radiation therapy formedium and large choroidalmelanoma: preservation of the eye and its functionality. Int J Radiat Oncol Biol Phys.2001;49(4):1053-1059.

376. GragoudasE,LiW,GoiteinM,etal.Evidence-basedestimatesofoutcomeinpatients irradiatedforintraocularmelanoma.ArchOphthalmol.2002b;120(12):1665-1671.

377. GragoudasES,LaneAM,MunzenriderJ,etal.Long-termriskoflocalfailureafterprotontherapyforchoroidal/ciliarybodymelanoma.TransAmOphthalmolSoc.2002a;100:43-50.

378. GragoudasES,LaneAM,ReganS,etal.Arandomizedcontrolledtrialofvaryingradiationdosesinthetreatmentofchoroidalmelanoma.ArchOphthalmol.2000;118(6):773-778.

379. Gragoudas ES, LiW, Lane AM, et al. Risk factors for radiationmaculopathy and papillopathy afterintraocularirradiation.Ophthalmology.1999;106(8):1571-1578.

380. Hadden PW, Damato BE, McKay IC. Bilateral uveal melanoma: a series of four cases. Eye.2003;17(5):613616.

381. Hannouche D, Frau E, Desjardins L, et al. Efficacy of proton therapy in circumscribed choroidalhemangiomasassociatedwithseriousretinaldetachment.Ophthalmology.1997;104(11):17801784.

382. Höcht S, BechrakisNE,NausnerM, et al. Proton therapy of uvealmelanomas in Berlin. 5 years ofexperienceattheHahn-MeitnerInstitute.StrahlentherOnkol.2004;180(7):419-424.

383. HöchtS,WachtlinJ,BechrakisNE,etal.Protonorphotonirradiationforhemangiomasofthechoroid?Aretrospectivecomparison.IntJRadiatOncolBiolPhys.2006;66(2):345-351.

384. HollidayEB,EsmaeliB,Picknard J, et al.AMultidisciplinaryOrbit-SparingTreatmentApproach thatIncludesProtonTherapyforEpithelialTumorsoftheOrbitandOcularAdnexa.IntJRadiatOncolBiolPhys.2016May1;95(1):344-352.

385. HrbacekJ,MishraKK,KacperekA,etal.Practicepatternsanalysisofocularprotontherapycenters:theInternationalOPTICSurvey.IntJRadiatOncolBiolPhys.2016May;95(1):336-343.

386. HussainR,HassanS,HoV,etal.Protonbeamradiotherapy(PBR)forthetreatmentofretinalcapillaryhaemangioblastoma.ActaOphthalmol.2016;94(S256).

387. HussainRN,KaliraiH,GroenewaldC,etal.Prognosticbiopsyofchoroidalmelanomaafterprotonbeamradiationtherapy.Ophthalmology.2016.

388. KamranSC,CollierJ,LaneAM,etal.Outcomesofprotontherapyforthetreatmentofuvealmelanoma.IntJRadiatOncolBiolPhys.2014December1;90(5):1044-1050.

389. KentD,NoonanCP,DamatoBE.ManagementofIrishpatientswithintraocularmelanomareferredtoLiverpool,England.ActaOphthalmolScand.1998;76(5):584-588.

390. KimIK,LaneAM,EganKM,etal.Naturalhistoryofradiationpapillopathyafterprotonbeamirradiationofparapapillarymelanoma.Ophthalmology.2010a;117(8):16171622.

391. KimJY,ParkY.Treatmentofretinoblastoma:theroleofexternalbeamradiotherapy.YonseiMedJ.2015November;56(6):1478-1491.

392. KimTW,ChoiE,ParkJ,etal.ClinicaloutcomesofprotonbeamtherapyforchoroidalmelanomaatasingleinstituteinKorea.CancerResTreat.2017Apr19.doi:10.4143/crt.2017.070.

Page 73: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page73

393. KodjikianL,RoyP,RouberolF,etal.Survivalafterproton-beamirradiationofuvealmelanomas.AmJOphthalmol.2004;137(6):1002-1010.

394. KonstantinidisL,RobertsD,ErringtonRD,etal.Wholeanteriorsegmentprotonbeamradiotherapyfordiffuseirismelanoma.BrJOphthalmol.2013;97(4):471-474.

395. LaneAM,KimIK,GragoudasES.Long-termriskofmelanoma-relatedmortalityforpatientswithuvealmelanomatreatedwithprotonbeamtherapy.JAMAOpthalmol.2015Jul;133(7):792-796.

396. LaneAM,KimIK,GragoudasES.Protonirradiationforperipapillaryandparapapillarymelanomas.ArchOphthalmol.2011;129(9):1127-1130.

397. Levy-GabrielC,Lumbroso-LeRouicL,PlancherC,etal. Long-termresultsof low-doseprotonbeamtherapyforcircumscribedchoroidalhemangiomas.Retina.2009;29(2):170-175.

398. LiW,GragoudasES,EganKM.Metastaticmelanomadeathratesbyanatomicsiteafterprotonbeamirradiationforuvealmelanoma.ArchOphthalmol.2000;118(8):1066-1070.

399. LiW,GragoudasES,EganKM.Tumorbasalareaandmetastaticdeathafterprotonbeamirradiationforchoroidalmelanoma.ArchOphthalmol.2003;121(1):6872.

400. LumbrosoL,DesjardinsL,LevyC,etal.Intraocularinflammationafterprotonbeamirradiationforuvealmelanoma.BrJOphthalmol.2001;85(11):1305-1308.

401. Lumbroso-Le Rouic L, Delacroix S, Dendale R, et al. Proton beam therapy for irismelanomas.Eye.2006;20(11):1300-1305.

402. Macdonald EC, Cauchi P, Kemp EG. Proton beam therapy for the treatment of uvealmelanoma inScotland.BrJOphthalmol.2011;95(12):1691-1695.

403. MarucciL,AncukiewiczM,LaneAM,etal.Uvealmelanomarecurrenceafterfractionatedprotonbeamtherapy:comparisonofsurvivalinpatientstreatedwithreirradiationorwithenucleation.IntJRadiatOncolBiolPhys.2011;79(3):842846.

404. MarucciL,LaneAM,LiW,etal.Conservationtreatmentoftheeye:conformalprotonreirradiationforrecurrentuvealmelanoma.IntJRadiatOncolBiolPhys.2006;64(4):1018-1022.

405. Mishra KK, Daftari IK,Weinberg V, et al. Risk factors for neovascular glaucoma after proton beamtherapyofuvealmelanoma:adetailedanalysisof tumoranddose-volumeparameters. Int JRadiatOncolBiolPhys.2013;87(2):330-336.

406. MizumotoM,NakayamaH,TokitaM,et al. Technical considerations fornoncoplanarprotonbeamtherapyofpatientswithtumorsproximaltotheopticnerve.StrahlentherOnkol.2010;186(1):36-39.

407. MosciC, LanzaFB,BarlaA,etal.Comparisonof clinicaloutcomes forpatientswith largechoroidalmelanomaafterprimarytreatmentwithenucleationorprotonbeamradiotherapy.Ophthalmologica.2012;227(4):190-196.

408. MouwKW,SethiRV,YeapBY,etal.Protonradiationtherapyforthetreatmentofretinoblastoma.IntJRadiatOncolBiolPhys.2014Nov15;90(4):863-869.

409. NaeserP,BlomquistE,MonteliusA,ThuomasK-A.Protonirradiationofmalignantuvealmelanoma.UpsJMedSci.1998;103(3):203-211.

410. PapakostasTD,LaneAM,MorrisonM.Long-termOutcomesAfterProtonBeamIrradiationinPatientsWith Large Choroidal Melanomas. JAMA Ophthalmol. 2017; 135(11): 1191-1196.doi:10.1001/jamaophthalmol.2017.3805.

Page 74: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page74

411. Park SS,Walsh SM,Gragoudas ES. Visual-field deficits associatedwith proton beam irradiation forparapapillarychoroidalmelanoma.Ophthalmology.1996;103(1):110-116.

412. PicaA,HrbacekJ,ZografosL,etal.Long-termvisualacuitypreservationafterprotontherapyforperi-and parapapillary melanoma patients treated at the Paul Scherrer Institute. Acta Ophthalmol.2016;94(S256).

413. QureshiS,HussainR,KaliraiH,etal.Histomorphologicalchangesofuvealmelanoma(UM)followingprotonbeamtherapy(PBR).ActaOphthalmol.2016;94(S256).

414. Rahmi A, Mammar H, Thariat J, et al. Proton beam therapy for presumed and confirmed irismelanomas:areviewof36cases.GraefesArchClinExpOphthalmol.2014Sep;252(9):1515-1521.

415. RiechardtAI,PilgerD,CordiniD2,etal.Neovascularglaucomaafterprotonbeamtherapyofchoroidalmelanoma:incidenceandriskfactors.GraefesArchClinExpOphthalmol.2017Nov;225(11):2263-2269.

416. RomanowskaDixonB,JasinskaK,MichalikM,etal.Uvealmelanomaclonogenicresponsetoprotonbeamirradiation.ActaOphthalmol.2016;94(S256)..

417. Rundle P, Singh AD, Rennie I. Proton beam therapy for irismelanoma: a review of 15 cases. Eye.2007;21(1):79-82.

418. SchonfeldS,CordiniD,RiechardtAI,etal.Protonbeamtherapyleadstoexcellentlocalcontrolratesinchoroidalmelanomaintheintermediatefunduszone.AmJOphthalmol.2014Dec;158(6):1184-1191.

419. SeibelI,CordiniD,HagerA,etal.Cataractdevelopmentinpatientstreatedwithprotonbeamtherapyforuvealmelanoma.GraefesArchClinExpOphthalmol.2016Aug;254(8):1625-1630.

420. Seibel I, Cordini D, Rehak M, et al. Local recurrence after primary proton beam therapy in uvealmelanoma:riskfactors,retreatmentapproachesandoutcome.AmJOphthalmol.2015Oct;160(4):628-636.

421. SethiRV,ShihHA,YeapBY,etal.Secondnonoculartumorsamongsurvivorsofretinoblastomatreatedwithcontemporaryphotonandprotonradiotherapy.Cancer.2014;120(1):126-133.

422. SikuadeMJ,SalviS,RundlePA,etal.Outcomesoftreatmentwithstereotacticradiosurgeryorprotonbeamtherapyforchoroidalmelanoma.Eye.2015Sep;29(9):1194-1198.

423. ThariatJ,GrangeJD,MosciC,etal.Visualoutcomesofparapapillaryuvealmelanomasfollowingprotonbeamtherapy.IntJRadiatOncolBiolPhys.2016May1;95(1):328-335.

424. Thariat J, JacobS,Caujolle JP,etal.CataractAvoidancewithProtonTherapy inOcularMelanomas.InvestOphthalmolVisSci.2017;58(12):5378-5386.

425. Tran E, Ma R, Paton K, et al. Outcomes of proton radiation therapy for peripapillary choroidalmelanomaattheBCCancerAgency.IntJRadiatOncolBiolPhys.2012;83(5):1425-1431.

426. TsinaEK,LaneAM,ZacksDN,etal.Treatmentofmetastatictumorsofthechoroidwithprotonbeamirradiation.Ophthalmology.2005;112(2):337-343.

427. VavvasD,KimI,LaneAM,etal.Posterioruvealmelanomainyoungpatientstreatedwithprotonbeamtherapy.Retina.2010;30(8):1267-1271.

428. Wang Z, Nabhan M, Schild SE, et al. Charged Particle Radiation Therapy for Uveal Melanoma:ASystematicReviewandMeta-Analysis.IntJRadiatOncolBiolPhys.2013:86(1):18-26.

Page 75: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page75

429. WillerdingGD,CordiniD,MoserL,etal.Neoadjuvantprotonbeamirradiationfollowedbytransscleralresectionofuvealmelanomain106cases.BrJOphthalmol.2016Apr;100(4):463-467.

430. WilsonMW,HungerfordJL.Comparisonofepiscleralplaqueandprotonbeamradiationtherapyforthetreatmentofchoroidalmelanoma.Ophthalmology.1999;106(8):1579-1587.

431. WuestmeyerH,SauerweinW,MellerD,etal.Protonradiotherapyasanalternativetoextenterationin the management of extended conjunctival melanoma. Graefes Arch Clin Exp Ophthalmol.2006;244(4):438-446.

432. Zografos L, Egger E, Bercher L, et al. Proton beam irradiation of choroidal hemangiomas. Am JOphthalmol.1998;126(2):261-268.

433. Zografos L, Schalenbourg A. Proton beam irradiation of choroidal hemangiomas after unsuccessfulphotodynamictherapy.ActaOphthalmol.2015;93(S255).

PEDIATRIC

434. Alapetite C, Puget S, Nauraye C, et al. Conservative surgery followed by proton therapy forcraniopharyngiomainchildren:aphaseIIstudytoexaminethefeasibilityofdoseescalation.Neuro-Oncology.2018;20(2):i42-i43.

435. AresC,AlbertiniF,Frei-WelteM,etal.Pencilbeamscanningprotontherapyforpediatricintracranialependymoma.JNeuroOncol.2016May;128(1):137-145.

436. ArmstrongFD,HoltzChildren’sHospital.Proton-beamradiationtherapyandhealth-relatedqualityoflifeinchildrenwithCNStumors.JClinOncol.2012;30(17):2028-2029.

437. BadiyanS,UlmerS,AhlhelmFA,etal.ClinicalandRadiologicOutcomesinAdultsandChildrenTreatedwithPencil-BeamScanningProtonTherapyforLow-GradeGlioma.IntJPartTher.2017Spring;3(4):450-460.

438. BishopAJ,GreenfieldB,MahajanA,etal.Protonbeamtherapyversusconformalphotonradiationtherapyforchildhoodcraniopharyngioma:multi-institutionalanalysisofoutcomes,cystdynamics,andtoxicity.IntJRadiatOncolBiolPhys.2014October1;90(2):354-61.

439. Bojaxhiu B, Ahlhelm F,WalserM, et al. Radiation Necrosis andWhiteMatter Lesions in PediatricPatientswithBrainTumorstreatedwithPencilBeamScanningProtonTherapy.IntJRadiatOncolBiolPhys.2017.10.1016/j.ijrobp.2017.11.037.

440. ChhabraA,MahajanA.TreatmentofcommonpediatricCNSmalignancieswithprotontherapy.ChinClinOncol.2016Aug;5(4):49.

441. ChildsSK,KozakKR,FriedmannAM,etal.Protonradiotherapyforparameningealrhabdomyosarcoma:clinicaloutcomesandlateeffects.IntJRadiatOncolBiolPhys.2012;82(2):635-642.

442. Cotter SE, Herrup DA, Friedmann A, et al. Proton radiotherapy for pediatric bladder/prostaterhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiationtherapy.IntJRadiatOncolBiolPhys.2011;81(5):1367-1373.

443. CotterSE,McBrideSM,YockTI.Protonradiotherapyforsolidtumorsofchildhood.TechnolCancerResTreat.2012;11(3):267-278.

444. DeB,CahlonO,HugEB,etal.GrowthOutcomesofPediatricPatientsReceivingProtonCraniospinalIrradiation.IntJRadiatOncolBiolPhys.2017October1;99(2):E566-567.

Page 76: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page76

445. De B, CahlonO, Sine K, et al. Early Axial GrowthOutcomes of Pediatric Patients Receiving ProtonCraniospinalIrradiation.JPediatrHematolOncol.2018June.doi:10.1097/MPH.0000000000001242.

446. EatonBR,ChowdryV,WeaverK,etal.Useofprotontherapyforre-irradiationinpediatricintracranialependymoma.RadiotherOncol.2015Aug;116(2):301-8.

447. Eaton BR, Esiashvili N, Kim S, et al. Clinical outcomes among children with standard riskmedulloblastomatreatedwithprotonandphotonradiotherapy:acomparisonofdiseasecontrolandoverallsurvival.IntJRadiatOncolBiolPhys.2016Jan1;94(1):133-138.

448. Fournier-Goodnight,A.S.,Ashford,J.M.,Merchant,T.E.etal.Neurocognitivefunctioninginpediatriccraniopharyngioma: performance before treatment with proton therapy. J Neurooncol. 2017.doi:10.1007/s11060-017-2492-y.

449. FussM,HugEB,SchaeferRA,etal.Protonradiationtherapy(PRT)forpediatricopticpathwaygliomas:comparisonwith3Dplannedconventionalphotonsandastandardphotontechnique.IntJRadiatOncolBiolPhys.1999;45(5):1117-1126.

450. Gallagher K. In silico clinical trial comparing predicted subsequentmalignant neoplasms in photonversusprotontherapyofapediatriccohortwithintracranialtumors.OregonStateLibraries.2017.

451. Geng C,MoteabbedM, Xie Y, et al. Assessing the radiation-induced second cancer risk in protontherapyforpediatricbraintumors:theimpactofemployingapatient-specificapertureinpencilbeamscanning.PhysMedBiol.2015;61(1):12-22.

452. GentileMS, Yeap BY, Goebel C, Get al. Brainstem Injury in Pediatric Patientswith Posterior FossaTumorsTreatedwithProtonBeamTherapyandAssociatedDosimetricFactors.IntJRadiationOncolBiolPhys.2017Nov.Https://doi.org/10.1016/j.ijrobp.2017.11.026.

453. GrantSR,GrosshansDR,BiltonSD,etal.Protonversusconventionalradiotherapyforpediatricsalivaryglandtumors:acutetoxicityanddosimetriccharacteristics.RadiotherOncol.2015August;116(2):309-315.

454. GreenbergerBA,PulsiferMB,EbbDH,etal.Clinicaloutcomesandlateendocrine,neurocognitive,andvisualprofilesofprotonradiationforpediatriclow-gradegliomas.IntJRadiatOncolBiolPhys.2014August1;89(5):1060-1068.

455. Greenfield BJ, Jaramillo S, AbboudM, et al. Outcomes for pediatric patients with central nervoussystemgermcelltumorstreatedwithprotontherapy.ClinTranslatRadiatOncol.2016;1:9-14.

456. GrewalAS,LiY,FisherMJ,etal.Primarysiteirradiationusingprotontherapyinyoungchildrenwithmedulloblastoma.IntJRadiatOncolBiolPhys.2018;102(3).

457. Haas-KoganD,IndelicatoD,PaganettiH,etal.NationalCancerInstituteWorkshoponProtonTherapyforChildren:ConsiderationsRegardingBrainstemInjury.IntJRadiatOncolBiolPhys.2018;101(1):152-168.

458. HabrandJ-L,MammarH,FerrandR,etal.Protonbeamtherapy(PT)inthemanagementofCNStumorsinchildhood.StrahlentherOnkol.1999;175(Suppl2):91-94.

459. HabrandJ-L,SchneiderR,AlapetiteC,etal.Protontherapyinpediatricskullbaseandcervicalcanallow-gradebonemalignancies.IntJRadiatOncolBiolPhys.2008;71(3):672-675.

Page 77: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page77

460. HallMD,BradleyJA,RotondoRL,etal.Incidenceandmultimodalitypredictorsofvasculopathyafterprotontherapyforpediatrictumorsofthecentralnervoussystemandskullbase.IntJRadiatOncolBiolPhys.2018July15;101(4):1008.

461. HattangadiJ,EstyB,WineyB,etal.RadiationrecallmyositisinpediatricEwingsarcoma.PediatrBloodCancer.2012;59(3):570572.

462. HattangadiJA,RombiB,YockTI,etal.Protonradiotherapyforhigh-riskpediatricneuroblastoma:earlyoutcomesanddosecomparison.IntJRadiatOncolBiolPhys.2012;83(3):1015-1022.

463. HessCB, IndelicatoDJ,PaulinoAC,etal.AnUpdatefromthePediatricProtonConsortiumRegistry.FrontOncol.2018.doi:10.3389/fonc.2018.00165.

464. Hill-KayserC,KirkM.Brainstem-sparingcraniospinalirradiationdeliveredwithpencilbeamscanningprotontherapy.PediatrBloodCancer.2015Apr;62(4):718-720.

465. Hill-KayserC,TochnerZ,BothS,etal.Protonversusphotonradiationtherapyforpatientswithhigh-riskneuroblastoma:theneedforacustomizedapproach.PediatrBloodCancer.2013;60(10):1606-1611.

466. HochBL,NielsenGP,LiebschNJ,RosenbergAE.Baseofskullchordomasinchildrenandadolescents.Aclinicopathologicstudyof73cases.AmJSurgPathol.2006;30(7):811-818.

467. Holtzman A, Flampouri S, Li Z, et al. Proton therapy in a pediatric patient with stage III Hodgkinlymphoma.ActaOncol.2013Apr;52(3):592594.

468. HugEB,AdamsJ,FitzekM,etal.Fractionated,threedimensional,planningassistedprotonradiationtherapyfororbitalrhabdomyosarcoma:anoveltechnique.IntJRadiatOncolBiolPhys.2000;47(4):979984.

469. HugEB,MuenterMW,AdamsJA,etal.3Dconformalradiationtherapyforpediatricgiantcelltumorsoftheskullbase.StrahlentherOnkol.2002;178(5):239-244.

470. Hug EB, Muenter MW, Archambeau JO, et al. Conformal proton radiation therapy for pediatriclow-gradeastrocytomas.StrahlentherOnkol.2002;178(1):10-17.

471. HugEB,SweeneyRA,NurrePM,etal.Protonradiotherapyinmanagementofpediatricbaseofskulltumors.IntJRadiatOncolBiolPhys.2002;52(4):1017-1024.

472. Jaramillo S, GrosshansDR, PhilipN, et al. Radiation for ETMR: literature review and case series ofpatientstreatedwithprotontherapy.ClinicalandTranslationalRadiationOncology.2018.

473. JimenezRB, Sethi R,DepauwN, et al. Proton radiation therapy for pediatricmedulloblastomaandsupratentorial primitive neuroectodermal tumors: outcomes for very young children treated withupfrontchemotherapy.IntJRadiatOncolBiolPhys.2013;87(1):120-126.

474. Journy N, Indelicato DJ, Withrow DR, et al. Patterns of proton therapy use in pediatric cancermanagementin2016:aninternationalsurvey.RadiotherapyandOncology.2018.

475. KahalleyLS,MahajanA,OkcuMF,etal.Prospective, longitudinalstudyofneurocognitivechange inpediatric brain tumor patients treatedwith proton beam radiotherapy versus surgery only.Neuro-Oncology.2018;20(2):i175.

476. KahalleyLS,RisMD,GrosshansDR,etal.Comparingintelligencequotientchangeaftertreatmentwithproton versus photon radiation therapy for pediatric brain tumors. J Clin Oncol. 2016 Apr1;34(10):1043-1049.

Page 78: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page78

477. KopeckyA,KhanA,PanW,etal.Outcomesandpatternsofcareinanationwidecohortofpediatricmedulloblastoma: factors affecting proton therapy utilization. Adv in Radiat Oncol. 2017 Jul19;2(4):588-596.

478. KralikSF,MereniukTR,GrignonL,etal.Radiationinducedcerebralmicrobleedsinpediatricpatientswithbraintumorstreatedwithprotonradiotherapy.IntJRadiatOncolBiolPhys.2018.

479. KuhlthauKA,PulsiferMB,YeapBY,etal.Prospectivestudyofhealth-relatedqualityoflifeforchildrenwithbraintumorstreatedwithprotonradiotherapy.JClinOncol.2012;30(17):2079-2086.

480. KumarRJ,ShaiH,BothS,TochnerZ,etal.Breastcancerscreeningforchildhoodcancersurvivorsaftercraniospinalirradiationwithprotonsversusxrays:adosimetricanalysisandreviewoftheliterature.JPediatrHematolOncol.2013Aug;35(6):462-467.

481. LaackNN,HarmsenWS,PaulinoAC,etal.Factorsassociatedwithacutetoxicityinpediatricpatientstreatedwithprotonradiationtherapy:areportofthePediatricProtonConsortiumRegistry.IntJRadiatOncol.2018.

482. LadraMM,SzymonifkaJD,MahajanA,etal.PreliminaryresultsofaphaseIItrialofprotonradiotherapyforpediatricrhabdomyosarcoma.JClinOncol.2014Oct20;epubaheadofprint.

483. LadraMM,YockTI.Protonradiotherapyforpediatricsarcoma.Cancers.2014Mar;6(1):112-127.

484. Laffond C, Dellatolas G, Alapetite C, et al. Quality-of-life, mood and executive functioning afterchildhood craniopharyngioma treated with surgery and proton beam therapy. Brain Inj.2012;26(3):270-281.

485. LeeCT,BiltonSD,FamigliettiRM,etal.Treatmentplanningwithprotonsforpediatricretinoblastoma,medulloblastoma,andpelvicsarcoma:howdoprotonscomparewithotherconformaltechniques?IntJRadiatOncolBiolPhys.2005,63(2):362-372.

486. Leiser D, Calaminus G, Malyapa R, et al. Tumour control and Quality of Life in children withrhabdomyosarcoma treatedwith pencil beam scanning proton therapy.RadiotherOncol. 2016 Jul;120(1):163-168.

487. Logan JK, Mahajan A, Grosshans DR, et al. Associations between Neurocognitive Outcomes andHippocampalandSubventricularDosesinChildrenReceivingProtonRadiation.IntJRadiatOncolBiolPhys.2017;99(2):E570.

488. Lucas JT, Ladra MM, MacDonald SM, et al. Proton therapy for pediatric and adolescentesthesioneuroblastoma.PediatrBloodCancer.2015Sep;62(9):1523-1528.

489. Lundkvist J,EkmanM,EricssonSR,etal.Cost-effectivenessofprotonradiation in the treatmentofchildhoodmedulloblastoma.Cancer.2005b;103(4):793-801.

490. Luu QT, Loredo LN, Archambeau JO, et al. Fractionated proton radiation treatment for pediatriccraniopharyngioma:preliminaryreport.CancerJ.2006;12(2):155159.

491. MacDonald SM, Safai S, Trofimov A, et al. Proton radiotherapy for childhood ependymoma: initialclinicaloutcomesanddosecomparisons.IntJRadiatOncolBiolPhys.2008;71(4):979-986.

492. MacDonald SM, Sethi R, Lavally B, et al. Proton radiotherapy for pediatric central nervous systemependymoma:clinicaloutcomesfor70patients.NeuroOncol.2013;15(11):1552-9.

493. MacDonaldSM,TrofimovA,SafaiS,etal.Protonradiotherapyforpediatriccentralnervoussystemgermcelltumors:earlyclinicaloutcomes.IntJRadiatOncolBiolPhys.2011;79(1):121-129.

Page 79: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page79

494. MahajanA,StrotherD,PollackI,etal.ATRT-10:Earlypostradiationchangesandefficacyinchildrenwith ATRT treated on COG ACNS 0333: A comparison of proton vs. photon therapy.Neuro Oncol.2017;19(suppl_4):iv3.

495. Mailhot VR, Kim J, BussièreM, et al. Cost effectiveness of proton therapy comparedwith photontherapyinthemanagementofpediatricmedulloblastoma.Cancer.2013;119(24):42994307.

496. MailhotVR,KimJ,HollanderA,etal.Costeffectivenessofprotonversusphotonradiationtherapywithrespecttotheriskofgrowthhormonedeficiencyinchildren.Cancer.2015May15;121(10):1694-1702.

497. MainC,DandapaniM,PritchardM,etal.Theeffectivenessandsafetyofprotonbeamradiationtherapyinchildrenwithmalignantcentralnervoussystem(CMS)tumours:protocolforasystematicreview.SystRev.2016;5(1):124.

498. McAllister B, Archambeau JO, Nguyen MC, et al. Proton therapy for pediatric cranial tumors:preliminary report on treatment and disease-related morbidities. Int J Radiat Oncol Biol Phys.1997;39(2):455-460.

499. McGovern SL, Okcu MF, Munsell MF, et al. Outcomes and acute toxicities of proton therapy forpediatricatypicalteratoid/rhabdoidtumorofthecentralnervoussystem.IntJRadiatOncolBiolPhys.2014December1;90(5):1143-1152.

500. MerchantTE,HuaCH,SabinND,etal.Progression-FreeSurvivalafterProtonTherapyforChildhoodCraniopharyngioma: Early Results From a Prospective Trial. Int J Radiat Oncol Biol Phys. 2017 Oct1;99(2):S59.

501. MiralbellR,LomaxA,BortfeldT,etal.Potentialroleofprotontherapyinthetreatmentofpediatriceduolloblastoma/primitiveneuroectodermal tumors: reductionof thesupratentorial targetvolume.IntJRadiotOncolBiolPhys.1997;38(3):477484.

502. MiralbellR,LomaxA,CellaL,SchneiderU.Potentialreductionoftheincidenceofradiation-inducedsecondcancersbyusingprotonbeams inthetreatmentofpediatric tumors. Int JRadiatOncolBiolPhys.2002;54(3):824-829.

503. MizumotoM,AkutsuH,YamamotoT,etal.Preliminaryresultofhypofractionatedhigh-doseprotonbeamradiotherapyforpediatricskullbasechordomas.JCancerTher.2017;(8):327-332.

504. MizumotoM,MurayamaS,AkimotoT,etal.Preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcoma:amulti-institutionalstudyinJapan.CancerMed.2018;doi:10.1002/cam4.1464.

505. MizumotoM,OshiroY,TakizawaD,etal.Protonbeamtherapyforpediatricependymoma.PediatrInt.2015Aug;57(4):567-571.

506. MoellerBJ,ChintagumpalaM,PhilipJJ,etal.Lowearlyototoxicityratesforpediatricmedulloblastomapatientstreatedwithprotonradiotherapy.RadiatOncol.2011;6:58.

507. MoteabbedM,YockTI,PaganettiH,etal.Theriskofradiation-inducedsecondcancersinthehightomediumdoseregion:acomparisonbetweenpassiveandscannedprotontherapy,IMRTandVMATforpediatricpatientswithbraintumors.PhysMedBio.2014Jun21;59(12):2883-2899.

508. MuX,Bjork-ErikksonT,Nill S, et al.Doeselectronandproton therapy reduce the riskof radiationinduced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatmentplanningstudy.ActaOncol.2005;44(6):554-562.

Page 80: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page80

509. NoëlG,HabrandJL,HelfreS,etal.Protonbeamtherapyinthemanagementofcentralnervoussystemtumorsinchildhood:thepreliminaryexperienceoftheCentredeProtonthérapied’Orsay.MedPediatrOncol.2003;40(5):309-315.

510. OshiroY,SugaharaS,FukushimaT,etal.Pediatricnasopharyngealcarcinomatreatedwithprotonbeamtherapy.Twocasereports.ActaOncol.2011;50(3):470-473.

511. Perez-AndujarA,NewhauserWD,TaddeiPJ,etal.Thepredicted relative riskofprematureovarianfailureforthreeradiotherapymodalitiesinagirlreceivingcraniospinalirradiation.PhysMedBiol.2013May21;58(10):3107-3123.

512. Perkins,StephanieM.andetal.AnupdatefromthePediatricProtonConsortiumRegistry.FrontiersinOncology.2018;8(165).https://digitalcommons.wustl.edu/open_access_pubs/6893

513. PetersS,FrischS,Stickan-VerfuerthM,PlaudeS,BlaséC,TippeltS,TimmermanB.Protonbeamtherapyforependymomasofchildhood;earlydatafromtheprospectiveKiProRegRegistry.IntJRadiatOncolBiolPhys.2018July15;101(4):1009.

514. PetrovicA,BerginC,SchalenbourgA,etal.Protontherapyforuvealmelanomain43juvenilepatients:long-termresults.Ophthalmology.2014Apr;121(4):898-904.

515. PhamA,WongK,ChangEL.Qualityoflifeinpediatricbraintumorpatientstreatedwithprotontherapy:areviewoftheliterature.ExpertRevQualLifeCancerCare.2016;1(4):329-338.

516. PulsiferMB,DuncansonH,GriecoJ,etal.CognitiveandAdaptiveOutcomesFollowingProtonRadiationfor Pediatric Patients with Brain Tumors. Int J Radiat Oncol Biol Phys. 2018;102(2):391-398.https://doi.org/10.1016/j.ijrobp.2018.05.069.

517. RayGL,BuchsbaumJC,McMullenKP,etal.Definitivetreatmentofleptomeningealspinalmetastasesinchildren.PediatrBloodCancer.2013;60(11):1839-1841.

518. RombiB,AresC,HugEB,etal.Spot-scanningprotonradiation therapy forpediatricchordomaandchondrosarcoma:clinicaloutcomeof26patientstreatedatPaulScherrerInstitute.IntJRadiatOncolBiolPhys.2013;86(3):578-584.

519. RombiB,DeLaneyTF,MacDonaldSM,etal.ProtonradiotherapyforpediatricEwing’ssarcoma:initialclinicaloutcomes.IntJRadiatOncolBiolPhys.2012;82(3):1142-1148.

520. RombiB,VennariniS,VinanteL,etal.Protonradiotherapyforpediatrictumors:reviewoffirstclinicalresults.ItalJPediatr.2014Sep26;40:74.

521. Rutz HP, Weber DC, Goitein G, et al. Postoperative spot-scanning proton radiation therapy forchordoma and chondrosarcoma in children and adolescents: initial experience at Paul ScherrerInstitute.IntJRadiatOncolBiolPhys.2008;71(1):220-225.

522. SabinND,MerchantTE,HarreldJH,etal.Imagingchangesinveryyoungchildrenwithbraintumorstreatedwithprotontherapyandchemotherapy.AJNRAmJNeuroradiol.2013;34(2):446-450.

523. SandsSA.Protonbeamradiationtherapy:thefuturemayprovebrighter forpediatricpatientswithbraintumors.JClinOncol.2016Apr1;34(10):1024-1026.

524. SeccoDE,CacchioneA,DelBufaloF,etal.Lateneuropsychologicaloutcomeswithprotonradiationinchildrenwithbraintumor.Neuro-Oncology.2018;20(2):i178.

Page 81: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page81

525. SongS,ParkHJ,YoonJH,etal.Protonbeamtherapyreducestheincidenceofacutehaematologicalandgastrointestinaltoxicitiesassociatedwithcraniospinalirradiationinpediatricbraintumors.ActaOncol.2014Sep;53(9):1158-1164.

526. StClairWH,AdamsJA,BuesM,etal.AdvantageofprotonscomparedtoconventionalX-rayorIMRTinthe treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys.2004;58(3):727-734.

527. SunejaG,PoorvuPD,Hill-KayserC, LustigRA.Acute toxicityofprotonbeamradiation forpediatriccentralnervoussystemmalignancies.PediatrBloodCancer.2013;60(9):1431-1436.

528. TannAW,McAleerMF,McGovernSL,etal.ClinicalOutcomesofPediatricPatientsWithPelvicTumorsTreatedWithProtonTherapy.IntJRadiatOncolBiolPhys.2016Oct1;96(2S):E555.

529. ThorpN.Protontherapyforchildren.RADMagazine.2010;36(418):17-18.

530. TimmermannB,SchuckA,NiggliF,etal.Spot-scanningprotontherapyformalignantsofttissuetumorsin childhood: first experiences at the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys.2007;67(2):497-504.

531. VegaRM,KimJ,HollanderA,etal.Costeffectivenessofprotonversusphotonradiationtherapywithrespecttotheriskofgrowthhormonedeficiencyinchildren.Cancer.2015May15;121(1):1694-1702.

532. Ventura LM,Grieco JA, EvansCL, et al. Executive functioning, academic skills, andquality of life inpediatric patients with brain tumors post-proton radiation therapy. J Neurooncol.2017.doi.org/10.1007/s11060-017-2703-6.

533. VogelJ,BothS,KirkM,etal.Protontherapyforpediatricheadandneckmalignancies.PediatrBloodCancer.2017Oct23.DOI:10.1002/pbc.26858.

534. WarrenE,ChildA,CirinoP,etal.Bettersocial,cognitive,andacademicoutcomesamongpediatricbraintumor survivors treated with proton versus photon radiation therapy. Neuro-Oncology.2018;20(2):i166.

535. WeberDC,AresC,AlbertiniF,etal.Pencilbeamscanningprotontherapyforpediatricparameningealrhabdomyosarcomas:clinicaloutcomeofpatientstreatedatthePaulScherrerInstitute.PediatrBloodCancer.2016Oct;63(170):1731-1736.

536. WeberDC,AresC,MalyaoaR,etal.TumorcontrolandQoLoutcomesofveryyoungchildrenwithatypical teratoid/rhabdoid tumor treatedwith focalonlychemoratiationtherapyusingpencilbeamscanningprotontherapy.JNeurooncol.2015Jan;121(2):389-397.

537. WeberDC,HabrandJL,HoppeBS.Protontherapyforpediatricmalignancies:fact,figures,andcosts.Ajoint consensus statement from thepediatric subcommitteeofPTCOG,PROS, andEPTN.RadiotherOncol.2018.

538. WelchGD,LinKY,FisherMJ,Hill-KayserC.CardiacToxicityAfterCraniospinalIrradiation:ALateEffectThat May be Eliminated With Proton Therapy. J Pediatr Hematol Oncol. 2017 Dec 1. doi:10.1097/MPH.0000000000001029.

539. WinkfieldKM,LinsenmeierC,YockTI,etal.Surveillanceofcraniopharyngiomacystgrowthinchildrentreatedwithprotonradiotherapy.IntJRadiatOncolBiolPhys.2009;73(3):716-721.

540. WrayJ,FlampouriS,SlaytonW,etal.ProtontherapyforpediatricHodgkinlymphoma.PediatrBloodCancer.2016Sep;63(9):1522-1526.

Page 82: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page82

541. YockT,SchneiderR,FriedmannA,etal.Protonradiotherapyfororbitalrhabdomyosarcoma:clinicaloutcome and a dosimetric comparison with photons. Inj J. Radiat Oncol Biol Phys. 2005,63(4):1161-1168.

542. YockTI,BhatS,SzymonifkaJ,etal.Qualityof lifeoutcomes inprotonandphotontreatedpediatricbraintumorsurvivors.RadiotherOncol.2014Oct;113(1):89-94.

543. Yock TI, Tarbell NJ. Technology insight: proton beam radiotherapy for treatment in pediatric braintumors.NatClinPractOncol.2004;1(2):97-103.

544. Yock TI, Yeap BY, Ebb DH, et al. Long-term toxic effects of proton radiotherapy for paediatricmedulloblastoma:aphase2single-armstudy.LancetOncol.2016Mar;17(3):287-298.

545. YuhGE,LoredoLN,YonemotoLT,etal.Reducingtoxicityfromcraniospinalirradiation:usingprotonbeamstotreatmedulloblastomainyoungchildren.CancerJ.2004;10(6):386-390.

546. ZhangR,HowellRM,GiebelerA,etal.Comparisonofriskofradiogenicsecondcancerfollowingphotonand proton craniospinal irradiation for a pediatric medulloblastoma patient. Phys Med Biol.2013;58(4):807-823.

547. ZhangR,HowellRM,HomannK,etal.Predictedrisksofradiogeniccardiactoxicity intwopediatricpatientsundergoingphotonorprotonradiotherapy.RadiatOncol.2013Jul23:8(1):184.

PROSTATE

548. Arimura T, Kondo N, Matsukawa K, et al. The role of proton beam therapy for patients withintermediate-andhigh-riskprostatecancer.JClinOncol.2018;36(6):97.

549. ArimuraT,YoshiuraT,MatsukawaK,etal.ProtonBeamTherapyAloneforIntermediate-orHigh-RiskProstate Cancer: An Institutional Prospective Cohort Study. Cancers. 2018;10(4):116.https://doi.org/10.3390/cancers10040116.

550. BenkVA,AdamsJA,ShipleyWU,etal.Laterectalbleedingfollowingcombinedx-rayandprotonhighdose irradiation for patients with stages T3-T4 prostate cancer. Int J Radiat Oncol Biol Phys.1993;26(3):551-557.

551. BowyerJ,NathaS,MarshI,FoyP.Visualcomplicationsofprotonbeamtherapyforclivalchordoma.Eye.2003;17(3):318?323.

552. BryantC,SmithTL,HendersonRH,etal.Five-yearbiochemicalresults,toxicity,andpatient-reportedqualityoflifefollowingdeliveryofdose-escalatedimage-guidedprotontherapyforprostatecancer.IntJRadiatOncolBiolPhys.2016;95(1):422-434.

553. ChoiS,BlanchardP,YeR,etal.OutcomesFollowingProtonTherapy for theTreatmentofProstateCancer:EfficacyandToxicityResultsfrom2ProspectiveSingleInstitutionCohorts.IntJRadiatOncolBiolPhys.2017;99(2S):E221.

554. ChuongMD,HartsellWH,LarsonGL,TsaiHK,LaramoreGE,RossiCJ,WilkinsonB,KaiserA,VargasCE.MinimalToxicityAfterProtonBeamTherapyforProstateandPelvicNodal Irradiation:ResultsFromtheProtonCollaborativeGroupREG001-09trial.IntJRadiatOncolBiolPhys.2017;99(2S):E223.

555. CoenJJ,BaeK,ZietmanAL,etal.Acuteandlatetoxicityafterdoseescalationto82GyEusingconformalprotonradiationforlocalizedprostatecancer:initialreportofAmericanCollegeofRadiologyphaseIIstudy03-12.IntJRadiatOncolBiolPhys.2011;81(4):1005-1009.

Page 83: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page83

556. CoenJJ,PalyJJ,NiemierkoA,etal.Long-termqualityoflifeoutcomeafterprotonbeammonotherapyforlocalizedprostatecancer.IntJRadiatOncolBiolPhys.2012;82(2):e201-e209.

557. CoenJJ,ZietmanAL,RossiCJ,etal.Comparisonofhigh-doseprotonradiotherapyandbrachytherapyinlocalizedprostatecancer:acase-matchedanalysis.IntJRadiatOncolBiolPhys.2012;82(1):e25-e31.

558. EfstathiouJA,GrayPJ,ZietmanAL.Protonbeamtherapyandlocalizedprostatecancer:currentstatusandcontroversies.BrJCancer.2013;108(6):1225-1230.

559. GalbraithME,RamirezJM,PedroLW.Qualityoflife,healthoutcomes,andidentityforpatientswithprostatecancerinfivedifferenttreatmentgroups.OncolNursForum.2001;28(3):551-560.

560. GardnerBG,ZietmanAL,ShipleyWU,etal.Latenormaltissuesequelaeintheseconddecadeafterhighdoseradiationtherapywithcombinedphotonsandconformalprotonsforlocallyadvancedprostatecancer.JUrol.2002;167(1):123-126.

561. Goenka A, NewmanNB, Fontanilla H, et al. Patient reported quality of life following proton beamtherapyforprostatecancer:theimpactofprostatesize.ClinGenitourinCancer.2017Dec;15(6):704-710.

562. Gray PJ, Paly JJ, Yeap BY, et al. Patient-reported outcomes after 3-dimensional conformal,intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer.2013;119(9):1729-1735.

563. HendersonRH,HoppeBS,MarcusRBJr,etal.Urinaryfunctionaloutcomesandtoxicityfiveyearsafterprotontherapyforlow-andintermediate-riskprostatecancer:resultsoftwoprospectivetrials.ActaOncol.2013;52(3):463-469.

564. HoCK,BryantCM,MendenhallNP,etal.Long-termoutcomesfollowingprotontherapyforprostatecancer in young men with a focus on sexual health. Acta Oncol. 2018.https://doi.org/10.1080/0284186X.2018.1427886.

565. HoppeBS,HarrisS,Rhoton-VlasakA,etal.Spermpreservationandneutroncontaminationfollowingprotontherapyforprostatecancerstudy.ActaOncol.2016.

566. HoppeBS,MichalskiJM,MendenhallNP,etal.Comparativeeffectivenessstudyofpatientreportedoutcomesafterprotontherapyorintensity-modulatedradiotherapyforprostatecancer.Cancer.2014Apr1;120(7):1076-1082.

567. HoppeBS,NicholsRC,HendersonRH,etal.Erectilefunction, incontinence,andotherqualityof lifeoutcomes following proton therapy for prostate cancer inmen 60 years old and younger.Cancer.2012.118(18):4619-4626.

568. Jabbari S, Weinberg VK, Shinohara K, et al. Equivalent biochemical control and improvedprostate-specificantigennadirafterpermanentprostateseedimplantbrachytherapyversushigh-dosethree-dimensionalconformalradiotherapyandhigh-doseconformalprotonbeamradiotherapyboost.IntJRadiatOncolBiolPhys.2010;76(1):36-42.

569. Jain et al. Acute and late toxicity report of post-prostatectomyproton therapy for prostate cancerpatientsundergoingadjuvantorsalvageradiotherapy.IntJRadiatOncolBiolPhys.2017;98(2):e25.

570. JohanssonS,ÅströmL,SandinF,etal.Hypofractionatedprotonboostcombinedwithexternalbeamradiotherapyfortreatmentoflocalizedprostatecancer.ProstateCancer.2012;654861.

Page 84: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page84

571. KilWJ,NicholsRCJr.,HoppeBS,etal.Hypofractionatedpassivelyscatteredprotonradiotherapyforlow- and intermediate-risk prostate cancer is not associated with posttreatment testosteronesuppression.ActaOncol.2013;52(3):492-497.

572. KimS,ShenS,MooreDF,etal.Lategastrointestinaltoxicitiesfollowingradiationtherapyforprostatecancer.EurUrol.2011;60(5):908-916.

573. KimYJ,ChoKH,PyoHR,etal.AphaseIIstudyofhypofractionatedprotontherapyforprostatecancer.ActaOncol.2013;52(3):477-485.

574. Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment ofadenocarcinomaoftheprostate?JClinOncol.2007;25(24):3603-3608.

575. Lee DT,Mendenhall NP, Smith TL, et al. Patient-reported quality of life inmenwith transurethralresectionof theprostateundergoingprotontherapy formanagementofprostatecancer. Int JPartTher.2016Spring;2(4):518-524.

576. LeeHJ,MacomberMW,SprakerMB,etal.Earlytoxicityandpatientreportedquality-of-lifeinpatientsreceivingproton therapy for localizedprostatecancer:a single institutional reviewofprospectivelyrecordedoutcomes.RadiatOncol.2018;13:179.

577. MaedaY,SatoY,ShibataS,etal.Effectsoforganmotiononprotonprostatetreatments,asdeterminedfromanalysisofdailyCTimagingforpatientpositioning.MedPhys.2018;doi:10.1002/mp.12869.

578. MahalBA,ChenYW,EfstathiouJA,etal.Nationaltrendsanddeterminantsofprotontherapyuseforprostatecancer:aNationalCancerDataBasestudy.Cancer.2016May15;122(10):1505-1512.

579. MayaharaH,MurakamiM,KagawaK,etal.Acutemorbidityofprotontherapyforprostatecancer:theHyogoIonBeamMedicalCenterexperience.IntJRadiatOncolBiolPhys.2007;69(2):434-443.

580. McGee L,Mendenhall NP, Henderson RH, et al. Outcomes inmenwith large prostates (≥60 cm3)treatedwithdefinitiveprotontherapyforprostatecancer.ActaOncol.2013;52(3):470-476.

581. Mendenhall NP, Hoppe BS, Nichols, RC et al. Five-Year Outcomes from 3 Prospective Trials ofImage-GuidedProtonTherapyforProstateCancer.IntJRadiatOncolBiolPhys.2013;88(3):596-602.

582. MendenhallNP,LiZ,HoppeBS,etal.Earlyoutcomesfromthreeprospectivetrialsof imageguidedprotontherapyforprostatecancer.IntJRadiatOncolBiolPhys.2012;82(1):213-221.

583. Mendenhall NP,WongW, Bryant C et al. Comparison of clinical outcomes with IMRT and protontherapyforprostatecancer.JClinOncol.2017;e16555-e16555.

584. Mendenhall NP, Wong W, Bryant C, et al. Potential Improved Outcomes with Proton Therapy inProstateCancer:aComparisonof IMRTandProtonCohorts. Int JRadiatOncolBiolPhys. 2017Oct1;99(2):E254.

585. NakajimaK,IwataH,OginoH,etal.Acutetoxicityofimage-guidedhypofractionatedprotontherapyforlocalizedprostatecancer.IntJRadiatOncolBiolPhys.2017.https://doi.org/10.1007/s10147-017-1209-8.

586. NguyenPL,ZietmanAL.High-doseexternalbeamradiationforlocalizedprostatecancer:currentstatusandfuturechallenges.CancerJ.2007;13(5):295-301.

587. NicholsRCJr,MorrisCG,HoppeBS,etal.Protonradiotherapyforprostatecancer isnotassociatedwithpost-treatmenttestosteronesuppression.IntJRadiatOncolBiolPhys.2012;82(3):1222-1226.

Page 85: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page85

588. NiheiK,OginoT,IshikuraS,etal.PhaseIIfeasibilitystudyofhigh-doseradiotherapyforprostatecancerusingprotonboosttherapy:firstclinicaltrialofprotonbeamtherapyforprostatecancerinJapan.JpnJClinOncol.2005;35(12):745-752.

589. Nihei K, Ogino T, OnozawaM, et al.Multi-institutional phase II study of proton beam therapy fororgan-confinedprostatecancerfocusingontheincidenceoflaterectaltoxicities.IntJRadiatOncolBiolPhys.2011;81(2):390-396.

590. Pan HY, Jiang J, Hoffman KE, et al. Comparative toxicities and Cost of Intensity-ModulatedRadiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men withProstateCancer.JClinOncol.2018;JCO.2017755371.

591. PolfJC,ChuongM,ZhangB,MehtaM.Anteriorlyorientedbeamarrangementswithdailyinvivorangeverificationforprotontherapyofprostatecancer:rectaltoxicityrates.IntJPartTher.2016:510-517.

592. RicksLJ,SambyalA,McDonaldJ,etal.UtilizationofMachineLearningandProtonCollaborativeGroupData toDevelop aModel for Predictive Prostate Cancer ProtonRadiation TherapyOutcomes. Int JRadiatOncolBiolPhys.2017Oct1;99(2):E262.

593. RossiCJJr,SlaterJD,YonemotoLT,etal.Influenceofpatientageonbiochemicalfreedomfromdiseasein patients undergoing conformal proton radiotherapy of organ-confined prostate cancer.Urology.2004;64(4):729-732.

594. SchmidtMQ,VargasCE,HartsellWF,etal.Toxicity,qualityoflifeoutcomes,anddosimetricimpactinphaseIIItrialofhypofractionatedorstandardfractionatedprotontherapyforlow-riskprostatecancerpatients:PCGGU002.JClinOncol.2017Feb;35(6):S48.

595. Schroeck FR, Jacobs BL, Bhayani SB, et al. Cost of new technologies in prostate cancer treatment:systematic review of costs and cost effectiveness of robotic-assisted laparascopic prostatectomy,intensity-modulatedradiotherapy,andprotonbeamtherapy.EurUrol.2017Nov;72(5):712-735

596. SchulteRW,SlaterJD,RossiCJJr,SlaterJM.Valueandperspectivesofprotonradiationtherapyforlimitedstageprostatecancer.StrahlentherOnkol.2000;176(1):3-8.

597. ScobioalaS,KittelC,WissmanN,etal.Atreatmentplanningstudycomparingtomotherapy,volumetricmodulatedarctherapy,SlidingWindowandprotontherapyfor low-riskprostatecarcinoma.RadiatOncol.2016;11(1):128.

598. ShahSK,LuiPD,BaldwinDD,RuckleHC.Urothelialcarcinomaafterexternalbeamradiationtherapyforprostatecancer.JUrol.2006;175(6):2063-2066.

599. SheetsNC,GoldinGH,MeyerA-M,etal. Intensity-modulatedradiationtherapy,protontherapy,orconformal radiation therapy andmorbidity anddisease control in localizedprostate cancer. JAMA.2012;307(15):1611-1620.

600. ShipleyWU,VerheyLJ,MunzenriderJE,etal.Advancedprostatecancer:theresultsofarandomizedcomparative trial of high dose irradiation boosting with conformal protons compared withconventionaldoseirradiationusingphotonsalone.IntJRadiolOncolBiolPhys.1995;32(1):3-12.

601. SlaterJD,RossiCJJr,YonemotoLT,etal.Conformalprotontherapyforearly-stageprostatecancer.Urology.1999;53(5):978-984.

602. SlaterJD,RossiCJJr,YonemotoLT,etal.Protontherapyforprostatecancer:the initialLomaLindaUniversityexperience.IntJRadiatOncolBiolPhys.2004;59(2):348-352.

Page 86: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page86

603. SlaterJD,YonemotoLT,RossiCJJr,etal.Conformalprotontherapyforprostatecarcinoma.IntJRadiatOncolBiolPhys.1998;42(2):299-304.

604. Talcott JA,RossiC, ShipleyWU,etal. Patient-reported long-termoutcomesafter conventional andhigh-dose combined proton and photon radiation for early prostate cancer. JAMA.2010;303(11):1046-1053.

605. ThakerNG,AliTN,PorterME,etal.Communicatingvalueinhealthcareusingradarcharts:acasestudyofprostatecancer.JOncolPract.2016Sep;12(9):813-820.

606. Underwood T, Giantsoudi D, Moteabbed M, et al. Can we advance proton therapy for prostate?ConsideringalternativebeamangelsandRBEvariationswhencomparingagainst IMRT. Int JRadiatOncolBiolPhys.2016May;95(1):454-464.

607. Valery R,Mendenhall NP,Nichols RC Jr, et al. Hip fractures and pain following proton therapy formanagementofprostatecancer.ActaOncol.2013;52(3):486-491.

608. Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy andintensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Mar1;70(3):744-751.

609. VargasCE,HartsellWF,DunnM,etal.Image-guidedhypofractionatedprotonbeamtherapyforlow-riskprostatecancer:analysisofqualityof lifeandtoxicity,PCGGU002.RepPractOncolRadiother.2016;21(3):207-212.

610. Walsh S, Roelofs E, Kuss P, et al. Towards a Clinical Decision Support System for External BeamRadiationOncologyProstateCancerPatients:Protonvs.PhotonRadiotherapy?ARadiobiologicalStudyofRobustnessandStability.Cancers.2018;10(55):1-16.

611. Wessels BW, Brindle JM, Cheng CW, et al. Retrospective prostate treatment plan comparison forproton,tomotherapy,andcyberknifetherapy.IntJPartTher.2015;2(2).

612. WisenbaughES,AndrewsPE,FerrigniRG,etal.Protonbeamtherapyforlocalizedprostatecancer101:basics,controversies,andfacts.RevUrol.2014;16(2):67-75.

613. YonemotoLT,SlaterJD,RossiCJJr,etal.Combinedprotonandphotonconformalradiationtherapyforlocallyadvancedcarcinomaoftheprostate:preliminaryresultsofaphaseI/IIstudy.IntJRadiatOncolBiolPhys.1997;37(1):21-29.

614. YuJB,SoulosPR,HerrinJ,etal.Protonversusintensity-modulatedradiotherapyforprostatecancer:patternsofcareandearlytoxicity.JNatlCancerInst.2013;105(1):25-32.

615. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dosewith high doseconformal radiation therapy inearly-stageadenocarcinomaof theprostate: long-term results fromProton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol.2010;28(7):1106-1111.

616. ZietmanAL.TheTitanicandIceberg:prostateprotontherapyandhealthcareeconomics.JClinOncol.2007;25(24):3565-3566.

617. ZietmanAL,DeSilvioML, Slater JD, et al. Comparisonof conventional-dosevshigh-dose conformalradiationtherapyinclinicallylocalizedadenocarcinomaoftheprostate:arandomizedcontrolledtrial.JAMA.2005;294(10):1233-1239.

SARCOMA

Page 87: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page87

RetroperitonealSarcoma

618. ChungCS,AdamsJ,TrofimovA,DelaneyT.Acomparisonof3Dconformalprotontherapy,intensitymodulatedprotontherapy,andintensitymodulatedphotontherapyforretroperintonealsarcoma.IntJRadiatOncolBiolPhys.2006;66(3S):116.

619. DeLaneyTF,ChenYL,AdamsJA,etal.Phase1TrialofPreoperativeImageGuidedIntensityModulatedProtonRadiationTherapy(IMPT)WithSimultaneously IntegratedBoost totheHighRiskMargin forRetroperitoneal Sarcomas. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S23.doi:10.1016/j.ijrobp.2016.06.068.PubMedPMID:27675854.

620. Swanson EL, Indelicato DJ, Loius D, et al. Comparison of three-dimensional (3D) conformal protonradiotherapy(RT),3DconformalphotonRT,andintensity-modulatedRTforretroperitonealandintra-abdominalsarcomas.IntJRadiatOncolBiolPhys.2012;83(5):1549-1557.

621. YoonSS,ChenY-L,KirschDG,etal.Proton-beam,intensity-modulated,and/orintraoperativeelectronradiationtherapycombinedwithaggressiveanteriorsurgicalresectionforretroperitonealsarcomas.AnnSurgOncol.2010;17(6):1515-1529.

SoftTissueSarcoma

622. GuttmannDM,FrickMA,CarmonaR,etal.Aprospectivestudyofprotonreirradiationforrecurrentandsecondarysofttissuesarcoma.RadiotherOncol.2017Jul8.pii:S0167-8140(17)32444-1.

OtherSarcoma

623. CiernikIF,NiemierkoA,HarmonDC,etal.Proton-basedradiotherapyforunresectableorincompletelyresectedosteosarcoma.Cancer.2011;117(19):4522-4530.

624. DeLaneyTF,HaasRL.Innovativeradiotherapyofsarcoma:protonbeamradiation.EurJCancer.2016July;62:112-123.

625. DeLaneyTF,LiebschNJ,PedlowFX,etal.PhaseIIstudyofhigh-dosephoton/protonradiotherapyinthemanagementofspinesarcomas.IntJRadiatOncolBiolPhys.2009;74(3):732-739.

626. FrischS,TimmermanB.TheEvolvingRoleofProtonBeamTherapy forSarcomas.ClinOncol (RCollRadiol).2017May12.pii:S0936-6555(17)30221-2.

627. FukumotoT,KomatsuS,HoriY,etal.Particlebeamradiotherapywithasurgicalspacerplacementforadvanced abdominal leiomyosarcoma results in a significant clinical benefit. J Surg Oncol.2010;101(1):97-99.

628. GrayST,ChenY-L,LinDT.EfficacyofprotonbeamtherapyinthetreatmentofEwing’ssarcomaoftheparanasalsinusesandanteriorskullbase.SkullBase.2009;19(6):409-416.

629. Uwa N, Terada T, Mohri T, et al. An unexpected skin ulcer and soft tissue necrosis after thenonconcurrentcombinationofprotonbeamtherapyandpazopanib:acaseofmyxofibrosarcoma.AurisNasusLarynx.2017Aug;44(4):484-488.

630. WeberDC,RutzHP,BolsiA,etal. Spot scanningproton therapy in thecurative treatmentofadultpatients with sarcoma: the Paul Scherrer Institute experience. Int J Radiat Oncol Biol Phys.2007;69(3):865-871.

SKULLBASEANDAXIALSKELETON

Page 88: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page88

631. AcharayaS,RobinsonCG,MichalskiJM,etal.Associationof1p/19qcodeletionandRadiationNecrosisin Adult Cranial Gliomas after Proton or Photon Therapy. Int J Radiat Oncol Biol Phys. 2018.https://doi.org/10.1016/j.ijrobp.2018.01.099.

632. AhmedKA,DemetriouSK,McDonaldM,JohnstonePA.Clinicalbenefitsofprotonbeamtherapyfortumorsoftheskullbase.CancerControl.2016Jul;23(3):213-9.

633. AibeN,DemizuY,SulaimanNS,etal.OutcomesofPatientswithPrimarySacralChordomaTreatedwithDefinitive Proton Beam Therapy. Int J Radiat Oncol Biol Phys. 2018;100(4):972-979.http://dx.doi.org/10.1016/j.ijrobp.2017.12.263.

634. AmichettiM,AmelioD,CianchettiM,etal.Asystematicreviewofprotontherapyinthetreatmentofchondrosarcomaoftheskullbase.NeurosurgRev.2010;33(2):155-165.

635. AmichettiM,AmelioD,CianchettiM,etal.Proton therapy inchordomaof thebaseof theskull:asystematicreview.NeurosurgRev.2009;32(4):403-416.

636. AmichettiM,AmelioD,CianchettiM,etal.Thetreatmentofchordomaandchondrosarcomaoftheskullbasewithparticularattentiontoradiotherapy.ClinicsinOncology.2017;2(1195):1-7.

637. AresC,HugEB,LomaxAJ,etal.Effectivenessandsafetyofspotscanningprotonradiationtherapyforchordomasandchondrosarcomasoftheskullbase:firstlong-termreport.IntJRadiatOncolBiolPhys.2009;75(4):1111-1118.

638. BenkV,LiebschNJ,MunzenriderJE,etal.Baseofskullandcervicalspinechordomasinchildrentreatedbyhigh-doseirradiation.IntJRadiatOncolBiolPhys.1995;31(3):577-581.

639. ChakravartiA,SpiroIJ,HugEB,etal.Megavoltageradiationtherapyforaxialandinoperablegiant-celltumorofbone.JBoneJointSurgAm.1999;81(11):1566-1573.

640. Chen Y-L, Liebsch N, Kobayashi W, et al. Definitive high-dose photon/proton radiotherapy forunresectedmobilespineandsacralchordomas.Spine.2013;38(15):E930-E936.

641. CombsSE,KesselK,Habermehl,etal.Protonandcarbonionradiotherapyforprimarybraintumorsandtumorsoftheskullbase.ActaOncol.2013;52(7):1504-1509.

642. CombsSE,LaperriereN,BradaM.Clinicalcontroversies:protonradiationtherapyforbrainandskullbasetumors.SeminRadiatOncol.2013;23(2):120-126.

643. DebusJ,HugEB,LiebschNJ,etal.Brainstemtolerancetoconformalradiotherapyofskullbasetumors.IntJRadiatOncolBiolPhys.1997;39(5):967-975.

644. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Long-term results of Phase II study of high dosephoton/proton radiotherapy in themanagementofpsine chordomas, chondrosarcomas, andothersarcomas.JSurgOncol.2014;110:115-122.

645. DemizuY,MizumotoM,OnoeT,etal.Protonbeamtherapyforbonesarcomasoftheskullbaseandspine:aretrospectivenationwidemulticenterstudyinJapan.CancerSci.2017May;108(5):972-977

646. DeraniyagalaRL,YeungD,MendenhallWM,etal.Protontherapyforskullbasechordomas:anoutcomestudy from the University of Florida Proton Therapy Institute. J Neurol Surg B Skull Base. 2014February;75(1):53-7.

647. Dutz A, Luhr A, Agolli L, et al. Development and validation of NTCPmodels for acute side-effectsresultingfromprotonbeamtherapyofbraintumours.RadiotherOncol.2018.

Page 89: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page89

648. FeuvretL,BracciS,CalugaruV,etal.Efficacyandsafetyofadjuvantprotontherapy incombinationwithsurgeryforchondrosarcomaoftheskullbase:aretrospective,population-basedstudy.IntJRadiatOncolBiolPhys.2016May1;95(1):312-21.

649. FungV,CalugaruV,BolleS,etal.Protonbeamtherapyforskullbasechordomasin106patients:Adoseadaptiveradiationprotocol.RadiotherOncol.2017.http://dx.doi.org/10.1016/j.radonc.2017.12.017.

650. Gentile MS, Miao R, Liebsch NJ, et al. Combined Surgical Resection and Adjuvant High DosePhoton/ProtonRadiationTherapyStrategyResultsinHighLocalControlinCervicalSpineChordomas.IntJRadiatOncolBiolPhys.2017;99(2):E752.

651. Glazer TA, Marentette LJ, Sullivan SE, McKean EL. Retrospective review of surgical and adjuvanttreatmentmodalitiesthataffectskullbasechordomarecurrencerates.JNeurolSurgB.2016;77-A012.

652. GrosshansDR,ZhuXR,MelanconA,etal.Spotscanningprotontherapyformalignanciesofthebaseofskull: treatmentplanning,acutetoxicities,andpreliminaryclinicaloutcomes. Int JRadiatOncolBiolPhys.2014Nov1;90(3):540-546.

653. GudjonssonO,BlomquistE,NybergG,etal.Stereotactic irradiationofskullbasemeningiomaswithhighenergyprotons.ActaNeurochir(Wien).1999;141(9):933-940.

654. Guillaume V, Valentin C, Bolle S, et al. Investigation of ectopic recurrent skull base and cervicalchordomas: The Institut Curie's proton therapy center experience.Head Neck. 2016 Apr;38 Suppl1:E1238-1246.

655. HallDC,TrofimovAV,WineyBA,etal.Predictingpatient-specificdosimetricbenefitsofprotontherapyforskull-basetumorsusingageometricknowledge-basedmethod.IntJRadiatOncolBiolPhys.2017Apr1;97(5):1087-1094.

656. HallMD,BradleyJA,RotondoRL,etal.RiskofRadiationVasculopathyandStrokeinPediatricPatientsTreatedwith Proton Therapy for Brain and Skull Base Tumors. Int J Radiat Oncol Biol Phys. 2018;https://doi.org/10.1016/j.ijrobp.2018.03.027.

657. HayashiY,MizumotoM,AkutsuH,etal.Hyperfractionatedhighdoseprotonbeamradiotherapyforclivalchordomasaftersurgicalremoval.BrJRadiol.2016Jul;89(1063):20151051.

658. Holliday EB, Mitra HS, Somerson JS, et al. Post operative proton therapy for chordomas andchondrosarcomasofthespine:adjuvantvs.salvageradiationtherapy.Spine.2015Apr15;40(8):544-549.

659. HugEB,FitzekMM,LiebschNJ,MunzenriderJE.Locallychallengingosteo-andchondrogenictumorsoftheaxialskeleton:resultsofcombinedprotonandphotonradiationtherapyusingthree-dimensionaltreatmentplanning.IntJRadiatOncolBiolPhys.1995;31(3):467-476.

660. HugEB,LoredoLN,SlaterJD,etal.Protonradiationtherapyforchordomasandchondrosarcomasoftheskullbase.JNeurosurg.1999;91(3):432-439.

661. HugEB, Slater JD.Proton radiation therapy for chordomasandchondrosarcomasof the skullbase.NeurosurgClinNAm.2000;11(4):627-638.

662. IannalfiA,E’IppolitoE,VitoloV,etal.P05.39Skull-basechordomatreatedwithprotonandcarbonionradiotherapy:C.N.A.O.clinicalexperience.Neuro-Oncology.2018;20(3).

663. IgakiH,TokuuyeK,OkumuraT,etal.ClinicalResultsofProtonBeamTherapyforSkullBaseChordoma.IntJRadiatOncolBiolPhys.2004;60(4):1120-6.

Page 90: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page90

664. IndelicatoDJ,RotondoRL,Begosh-MayneD,etal.Aprospectiveoutcomesstudyofprotontherapyforchordomasandchondrosarcomasofthespine.IntJRadiatOncolBiolPhys.2016;95(1):297-303.

665. KabolizadehP,ChenYL,LiebschN,etal.Updatedoutcomeandanalysisoftumorresponseinmobilespineandsacralchordomatreatedwithdefinitivehigh-dosephoton/protonradiation therapy. Int JRadiatOncolBiolPhys.2017;97(2):254-262.

666. KralikJC,XiL,SolbergTD,etal.Comparingprotontreatmentplansofpediatricbraintumorsintwopencilbeamscanningnozzleswithdifferentspotsizes.JApplClinMedPhys.2015;16(6):41-50.

667. LeemanJE,LeeNY,ZhouY,etal.Endoscopicresectionfollowedbyprotontherapywithpencilbeamscanningforskullbasetumors.TheLaryngoscope.2018.

668. McDonaldMW, LintonOR, ShahMV. Proton Therapy for Reirradiationof Progressive or RecurrentChordoma.IntJRadiatOncolBiolPhys.2013;87(5):1107-1114.

669. MimaM,DemizuY,JinD,etal.ParticleTherapyUsingCarbonIonsorProtonsasaDefinitiveTherapyforPatientswithPrimarySacralChordoma.BrJRadiol.2014Jan;87(1033):20130512.

670. MiyawakiD,MurakamiM,DemizuY,etal.Braininjuryafterprotontherapyorcarboniontherapyforhead-and-neckcancerandskullbasetumors.IntJRadiatOncolBiolPhys.2009;75(2):378-384.

671. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol.1990;175(Suppl2):57-63.

672. NoëlG,FeuvretL,CalugaruV,etal.Chordomasofthebaseoftheskullanduppercervicalspine.Onehundredpatientsirradiatedbya3Dconformaltechniquecombiningphotonandprotonbeams.ActaOncol.2005;44(7):700-708.

673. Noël G, Feuvret L, Ferrand R, et al. Radiotherapeutic factors in themanagement of cervical-basalchordomasandchondrosarcomas.Neurosurgery.2004;55(6):1252-1260.

674. NoëlG,HabrandJL,JauffretE,etal.Radiationtherapyforchordomaandchondrosarcomaoftheskullbase and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol.2003;179(4):241-248.

675. Noël G, Habrand JL, Mammar H, et al. Combination of photon and proton radiation therapy forchordomasandchondrosarcomasoftheskullbase:theCentredeProtonthérapied’Orsayexperience.IntJRadiatOncolBiolPhys.2001;51(2):392-398.

676. PaiHH,ThorntonA,KatznelsonL,etal.Hypothalamic/pituitaryfunctionfollowinghigh-doseconformalradiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volumehistogramanalysis.IntJRadiatOncolBiolPhys.2001;49(4):1079-1092.

677. Park L, DeLaney TF, Liebsch NJ, et al. Sacral chordomas: impact of high-dose proton/photonbeamradiationtherapycombinedwithorwithoutsurgeryforprimaryversusrecurrenttumor.IntJRadiatOncolBiolPhys.2006;65(5):1514-1521.

678. ParsonsM,HoebelK,ChangK,etal.Effectsofprotonradiationonbrainstructureandfunctioninlowgradeglioma.Neuro-Oncology.2018;20(6).

679. PehlivanB,AresC,LomaxAJ,etal.Temporallobetoxicityanalysisafterprotonradiationtherapyforskullbasetumors.IntJRadiatOncolBiolPhys.2012;83(5):1432-1440.

Page 91: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page91

680. Phan J, Frank SJ, Chun S, et al. Evaluation of IntensityModulated Proton Therapy for StereotacticAblativeRadiationTherapyofRecurrentSkullBaseTumors:AComparativeTreatmentPlanningStudyWithVolumetricModulatedArcTherapy.IntJRadiatOncolBiolPhys.2016Oct1;96(2S):E677.

681. PommierP,LiebschNJ,DeschlerDG,etal.Protonbeamradiationtherapyforskullbaseadenoidcysticcarcinoma.ArchOtolaryngolHeadNeckSurg.2006;132(11):1242-1249.

682. Rief H, Chaudhri N, Tonndorf-Martini E, et al. Intensity-modulated radiotherapy versus protonradiotherapyversuscarbonionradiotherapyforspinalbonemetastases:atreatmentplanningstudy.JApplClinMedPhys.2015Nov;16(6):186-194.

683. RodaRH,GalliaGL,EberhartCG,etal.Epilepsyandtemporallobeinjuryafterskullbaseprotonbeamtherapy.JClinNeurosci.2009;16(9):1220-1221.

684. RongthongW, Laack N, Beltran C, et al. Radiation induced signal changes onmagnetic resonanceimaginginadultpatientswithbraintumorstreatedwithpencilbeamscanningprotontherapy.Neuro-Oncology.2018;20(6).

685. RotondoR,FlokertW,LiebschNJ,etal.High-doseproton-basedradiationtherapyinthemanagementof spine chordomas: outcomes and clinicopathological prognostic factors. J Neurosurg Spine.2015;23(6):788-797.

686. Rutz HP, Weber DC, Sugahara S, et al. Extracranial chordoma: outcome in patients treated withfunction-preservingsurgeryfollowedbyspot-scanningprotonbeamirradiation.IntJRadiatOncolBiolPhys.2007;67(2):512-520.

687. SantoniR,LiebschN,FinkelsteinDM,etal.Temporallobe(TL)damagefollowingsurgeryandhigh-dosephotonandprotonirradiationin96patientsaffectedbychordomasandchondrosarcomasofthebaseoftheskull.IntJRadiatOncolBiolPhys.1998;41(1):59-68.

688. ScalaM,VennariniS,GarreML,etal.Radiation-inducedmoyamoyasyndromeafterprotontherapyina childwith clival craniopharyngioma: natural history and surgical treatment.WorldNeurosurgery.2018.

689. SciubbaDM,ChiJH,RhinesLD,etal.Chordomaofthespinalcolumn.NeurosurgClinNAm.2008;19(1):5-15.

690. StaabA,RutzHP,AreaC,etal.Spot-scanning-basedprotontherapyforextracranialchordoma.IntJRadiatOncolBiolPhys.2011;81(4):e489-e496.

691. StadeF,DittmarJO,JäkelO,etal.Influenceof68Ga-DOTATOConsparingofnormaltissueforradiationtherapy of skull base meningioma: differential impact of photon and proton radiotherapy. RadiatOncol.2018;https://doi.org/10.1186/s13014-018-1008-z.

692. Stieb S, Snider III JW, Placidi L, et al. Long-term clinical safety of high-dose proton radiotherapydeliveredwithpencilbeamscanningtechniqueforextracranialchordomasandchondrosarcomasinadult patients: Clinical evidence of spinal cord tolerance. 2017. Int J Radiat Oncol Biol Phys.https://doi.org/10.1016/j.ijrobp.2017.08.037

693. Stoker J, Keole SR, Grosshans DR, et al. An Investigation of Hippocampal-Sparing Capabilities ofIntensityModulatedProtonTherapyDuringWhole-BrainIrradiation.IntJRadiatOncolBiolPhys.2016Oct1;96(2S):E129.

Page 92: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page92

694. Terahara A, Niemierko A, Goitein M, et al. Analysis of the relationship between tumor doseinhomogeneityand localcontrol inpatientswithskullbasechordoma. Int JRadiatOncolBiolPhys.1999;45(2):351-358.

695. VernimmenFJ,HarrisJK,WilsonJA,etal.Stereotacticprotonbeamtherapyofskullbasemeningiomas.IntJRadiatOncolBiolPhys.2011;49(1):99-105.

696. WeberDC,MurrayF,CombescureC,etal.Longtermoutcomeofskull-basechondrosarcomapatientstreated with high-dose proton therapy with or without conventional radiation therapy. RadiotherOncol.2018.

697. WeberDC,RutzHP,PedroniES,etal.Resultsofspot-scanningprotonradiationtherapyforchordomaandchondrosarcomaoftheskullbase:thePaulScherrer Institutexperience. Int JRadiatOncolBiolPhys.2005;63(2):401-409.

698. YasudaM, Bresson D, Chibbaro S, et al. Chordomas and the skull base and cervical spine: clinicaloutcomesassociatedwithamultimodalsurgicalresectioncombinedwithproton-beamradiationin40patients.NeurosurgRev.2012;35(2):171-182.

THORACIC

ChestWallandLymphatic

699. MacDonaldSM,JimenezR,PaetzoldP,etal.Protonradiotherapyforchestwallandregionallymphaticradiation;dosecomparisonsandtreatmentdelivery.RadiatOncol.2013Mar24;8(71).

Lung

700. AkitaK,IwataH,OginoH,etal.AphaseIItrialofS-1pluscisplatinwithconcurrentproton-beamtherapyforlocallyadvancednon-smallcelllungcancer.JClinOncol.2017;35(15):e20070

701. BadiyanS,MohindraP, LarsonGL,etal.ClinicalOutcomesofPatientsWithRecurrentLungCancerReirradiatedwithProtonTherapyontheProtonCollaborativeGroupProspectiveRegistryTrial.IntJRadiatOncolBiolPhys.2017;99(2):S209.

702. BermanAT,JamesSS,RenganR.Protonbeamtherapyfornon-smallcelllungcancer:currentclinicalevidenceandfuturedirections.Cancers.2015July2;7(3):1178-90.

703. BonnetRB,BushD,CheekGA,etal.Effectsofprotonandcombinedproton/photonbeamradiationonpulmonary function inpatientswith resectablebutmedically inoperablenonsmall cell lung cancer.Chest.2001;120(6):1803-1810.

704. BushDA,CheekG,ZaheerS,etal.High-dosehypofractionatedprotonbeamradiationtherapyissafeandeffective for central andperipheral early-stagenon-small cell lung cancer: resultsof a12-yearexperienceatLomaLindaUniversityMedicalCenter.IntJRadiatOncolBiolPhys.2013;86(5):964-968.

705. Bush DA, Slater JD, Bonnet R, et al. Proton-beam radiotherapy for early-stage lung cancer. Chest.1999;116(5):1313-1319.

706. BushDA,SlaterJD,ShinBB,etal.HypofractionatedprotonbeamradiotherapyforstageIlungcancer.Chest.2004;126(4):1198-1203.

707. ChangJY,JabbourSK,DeRuysscherD,etal.Consensusstatementonprotontherapyinearly-stageandlocallyadvancednon-smallcelllungcancer.IntJRadiatOncolBiolPhys.2016May;95(1):505-16.

Page 93: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page93

708. Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrentchemotherapyforunresectablestageIIInonsmallcelllungcancer.Cancer.2011;117(20):4707-4713.

709. ChangJY,KomakiR,WenHY,etal.Toxicityandpatternsoffailureofadaptive/ablativeprotontherapyfor early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys.2011;80(5):1350-1357.

710. ChangJY,NantavithyaC,GomezDR,etal.(OA03)APhaseIIStudyofStereotacticBodyRadiotherapyandStereotacticBodyProtonTherapyforHigh-RiskMedicallyInoperableEarly-StageNon-SmallCellLungCancer.IntJRadiatOncolBiolPhys.2018;101(2):E2.

711. Chang JY, Verma V, Li M, et al. Proton Beam Radiotherapy and Concurrent Chemotherapy forUnresectableStageIIINon–Small-CellLungCancer:FinalResultsofaPhase2Study.JAMAOncol.July2017.doi:10.1001/jamaoncol.2017.2032.

712. Chang JY, ZhangW, Komaki R, et al. Long-term outcome of phase I/II prospective study of dose-escalatedprotontherapyforearly-stagenon-smallcelllungcancer.RadiotherOncol.2017;122(2):274-80.

713. ChangJY,ZhangX,WangX,etal.Significantreductionofnormaltissuedosebyprotonradiotherapycomparedwith three-dimensional conformalor intensity-modulated radiation therapy in Stage I orStageIIInon-small-celllungcancer.IntJRadiatOncolBiolPhys.2006;65(4):1087-1096.

714. ChaoHH,BermanAT,SimoneCB2nd,etal.Multi-institutionalprospectivestudyofreirradiationwithprotonbeamradiotherapyforlocoregionallyrecurrentnon-smallcelllungcancer.JThoracOncol.2017February;12(2):281-292.

715. ColacoRJ,HuhS,NicholsRC,etal.DosimetricrationaleandearlyexperienceatUFPTIofthoracicprotontherapyandchemotherapyinlimited-stagesmallcelllungcancer.ActaOncol.2013;52(3):506-513.

716. CooperBT,MahD,ChenCC,etal.HypofractionatedProtonTherapy forEarlyStageNon–smallCellLung Cancer: ClinicalOutcomes and ComparativeDosimetric Analysis. Int J RadiatOncol Biol Phys.2017;99(2):E449.

717. Cox J, et al. MDACC - Presentation of Findings in Lung Cancer and Proton Therapy; ChicagoMultimodalityLung;November2008.

718. CushmanTR,VermaV,RwigemaJM.Comparisonofprotontherapyandintensitymodulatedphotonradiotherapyforlocallyadvancednon-smallcelllungcancer:considerationsforoptimaltrialdesign.JThoracDis.2018;3(2).

719. DaganR,BryantCM,BradleyJA,etal.Aprospectiveevaluationofacutetoxicityfromprotontherapyfortargetsoftheparotidregion.IntJPartTher.2016Fall;3(2):285-290.

720. Das M. Concurrent chemotherapy and proton beam therapy in NSCLC. Lancet Oncol. 2017Sep;18(9):e515.http://dx.doi.org/10.1016/S1470-2045(17)30570-3.

721. DeistTM,YangP,OberjieC,etal.Dosimetricanalysisofrandomizedprotonandphotonplanswithrespecttoradiationtoxicity:theimportanceofhighdoseregionsinlungandesophagus.IntJRadiatOncolBiolPhys.2017May1;98(1):246.

722. FujiiO,DemizuY,HashimotoN,etal.AretrospectivecomparisonofprotontherapyandcarboniontherapyforstageInon-smallcelllungcancer.RadiotherOncol.2013;109(1):32-37.

Page 94: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page94

723. GomezDR,ChangJY.Accelerateddoseescalationwithprotonbeamtherapyfornon-smallcell lungcancer.JThoracDis.2014April;6(4):348-55.

724. GomezDR,GillinM,LiaoZ,etal.Phase1studyofdoseescalationinhypofractionatedprotonbeamtherapyfornon-smallcelllungcancer.IntJRadiatOncolBiolPhys.2013;86(4):665-670.

725. GomezDR,LiH,ChangJY.Protontherapyforearly-stagenon-smallcell lungcancer(NSCLC).TranslLungCancerRes.2018;7(2):199-204.

726. Gomez DR, Tucker SL, Martel MK, et al. Predictors of high-grade esophagitis after definitivethree-dimensionalconformaltherapy,intensity-modulatedradiationtherapy,orprotonbeamtherapyfornon-smallcelllungcancer.IntJRadiatOncolBiolPhys.2012;84(4):1010-1016.

727. GridleyDS,BonnetRB,BushDA,etal.Timecourseofserumcytokinesinpatientsreceivingprotonorcombinedphoton/protonbeamradiationforresectablebutmedicallyinoperablenon-small-celllungcancer.IntJRadiatOncolBiolPhys.2004;60(3):759-766.

728. Grutters JPC,Pijls-JohannesmaM,DeRuysscher,etal. Thecost-effectivenessofparticle therapy innon-smallcelllungcancer:exploringdecisionuncertaintyandareasforfutureresearch.CancerTreatRev.2010;36(6):468-476.

729. Harada H, Fuji H, Ono A, et al. Dose escalation study of proton beam therapy with concurrentchemotherapyforstageIIInon-smallcelllungcancer.CancerSci.2016July;107(7):1018-1021.

730. Hata M, Tokuuye K, Kagei K, et al. Hypofractionated high-dose proton beam therapy for stage Inon-small-celllungcancer:preliminaryresultsofaphaseI/IIclinicalstudy.IntJRadiatOncolBiolPhys.2007;68(3):786-793.

731. Hoppe BS, Flampouri S, Henderson RH, et al. Proton therapy with concurrent chemotherapy fornon-small-celllungcancer:techniqueandearlyresults.ClinLungCancer.2012;13(5):352-358.

732. Hoppe BS, Henderson R, Pham D, et al. A Phase 2 Trial of Concurrent Chemotherapy and ProtonTherapyforStageIIINon-SmallCellLungCancer:ResultsandReflectionsFollowingEarlyClosureofaSingle-InstitutionStudy.IntJRadiatOncolBiolPhys.2016;95(1):517-522.

733. HoppeBS.PhaseIItrialofconcurrentchemotherapyandprotontherapyforstage3NSCLC.IntJPartTher.2014;2:58.

734. IwataH,DemizuY,FujiiO,etal.Long-termoutcomeofprotontherapyandcarbon-therapyforlarge(T2a-T2bN0M0)non-small-celllungcancer.JThoracOncol.2013;8(6):726-735.

735. IwataH,MurakamiM,DemizuY,etal.High-doseprotontherapyandcarbon-iontherapyforstageInonsmallcelllungcancer.Cancer.2010;116(10):2476-2485.

736. JeterMD,GomezD,NguyenQ,etal.SimultaneousIntegratedBoostforRadiationDoseEscalationtotheGrossTumorVolumewithIntensity-Modulated(Photon)RadiationTherapyorIntensity-ModulatedProtonTherapyandConcurrentChemotherapyforStageII-IIINon-SmallCellLungCancer:APhaseIStudy.IntJRadiatOncolBiolPhys.2017;https://doi.org/10.1016/j.ijrobp.2017.10.042.

737. KesarwalaAH,KoCJ,NingH,etal.Intensitymodulatedprotontherapyforelectivenodalirradiationandinvolvedfieldradiationinthedefinitivetreatmentoflocallyadvancednonsmallcelllungcancer:adosimetricstudy.ClinLungCancer.2015May;16(3):237-244.

Page 95: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page95

738. KoayEJ,LegeD,MohanR,etal.Adaptive/nonadaptiveprotonradiationplanningandoutcomesinaphase II trial for locally advanced non small cell lung cancer. Int J Radiat Oncol Biol Phys.2012;84(5):10931100.

739. KrayenbuehlJ,HartmannM,LomaxAJ,etal.Protontherapyformalignantpleuralmesotheliomaafterextrapleuralpleuropneumonectomy.IntJRadiatOncolBiolPhys.2010;78(2):628-634.

740. LeeH,ZengJ,BowenS,RenganR.ProtonTherapyforMalignantPleuralMesothelioma:AThreeCaseSeriesDescribingtheClinicalandDosimetricAdvantagesofProton-BasedTherapy.Cureus.2017;9(9):e1705.

741. LeeSU,MoonSH,ChoKH,etal.AblativedoseprotonbeamtherapyforstageIandrecurrentnon-smallcelllungcarcinomas:ablativedosePBTforNSCLC.StrahlenOnkolo.2016Sep;192(9):649-657.

742. LiH,ZhuXR,ZhangX.Reducingdoseuncertaintyforspot-scanningprotonbeamtherapyofmovingtumorsbyoptimizingthespotdeliverysequence.IntJRadiatOncolBiolPhys.2015;93(3):547-556.

743. Liao Z, Lee JJ, Komaki R, et al. BayesianAdaptive Randomization Trial of Passive Scattering ProtonTherapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non–Small-Cell LungCancer.JClinOncol.2018.doi:10.1200/JCO.2017.74.0720.

744. LopezGuerraJL,GomezDR,ZhuangY,etal.Changes inpulmonaryfunctionafterthreedimensionalconformalradiotherapy,intensity-modulatedradiotherapy,orprotonbeamtherapyfornon-small-celllungcancer.IntJRadiatOncolBiolPhys.2012;83(4):e537-e543.

745. Makita C, Nakamura T, Takada A, et al. Clinical outcmes and toxicity of proton beam therapy foradvancedcholangiocarcinoma.RadiatOncol.2014;9(26).

746. MakitaB,NakamuraT,TakadaA,etal.HighdoseprotonbeamtherapyforstageInonsmallcelllungcancer:clinicaloutcomesandprognosticfactors.ActaOncol.2015Mar:54(3):307-314.

747. McAvoySA,CiuraK,WeiC,etal.Definitivereirradiationforlocoregionallyrecurrentnon-smallcelllungcancerwithprotonbeamtherapyorintensitymodulatedradiationtherapy:predictorsofhigh-gradetoxicityandsurvivaloutcomes.IntJRadiatOncolPhys.2014Nov15;90(4):819-827.

748. McAvoy SA, Ciura KT, Rineer JM, et al. Feasibility of proton beam therapy for reirradiation oflocoregionallyrecurrentnon-smallcelllungcancer.RadiotherOncol.2013;109(1):38-44.

749. MorenoAC,ZhangN,GiordanoSH,etal.TrendsandOutcomesofProtonRadiationTherapyUseforNon–SmallCellLungCancer.IntJPartTher.2018;5(2):18-27.

750. MuraiT,MuramatsuR,OmachiC,etal.LungDensityChangesAfterProtonTherapyforLungTumors:CanDoseConstraintsforPhotonTherapybeAppliedtoProtonTherapy?IntJRadiatOncolBiolPhys.2017;99(2S):E483.

751. NakajimaK,IwataH,OginoH,etal.Clinicaloutcomesofimage-guidedprotontherapyforhistologicallyconfirmedstageInon-smallcelllungcancer.RadiatOncol.2018;13:199.

752. NakajimaK,IwataH,OginoH,etal.ClinicalOutcomesofImage-GuidedProtonTherapyforStageINon-smallCellLungCancer.IntJRadiatOncolBiolPhys.2017;99(2S):E483.

753. NakamuraN,HojoH,InouyeK,etal.LateradiologicalchangesafterpassivescatteringprotonbeamtherapyforStageIlungcancer.JRadiatRes.2018.doi:10.1093/jrr/rry028.

754. NakayamaH,SatohH,SugaharaS,etal.ProtonbeamtherapyofstageIIandIIInon-small-cell lungcancer.IntJRadiatOncolBiolPhys.2011;81(4):979-984.

Page 96: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page96

755. NakayamaH,SugaharaS,TokitaM,etal.Protonbeamtherapyforpatientswithmedicallyinoperablestage I non-small-cell lung cancer at the University of Tsukuba. Int J Radiat Oncol Biol Phys.2010;78(2):467-471.

756. NguyenQN,BlanchardP,KomakiRU,etal.ReportedOutcomesandToxicitiesforInoperable,StageII-III Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and IntensityModulatedProtonTherapy.IntJRadiatOncolBiolPhys.2017;99(2S):E484.

757. Nguyen QN, Ly NB, Komaki R, et al. Long-term outcomes after proton therapy, with concurrentchemotherapy,forstageII-IIIinoperablenon-smallcelllungcancer.RadiotherOncol.2015;115:367-372.

758. NiheiK,OginoT,IshikuraS,NishimuraH.High-doseprotonbeamtherapyforstageInonsmall-celllungcancer.IntJRadiatOncolBiolPhys.2006;65(1):107-111.

759. OhnishiK,HaradaH,NakamuraN,etal.P2.05-005ProtonBeamTherapyforEarlyStageLungCancer:AMulti-InstitutionalRetrospectiveStudyinJapan.JThoracOncol.2017;12(11):S2405.

760. OhnoT,OshiroY,MizumotoM,etal.Comparisonofdose-volumehistogramsbetweenprotonbeamandX-rayconformalradiotherapyforlocallyadvancednonsmall-celllungcancer.JRadiatRes.2015Jan;56(1):128-133.

761. OnoT,HareyamaM,NakamuraT,etal.Theclinicalresultsofprotonbeamtherapyinpatientswithidiopathicpulmonaryfibrosis:asinglecenterexperience.RadiatOncol.2016;11(1):56.

762. Oshiro Y, Mizumoto M, Okumura T, et al. Results of proton beam therapy without concurrentchemotherapyforpatientswithunresectablestageIIInon-smallcelllungcancer.JThorOncol.2012February;7(2):370-375.

763. Oshiro Y, Okumura T, Kurishima K, et al. High-dose concurrent chemo-proton therapy for stage IIINSCLC:preliminaryresultsofaphaseIIstudy.JRadiatRes.2014;55:959-965.

764. PanHY,JiangS,SuttonJ,etal.Earlyexperiencewithintensitymodulatedprotontherapyforlung-intactmesothelioma:acaseseries.PractRadiatOncol.2015Jul-Aug;5(4):e345-353.

765. SchildSE,RuleWG,AshmanJB,etal.Protonbeamtherapyforlocallyadvancedlungcancer:areview.WorldJClinOncol.2014Oct10;5(4):568-575.

766. SejpalS,KomakiR,TsaoA,etal.Early findingsontoxicityofprotonbeamtherapywithconcurrentchemotherapyfornonsmallcelllungcancer.Cancer.2011;117(13):3004-3013.

767. ShioyamaY,TokuuyeK,OkumuraT,etal.Clinicalevaluationofprotonradiotherapyfornonsmall-celllungcancer.IntJRadiatOncolBiolPhys.2003;56(1):7-13.

768. VermaV,RwigemaJCM,AdebergS,SimoneCB.Enrollmentofelderlypatientswithlocallyadvancednon-smallcell lungcancerontomulti-institutional trialsofprotonbeamradiation therapy. JThoracOncol.2016.

769. WangX,ShiQ,LiaoZ,etal.OA01.07TrackingMajorSymptomBurdenfromChemotherapyConcurrentwith3Dvs.IMRTvs.ProtonBeamRadiotherapyforNSCLC.JThoracOncol.2017;12(11):S1745-S1746.

770. WangX,ShiQ,WilliamsLA,etal.Prospectivestudyofpatient-reportedsymptomburdeninpatientswithnon-small-celllungcancerundergoingprotonorphotonchemoradiationtherapy.JPainSymptomManage.2016May;51(5):832-838.

Page 97: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page97

771. WestoverKD,SecoJ,AdamsJA,etal.ProtonSBRTformedically inoperablestage INSCLC.JThoracOncol.2012;7(6):1021-1025.

772. Xiang Z-L, Erasmus J, Komaki R, et al. FDG uptake correlates with recurrence and survival aftertreatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy andchemotherapy.RadiatOncol.2012;7:144.

773. YangP,XuT,GomezDR,DengW,etal.Patternsof local-regional failureafter intensity-modulatedradiationtherapyorpassivescatteringprotontherapywithconcurrentchemotherapyfornon-smallcelllungcancer.IntJRadiatOncolBiolPhys.2018.

774. Yegya-RamanN,ZouW,Malhotra J,etal.Advancedradiationtechniques for locallyadvancednon-smallcelllungcancer:intensity-modulatedradiationtherapyandprotontherapy.JThorDis.2018.

775. YueJ,JeterMD,XuT,etal.LungDosimetry,RadiationPneumonitis,andFDGUptakeinPatientsWithStage II-IIINon-SmallCell LungCancerTreatedWithPassivelyScatteredProtonTherapyor IntensityModulatedPho.IntJRadiatOncolBiolPhys.2016Oct1;96(2S):E455-E456.

Thymoma

776. VogelJ,LinL,LitzkyLA,etal.Predictedrateofsecondarymalignanciesfollowingadjuvantprotonversusphotonradiationtherapyforthymoma.IntJRadiatOncolBiolPhys.2017Oct1;99(2):427-433.

ThoracicMalignancies

777. ChangJY,LiH.ZhuXR,etal.Clinicalimplementationofintensitymodulatedprotontherapyforthoracicmalignancies.IntJRadiatOncolBiolPhys.2014November15;90(4):809-18.

778. Contreras J, Chundury A, Reynoso F, et al. Proton Therapy Reirradiation for Thoracic Recurrences:ToxicityandOutcomes.IntJRadiatOncolBiolPhys.2017;99(2):E448.

779. HoJC,etal.Reirradiationof thoraciccancerswith intensitymodulatedprotontherapy. Int JRadiatOncolBiolPhys.2017;98(1):222.

780. KojimaH,IsakaM,NagataM,etal.Preoperativeprotonbeamtherapyforthymoma:acasereport.AnnThoracCardiovascSurg.2016June;22(3):186-188.

781. LiaoZ,GandhiSJ,LinSH,BradleyJ.DoesProtonTherapyOfferDemonstrableClinicalAdvantagesforTreatingThoracicTumors?SeminRadiatOncol.2018;28(2):114-124.

782. LidestahlA,MondlaneG,GubanskiM,etal.Normaltissuetoxicityfollowingradiotherapywithphoton-orscannedproton-beamsinpatientswiththymictumors.ActaOncologica.2018.

783. NandaR,etal.Pulmonarytoxicityfollowingprotontherapyforthoraciclymphoma.IntJRadiatOncolBiolPhys.2017Oct1;99(2):494-497.

GENERAL

784. AhmadiT, Itai Y,OnayaH,et al.CTevaluationofhepatic injury followingprotonbeam irradiation:appearance, enhancement, and 3D size reduction pattern. J Comput Assist Tomogr.1999;23(5):655-663.

785. Amichetti,M.Theactualinterestinradiotherapyfortheutilizationofprotonbeam,highlightingphysicsbasis,technologyandcommonclinicalindications.JTumor.2016;4(2):378-385.

786. ArchambeauJO,BennettGW,LevineGS,etal.Protonradiationtherapy.Radiology.1974;110:445-457.

Page 98: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page98

787. BettegaD,CalzolariP,CioccaM,etal.CombiningprotonorphotonirradiationwithEpothiloneB.Aninvitrostudyofcytotoxicityinhumancancercells.BiomedPhysEng.24July2017;3(055009).

788. BushDA,DunbarRD,BonnetR,etal.PulmonaryinjuryfromprotonandconventionalradiotherapyasrevealedbyCT.AJRAmJRoentgenol.1999;172(3):735-739.

789. ChaikhA,CalugaruV,BondiauPY,etal. ImpactoftheNTCPmodelingonmedicaldecisiontoselecteligiblepatientforprotontherapy:theusefulnessofEUDasanindicatortorankmodernphotonvsprotontreatmentplans.IntJRadiatBiol.2018;7:1-26.doi:10.1080/09553002.2018.1486516.

790. ChungCS,KeatingN,YockT,TarbellN.“Comparativeanalysisofsecondmalignancyrisk inpatientstreated with Proton Therapy versus conventional Photon Therapy”, Red JournalS0360-3016(08)01001-8.IntJRadiatOncolBiolPhys.2008,72(1):S8.

791. Chung CS, Yock TI, Nelson K, et al. Incidence of secondmalignancies among patients treatedwithprotonversusphotonradiation.IntJRadiatOncolBiolPhys.2013;87(1):46-52.

792. CorkumMT,LiuW,PalmaDA,etal.OnlineAdvertisingandMarketingClaimsbyProvidersofProtonBeamTherapy:AreTheyGuidelineBased?IntJRadiatOncolBiolPhys.2017;99(2S):E651.

793. DeLaney TF, KooyHM. Proton andChargedParticle Radiotherapy. LippincottWilliams andWilkins,2007.

794. DoSY,BushDA,SlaterJD.Comorbidity-adjustedsurvival inearlystage lungcancerpatientstreatedwithhypofractionatedprotontherapy.JOncol.2010;251208.

795. DoyenJ,FalkAT,FloquetV,etal.Protonbeamsincancertreatments:clinicaloutcomesanddosimetriccomparisonswithphotontherapy.CancerTreatRev.2016Feb;43:104-112.

796. DvorakT,WazerDE.Evaluationofpotentialprotontherapyutilizationinamarket-basedenvironment.JAmCollRadiol.2010;7(7):522-528.

797. EatonBR,MacDonaldSM,YockTI,TarbellNJ.Secondarymalignancyrisk followingprotonradiationtherapy.FrontOncol.2015Nov;5:261.

798. ElnahalSM,KerstiensJ,HelsperRS,etal.Protonbeamtherapyandaccountablecare:thechallengesahead.IntJRadiatOncolBiolPhys.2013;85(4):e165e172.

799. FooteRL,StaffordSL,PetersenIA,etal.Theclinicalcaseforprotonbeamtherapy.RadiatOncol.2012Oct22;7:174.

800. FukumitsuN,TakahashiS,OkumuraT,etal.Normallivertissuechangeafterprotonbeamtherapy.JpnJRadiol.2018.https://doi.org/10.1007/s11604-018-0757-9.

801. GoiteinM, JermannM. The relative costs of proton and x-ray radiation therapy.ClinOncol (R CollRadiol).2003;15(1):S37-S50.

802. GoiteinM.Magicalprotons?IntJRadiatOncolBiolPhys.2008;70(3):654-656.

803. GruttersJPC,AbramsKR,deRuysscherD,etal.Whentowaitformoreevidence?Realoptionsanalysisinprotontherapy.Oncologist.2011;16(12):1752-1761.

804. GuptaA,MillevoiR,ElSebaiN,etal.Impactofinsurancepreauthorizationrequirementsondelaysinadministeringprotonbeamtherapy.IntJRadiatOncolBiolPhys.2018;102(3).

805. HashimotoT,IsobeT,HashiiH,etal.Influenceofsecondaryneutronsinducedbyprotonradiotherapyforcancerpatientswithimplantablecardioverterdefibrillators.RadiatOncol.2012;7:10.

Page 99: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page99

806. HofmannB.Fallaciesintheargumentsfornewtechnology:thecaseofprotontherapy.JMedEthics.2009;35(11):684-687.

807. JarlskogCZ,PaganettiH.Sensitivityofdifferentdosescoringmethodsonorgan-specificneutrondosecalculationsinprotontherapy.PhysMedBiol.2008;53(17):4523-4532.

808. JarosekS,ElliottS,VirnigBA.ProtonbeamradiotherapyintheU.S.Medicarepopulation:growthinusebetween 2006 and 2009 (2012). AHRQ publication No.12-EHC005.http://www.effectivehealthcare.ahrq.gov/ehc/products/439/1062/Data-Points-10_20120529.pdf.AccessedDecember,2013.

809. Johnstone PAS, Kerstiens J, Helsper R. Proton facilities economics: the importance of “simple”treatments.JAmCollRadiol.2012;9(8):560-563.

810. Kerstiens J, JohnstoneGP, JohnstonePAS.Proton facilityeconomics:single-roomcenters. JAmCollRadiol.2018.

811. KhooA,SahooN,KrishnanS,DiagaradjaneP.EnhancingtheRelativeBiologicalEffectivenessofProtonTherapyUsingEGFR-TargetedGoldNanorods. Int JRadiatOncolBiolPhys.2016Oct1;96(2S):S236-S237.doi:10.1016/j.ijrobp.2016.06.587.PubMedPMID:27675870.

812. Kristensen I, Nilsson K, Nilsson P. Comparative proton and photon treatment planning in pediatricpatientswithvariousdiagnoses.IntJPartTher.2015Fall;2(2):367-375.

813. LaackNN,WhitakerTJ,HarmsenWS,etal.Patient-reportedqualityoflifeduringphotonandprotonradiation therapy: resultsofaprospective registryofpatient reportedoutcomes ina large-volume,multi-sitepractice.IntJRadiatOncolBiolPhys.2018.

814. Langendijk JA, LambinP,DeRuysscherD et al. Selectionof patients for radiotherapywithprotonsaimingatreductionofsideeffects:Themodelbasedapproach.RadiotherOncol.2013Jun;107(3):267–273.

815. Langendijk JA,OrecchiaR,HaustermansK, et al. Prospectivedata registrationand clinical trials forparticletherapyinEurope.RadiotherOncol.2018;128(1):9-13.

816. LarssonB,LeksellL,RexedB,SouranderP,MairW,AnderssonB.Thehigh-energyprotonbeamasaneurosurgicaltool.Nature.1958Nov1;182(4644):1222-1223.

817. LinR,HugEB,SchaeferRA,etal.Conformalprotonradiationtherapyintheposteriorfossa:astudycomparingprotonswiththreedimensionalplannedphotonsinlimitingdosetoauditorystructures.IntJRadiatOncolBiolPhys.2000;48(4):1219-1226.

818. LundkvistJ,EkmanM,EricssonSR,etal.Protontherapyofcancer:potentialclinicaladvantagesandcosteffectiveness.ActaOncol.2005c;44(8):850861.

819. Macbeth FR, Williams MV. Proton therapy should be tested in randomized trials. J Clin Oncol.2008;26(15):2590-2591.

820. MarucciL,NiemierkoA,LiebschNJ,etal.Spinalcordtolerancetohighdosefractionated3Dconformalproton photon irradiation as evaluated by equivalent uniform dose and dose volume histogramanalysis.IntJRadiatOncolBiolPhys.2004;59(2):551555.

821. MishraMV,AggarwalS,BentzenSM,etal.Establishingevidence-basedindicationsforprotontherapy:anoverviewofcurrentclinicaltrials.IntJRadiatOncolBiolPhys.2017Feb;97(2):228-235.

Page 100: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page100

822. Moteabbed M, Yock TI, Depauw N, et al. Impact of spot size and beam-shaping devices on thetreatmentplanqualityforpencilbeamscanningprotontherapy.IntJRadiatOncolBiolPhys.2016May1;95(1):190-198.

823. MunckAR,RosenscholdP,EngelholmSA,etal.Aretrospectiveevaluationofthebenefitofreferringpediatric cancer patients to an external proton therapy center. Pediatr Blood Cancer. 2016Feb;63(2):262-269.

824. Oborn B, Dowdell S, Metcalfe P, et al. A Feasible Small Footprint Bunker Concept for Real-TimeMagnetic Resonance Imaging-GuidedProtonBeamTherapy. Int J RadiatOncol Biol Phys. 2016Oct1;96(2S):E602.

825. OdeiBCL,BoothD,KeoleS,etal.A20-yearanalysisofclinicaltrialsinvolvingprotonbeamtherapy.IntJPartTher.2016Winter;3(3):398-406.

826. PaganettiH,etal.Assessmentofradiation-inducedsecondrisksinprotontherapyandIMRTfororgansinsidetheprimaryradiationfield.PhysMedBio.2012;57(19):6047-6061.

827. PaganettiH,NiemierkoA,AncukiewiczM,etal.Relativebiologicaleffectiveness(RBE)valuesforprotonbeamtherapy.IntJRadiatOncolBiolPhys.2002;53(2):407-421.

828. PatelSH,KostarasX,ParliamentM,etal.Recommendations for thereferralofpatients forproton-beamtherapy,anAlbertaHealthServicesreport:amodelforCanada?CurrOncol.2014;21(5):251-262.

829. PeetersA,Grutters JPC, Pijls-JohannesmaM, et al.How costly is particle therapy?Cost analysis ofexternalbeamradiotherapywithcarbonions,protonandphotons.RadiotherOncol.2010;95(1):45-53.

830. Pieters RS, Niemierko A, Fullerton BC, Munzenrider JE. Cauda equine tolerance to high-dosefractionatedirradiation.IntJRadiatOncolBiolPhys.2006;64(1):251-257.

831. QuantitativeAnalysisofNormalTissueEffectsintheClinical(QUANTEC).IntJRadiatOncolBiolPhys.2010:76(3):S1-S160.

832. RanaS,ZeidanO,RamirezE,etal.Measurementsof lateralpenumbraforuniformscanningprotonbeamsundervariousbeamdeliveryconditionsandcomparisontotheXiOtreatmentplanningsystem.MedPhys.2013;40(9):091708.

833. SchneiderU, LomaxA,PemlerP, et al. The impactof IMRTandproton radiotherapyon secondarycancerincidence.StrahlentherOnkol.2006,182(11):647-652.

834. ShahA,A,RicciKI,EfstathiouJA.Beyondamoonshot:insurancecoverageforprotontherapy.LancetOncol.2016May;17(5):559-561.

835. ShusharinaN,LiaoZ,MohanR,etal.RadiationPneumonitisDoseResponseAfterPhotonorProtonRadiationTherapyAssessedby(18)F-FDGUptake.IntJRadiatOncolBiolPhys.2016Oct1;96(2S):E615.

836. SlaterJD.ClinicalApplicationsofProtonRadiationTreatmentatLomaLindaUniversity:Reviewofa15YearExperience.TechnolCancerResTreat.2006;5(2):81-89.

837. SmithAR.Vision20/20:protontherapy.MedPhys.2009;36(2):556-568.

838. SuzukiK,PalmerMB,SahooN,etal.Quantitativeanalysisoftreatmentprocesstimeandthroughputcapacityforspotscanningprotontherapy.MedPhys.2016Jul;43(7):3975.

839. ThakerNG,GuzmanAB,FeeleyTW,etal.Definingthevalueofprotontherapyusingtime-drivenactivitybasedcosting.OncolPayers.2014;1(1):22-28.

Page 101: Coverage of Proton Therapy · 2019-03-22 · scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing,

Page101

840. ThorwarthD,SoukupM,AlberM.DosepaintingwithIMPT,helicaltomotherapyandIMXT:adosimetriccomparison.RadiotherOncol.2008;86:30–34.

841. Thuomas K-A, Naeser P. Long-term follow-up of proton irradiated malignant melanoma byglucose-fructoseenhancedmagneticresonanceimaging.ActaOphthalmolScand.1997;75(1):17-21

842. TsujiiH,TsujiH,InadaT,etal.ClinicalResultsofFractionatedProtonTherapy.IntJRadiationOncologyBiolPhys.1992;25(1):49-60.UmebayashiY,UyenoK,TsujiiH,OtsukaF.Protonradiotherapyofskincarcinomas.BrJDermatol.1994;130(1):88-91.

843. Umebayashi Y,UyenoK, TsujiiH,OtsukaF.Proton radiotherapyof skin carcinomas.Br JDermatol.1994;130(1):8891.

844. UnkelbachJ,ChanTC,BortfeldT.Accountingforrangeuncertaintiesintheoptimizationofintensitymodulatedprotontherapy.PhysMedBiol.2007May;52(10):2755-2773.

845. VemimmenFJ,FredericksS,WallaceF.Longtermfollowupofpatientstreatedatasingleinstitutionusingapassivelyscatteredprotonbeam;observationsaroundtheoccurrenceofsecondmalignancies.IntJRadiatOncolBiolPhys.2018.

846. VermaV,MishraMV,MehtaMP.A systematic reviewof thecostandcost-effectiveness studiesofprotonradiotherapy.Cancer.2016.

847. WaddleMR,SioTS,VanHoutenHK,etal.Photonandprotonradiotherapyutilizationinapopulationof over 100 million commercially insured patients. Int J Radiat Oncol Biol Phys. 2017, doi:10.1016/j.ijrobp.2017.07.042.

848. WangX,PoenischF,SahooN,etal.Spotscanningprotontherapyminimizesneutrondoseinthesettingofradiationtherapyadministeredduringpregnancy.JApplClinMedPhys.2016Sep8;17(5):6327.

849. Yoon M, Ahn SH, Kim J, et al. Radiation-induced cancers from modern radiotherapy techniques:intensity-modulatedradiotherapyversusprotontherapy.IntJRadiatOncolBiolPhys.2010;77(5):1477-85.